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ABSTRACT 
Cancer is a leading cause of death that affects millions of people across the globe each year. 
Photodynamic therapy (PDT) is a relatively new treatment approach for cancer in which 
anticancer drugs are activated by light at an appropriate wavelength to generate highly 
cytotoxic reactive oxygen species (ROS) and achieve tumor destruction. Compared with 
conventional chemo- and radiotherapy, PDT can be performed with minimal invasiveness, 
local targeting and reduced side effects. However, most of the currently available PDT drugs 
mainly absorb in the visible part of the spectrum, where light penetration depth into human 
tissues is very limited. Therefore, increasing the treatment depth of PDT has been considered 
to be an important approach to improve the effectiveness of PDT for treating larger and 
thicker tumor masses. In this thesis, we present our investigation into the potential of two-
photon activated PDT (2-γ PDT), combination therapy of PDT and chemotherapy, and 
bioluminescence-activated PDT as a means to increase the treatment depth of this modality. 
 In 2-γ PDT, the photosensitizing agents are activated through simultaneous absorption 
of two photons. This approach allows the use of near-infrared (NIR) light that can penetrate 
deeper into tissues and thus, has the potential of treating deep-seated tumors and reducing 
side effects, while the non-linear nature of two-photon excitation (TPE) may improve tumor 
targeting. We have evaluated the PDT efficacy of a second-generation photosensitizer 
derived from chlorophyll a, pyropheophorbide a methyl ester (MPPa), through both one- and 
two-photon activation. We observed that MPPa had high one-photon (1-γ) PDT efficacy 
against both cisplatin-sensitive human cervical (HeLa) and cisplatin-resistant human lung 
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(A549) and ovarian (NIH:OVCAR-3) cancer cells when activated by femtosecond (fs) laser 
pulses at 674 nm. At a low light dose of 0.06 J cm-2, the MPPa concentration required to 
produce a 50% cell killing effect (IC50) was determined to be 5.3 ± 0.3, 3.4 ± 0.3 and          
3.6 ± 0.4 µM in HeLa, A549 and NIH:OVCAR-3 cells, respectively. More significantly, we 
also found that MPPa could be effectively activated at the optimal tissue-penetrating 
wavelength of 800 nm through TPE. At a light dose of 886 J cm-2, where no measurable 
photodamage was observed in the absence of MPPa, the IC50 values were measured to be    
4.1 ± 0.3, 9.6 ± 1.0 and 1.6 ± 0.3 µM in HeLa, A549 and NIH:OVCAR-3 cells, respectively. 
We obtained corresponding LD50 (the light dose required to produce a 50% killing effect) 
values of 576 ± 13, 478 ± 18 and 360 ± 16 J cm-2 for 10 µM MPPa, which were 
approximately 3-5 times lower than the published 2-γ LD50 of Visudyne® and 20-30 times 
lower than that of Photofrin®. These results indicate that MPPa may serve as a 
photosensitizer for both 1- and 2-γ activated PDT treatment of difficult-to-treat tumors by 
conventional therapies. 
 Indocyanine green (ICG), a dye having an absorption maximum near 800 nm, has been 
considered to be a potential NIR PDT agent. However, the PDT efficacy of ICG has been 
found to be very limited probably due to the low yield of cytotoxic ROS. In the present work, 
we have evaluated the combination effects of ICG-mediated PDT with conventional 
chemotherapy mediated by two types of chemotherapeutic drugs, namely the type II 
topoisomerase (TOPII) poisons etoposide (VP-16)/teniposide (VM-26) and the platinum-
based drugs cisplatin (CDDP)/oxaliplatin (OXP). Synergistic enhancement of cytotoxicity 
and increased yields of DNA double strand breaks (DSBs) were observed in HeLa, A549 and 
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NIH:OVCAR-3 cancer cells treated with the combination of ICG-PDT and VP-16. The 
presence of VP-16 during the laser irradiation process was found to be critical for producing 
a synergistic effect. An electron-transfer-based mechanism, in which ICG could increase the 
yield of highly cytotoxic VP-16 metabolites, was proposed for the observed synergistic 
effects, although direct spectroscopic detection of the reaction products was found to be very 
challenging. Moreover, we observed a much lower degree of synergy in the human normal 
fibroblast GM05757 cells than that in the three cancer cell lines investigated. Synergistic 
effects were also observed in A549 cells treated with the combination of ICG-PDT and   
VM-26 (i.e. an analog of VP-16). Furthermore, the combination of low-dose CDDP/OXP and 
ICG-PDT was demonstrated to produce an additive or synergistic effect in selected cancer 
cell lines. These preliminary results suggest that the combination of ICG-PDT with           
VP-16/VM-26 or CDDP/OXP chemotherapy may offer the advantages of enhancing the 
therapeutic effectiveness of ICG-PDT and lowering the side effects associated with the 
chemotherapeutic drugs. 
 Bioluminescence, the generation of light in living organisms through chemical 
reactions, has been explored as an internal light source for PDT in recent years. This 
approach, in principle, does not suffer from the limited tissue penetration depth of light. In 
the present project, we have evaluated the effectiveness of luminol bioluminescence in 
activating the porphyrin photosensitizers meso-tetra(4-sulfonatophenyl)porphine 
dihydrochloride (TPPS4) and Fe(III) meso-tetra(4-sulfonatophenyl)porphine chloride 
(FeTPPS). The combination treatment induced significant killing of HeLa cells, while 
additive effects were observed in two normal human fibroblast cell lines (GM05757 and 
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MRC-5). Our observations indicate that bioluminescence of luminol may generate sufficient 
light for intracellular activation of PDT sensitizers. Furthermore, the combination treatment 
may have intrinsic selectivity towards cancerous tissues. 
 In summary, we have demonstrated effective killing of cancer cells by MPPa-mediated 
1- and 2-γ PDT, combination of ICG-PDT and VP-16/VM-26 or CDDP/OXP chemotherapy, 
and bioluminescence of luminol activated PDT mediated by TPPS4/FeTPPS. These positive 
preliminary results indicate that all these three approaches have the potential of increasing 
the treatment depth of PDT and facilitating the development of more effective PDT treatment 
strategies.   
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1 Introduction 
Cancer is not a single disease but a group of diseases characterized by unregulated growth 
and spread of cells. It affects millions of people around the world each year and is the second 
cause of death from diseases after heart disease. In Canada, an estimated 186,400 new cases 
and 75,700 cancer deaths occurred in 2012 (1). According to the American Cancer Society, 
there were over 1.66 million new cancer cases and nearly 0.6 million cancer deaths in the 
United States in 2013 (2). 
1.1 Cancer staging 
Cancer cells, also known as malignant cells, differ from their normal counterparts in a 
number of ways, including morphology, growth control, cell-to-cell interactions, cell-surface 
markers, and protein or gene expression. Cancer staging is the determination of the extent to 
which a cancer has developed by spreading and plays an important role in treatment 
planning. There are five main stages:  
• Stage 0: carcinoma in situ. Abnormal cells are found only within the layer of cells 
where they began. 
• Stage I: cancers are localized to the organ in which they developed. 
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• Stage II: cancers are locally advanced. Cancer cells can also be found in nearby 
lymph nodes, organs, or tissues. 
• Stage III: cancers are also locally advanced. The specific criteria for Stages II and III 
are cancer type-dependent. 
• Stage IV: metastasis. Cancers are found in organs or lymph nodes distant from the 
primary site. 
1.2 Lung cancer  
Despite great improvements in diagnosis and treatment modalities, lung cancer remains the 
deadliest among all the cancers. It was the second most common cancer (14%) and also the 
leading cause of cancer death in both men (27%) and women (26%) in Canada in 2012 (1). In 
the United States, it was estimated that there were 228,190 newly diagnosed cases and 
159,480 deaths associated with lung and bronchus cancer in 2013, which accounted for about 
14% and 27% of the total numbers (2).  
 The two main types of lung cancer are the small-cell lung carcinoma (SCLC) and non-
small-cell lung carcinoma (NSCLC), which can be distinguished based on the appearance of 
the cells under a microscope. The overall 5-year survival rates for SCLC and NSCLC have 
been reported to be 6.1% and 17.1%, respectively (3). Radiation therapy alone or in 
combination with chemotherapy is the standard treatment for SCLC. Surgery is usually 
performed in patients with early stage NSCLC. For patients with advanced stage NSCLC, the 
treatment options are either chemotherapy/radiation therapy alone or in combination. In the 
case of advanced stages diseases, patients may receive the combination of chemotherapy and 
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targeted therapy. For example, an agent designed to target specific molecular pathways in 
lung cancer cells (bevacizumab (Avastin®)) has been approved in the United States (3). Some 
cases of early-stage lung cancer may also be treated with photodynamic therapy (PDT) to 
help relieve symptoms of a blocked airway. 
1.3 Ovarian and cervical cancers 
Ovarian and cervical cancers are also commonly diagnosed in women. Ovarian cancer causes 
more deaths than any other gynecological cancers (cancers of the female reproductive 
system). According to the Canadian Cancer Society, over 2,600 new cases were diagnosed 
and about 1,750 deaths occurred in 2012 in Canada (1). In the United States, approximately 
22,240 (3%) new cases and 14,030 (5%) deaths occurred in 2013 (2). Currently, surgery, 
chemotherapy and radiation therapy are the three main treatment options for ovarian cancer 
patients. The extent of treatment depends on a number of factors, including cancer type, the 
stage of the disease, the patient’s overall health status, and personal considerations.  
 The number of estimated new cases and deaths from cervical cancer were 1,350 and 
390 in 2012 in Canada (1), while this disease was expected to account for 1.5% (12,340) of 
the new cases and 1.5% (4,030) of the deaths associated with cancer in women in 2013 in the 
United States (2). In patients with early stage cervical cancers, treatment options include 
electrocoagulation (tissue destruction by high-frequency electric current), cryotherapy 
(killing of abnormal cells by extremely low temperature), laser ablation, or local surgery. 
Surgery, chemotherapy, or radiotherapy may be applied in more advanced stages.  
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1.4 Conventional cancer therapies 
 Surgery 1.4.1
Surgery is a medical procedure in which the diseased tissue or organ is removed from the 
body. It may be performed for diagnosis purposes such as to determine the type, stage and 
extent of spread of tumors. As a treatment approach, surgery remains one of the main options 
for cancer, especially solid tumors. When the disease is completely contained in one area, the 
cancer may be cured by physical removal of the cancerous tissue. However, complete 
excision is impossible if the cancer cells have spread to other remote sites prior to surgery. 
Moreover, even a single cancer cell can regrow into a new tumor. Therefore, complete cure 
of the cancer often requires the combination of two or more therapies. The combination of 
surgery with chemotherapy or radiotherapy can greatly improve the treatment outcomes.  
 Side effects of cancer surgery may include anesthesia complications, infections, 
inflammation, loss of function, scarring, etc. Development of secondary cancers (metastasis), 
which is usually difficult to treat, has also been found in some cases following the removal of 
the primary tumor (4, 5).  
 Chemotherapy 1.4.2
Chemotherapy is a type of cancer treatment where one or more medicines are given either 
orally or intravenously to kill the cancer cells. It is one of the most important treatment 
 5 
 
modalities currently available for cancer. Many chemotherapeutic drugs have been approved 
by the United States (U.S.) Food and Drug Administration (FDA). For example, 10 new 
drugs were approved in fiscal year 2012 for the treatment of cancer (6). Based on their 
chemical structures and action mechanisms, chemotherapeutic drugs may be classified into 
the following groups: alkylating agents, topoisomerase inhibitors, antimetabolites, mitotic 
inhibitors, antitumor antibiotics, corticosteroids, and some other drugs that do not fit well 
into any of the these categories.  
1.4.2.1 Platinum-based chemotherapeutic drugs 
Cisplatin (CDDP) is the first platinum-based chemotherapeutic drug that acts by causing 
direct and indirect damages to cellular DNA and sometimes is grouped with alkylating agents 
because their mechanisms of action are similar. CDDP is widely used for the treatment of a 
variety of cancers, including bladder, blood vessel, bone, brain, cervical, lymphoma, lung 
and ovarian cancers (7-9). It has been estimated that approximately 50-70% of the cancer 
patients have received CDDP treatment (10). Over the past decades, great efforts have been made 
in developing more effective platinum-based anticancer compounds. Thousands of CDDP 
analogues have been prepared and tested, but only two of them (carboplatin and oxaliplatin 
(OXP)) have been approved by FDA for clinical use. 
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Figure 1-1: Chemical structures of cisplatin (CDDP), carboplatin and oxaliplatin (OXP). 
1.4.2.2 Type II topoisomerase inhibitors 
Type II topoisomerases (TOPII) are enzymes that cut both strands of one DNA double helix 
during replication and transcription in order to facilitate DNA untangling. A number of 
TOPII poisons have been developed as effective anticancer drugs and can be classified into 
two groups according to their mechanisms of action (11-14). The drugs etoposide (VP-16) 
and teniposide (VM-26) (Figure 1-2) belong to the class of interfacial poisons that interact 
non-covalently at the protein-DNA interface. Etoposide was first approved by FDA in 1983. 
It is currently used for treating acute myeloid leukemia, choriocarcinoma, small and non-
small cell lung carcinoma, lymphoma, advanced ovarian carcinoma, and testicular cancers 
(15, 16). Teniposide was approved later in 1992 for the treatment of bladder cancer, 
malignant lymphoma, and central nervous system tumors. Covalent poisons can form adducts 
with the sulfhydryl groups on cysteine residues of TOPII. Quinones have been found to 
belong to this class (11, 12). The catechol and quinone metabolites of VP-16 also belong to 
this class and have been found to be a few times more active than the parent compound VP-
16 in inducing TOPII-mediated DNA double strand breaks (DSBs) (13, 14). 
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Figure 1-2: Chemical structures of etoposide (VP-16) and teniposide (VM-26). 
 Despite the great success of chemotherapeutic drugs, especially CDDP, in treating 
cancers, they destroys not only cancer cells, but also many rapidly dividing normal cells 
resulting in severe side effects such as nausea, vomiting, hair loss, etc. Generally speaking, 
chemotherapeutic drugs accumulate not only in cancer cells but also in proliferating normal 
cells by inhibiting DNA synthesis or interfering with cellular processes, including cell 
division and metabolism. As a consequence, chemotherapeutic treatments often cause 
damages to healthy tissues, especially bone marrow, skin, and gastro-intestinal mucosa. In 
addition, cancer cells readily acquire resistance to chemotherapeutic agents. The poor 
specificity of chemotherapeutic agents commonly prevents aggressive and effective 
treatment of the cancer.  
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 Radiotherapy 1.4.3
Radiotherapy is another common cancer therapy in which ionizing radiation, such as hard X-
rays, γ-rays, electron beams, or protons, is used to kill or control the growth of cancer cells. It 
has been estimated that ~50-60% of all cancer patients will be treated with radiotherapy 
either alone or together with other cancer therapies such as surgery and chemotherapy during 
the course of illness (17, 18). The energy of the ionizing radiation can be deposited directly 
into the target molecules causing excitation or direct ionization of important biological 
molecules such as nuclear DNA and thus, induce cell death. Ionizing radiation can also 
induce cell death by causing indirect damages to DNA of exposed tissue by generating free 
radicals, including prehydrated electrons (epre-), hydrated electrons (ehyd-), and hydroxyl 
radicals (∙OH), from radiolysis of water (19). It has been found that more damages are 
produced in the indirect pathway than the direct pathway (20).  
 During the process of radiation treatment, surrounding normal tissues may also be 
damaged due to the fact that most types of radiation lack specificity against cancer cells. 
Although low-dose radiation therapy causes minimal or no side effects, a number of acute 
side effects, such as vomiting and swelling, long-term side effects, such as secondary cancer 
and heart diseases, or cumulative side effects, may be caused at high doses. Therefore, 
radiosensitizers that can make the cancer cells more sensitive to radiation therapy are studied 
extensively in preclinical and clinical studies (18, 21). On the other hand, various radiation 
protectors are also being developed to protect normal cells from damages caused by radiation 
therapy (18). Although further study of these compounds in clinical trials is required, the use 
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of radiosensitizers and radioprotectors is believed to be crucial to improving the clinical 
outcomes of radiation treatment of cancer.  
1.5 Photodynamic therapy 
Photodynamic therapy (PDT) is a novel cancer therapy in which tumor destruction is 
achieved through the generation of cytotoxic reactive oxygen species (ROS) by exposing the 
diseased tissue to a photosensitizer and light of an appropriate wavelength. Over 100 years 
ago, a German student named Oscar Rabb reported the first case of cell death induced by the 
interaction of light and a chemical compound (22). Three years later, the first medical 
application of PDT was reported by von Tappeiner and Jesionkek, who used the combination 
of eosin and white light to treat basal cell carcinomas (BCCs) (23). However, therapeutic 
applications of PDT were not widely explored until 1972, when Diamond et al. proposed that 
the tumor-specificity and phototoxicity of porphyrins might be combined for the treatment of 
cancers (24). Later in 1975, Dougherty and coworkers successfully treated tumors in 
experimental animals by haematoporphyrin-mediated PDT for the first time (25). In the same 
year, Kelly et al. reported that haematoporphyrin derivative (HpD) and light could induce 
marked destruction of human bladder tumor transplanted into mice (26). Three years later, 
Dougherty et al. demonstrated the first case of successful treatment of more than one 
hundred patients by PDT (27). Since then, a large number of studies have shown the clinical 
effectiveness of PDT in treating various cancers and some other diseases (28-38). 
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 Mechanism of photodynamic therapy 1.5.1
Figure 1-3 is a Jablonski diagram illustrating the major processes that may occur when a 
molecule absorbs a photon of appropriate energy. Upon excitation, the molecule may be 
promoted from its ground electronic state (usually a singlet state, S0) to an excited singlet 
state Sn (n = 1, 2 …). According to the Frank-Condon principle, no significant displacement 
of nuclei will occur during the process of an electronic transition, which takes place on a 
much shorter timescale (on the order of 10-15 s) than that of nuclear rearrangement (on the 
order  of 10-14 to 10-13 s)  (39). If an excited singlet state higher than S1 is reached, the 
molecule will undergo a fast (~ 10-14 – 10-11 s) internal conversion (IC) process to an excited 
vibrational state S1 (S1v). The molecules in the S1v state may lose their excess energy through 
vibrational relaxation (VR), which takes place between 10-14 and 10-11 seconds. From the 
lowest, zero-point vibration level of S1 state (S10), the molecule may go back to its ground 
state via either radiation emission (fluorescence; on the order  of 10-9 to 10-7 s) or IC. A 
crossing from S10 to the excited triplet state (T1v) can also take place through another 
radiationless process, called intersystem crossing (ISC; on the order  of 10-8 to 10-3 s). From 
T10, the molecule may lose its excess energy by emitting light through a process known as 
phosphorescence, a slow (~ 10-8 – 10-3 s) and spin-forbidden transition, or react with other 
molecules such as molecular oxygen (O2) and the solvent. 
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Figure 1-3: Jablonski diagram illustrating the photosensitization processes. Upon absorbing 
one photon of appropriate energy, a photosensitizer is promoted from its ground state (S0) 
to the first excited singlet state (S1). From S1 state, the molecule may undergo intersystem 
crossing (ISC) to an excited triplet state (T1), which can transfer its energy to an oxygen 
molecule (3O2) through an energy transfer reaction to form singlet oxygen (1O2) or form 
other free radicals through electron/hydrogen transfer reactions. The generated 1O2, O2-.,      
∙OH and H2O2 are called reactive oxygen species (ROS), which are cytotoxic. (IC: internal 
conversion; VR: vibrational relaxation; ISC: intersystem crossing.) 
 The ground state of O2 is a triplet state (3Σg-) while the lowest excited state is a singlet 
state (1∆g), which is located at 0.98 eV above the ground state (40). It has been found that 
both the excited singlet and triplet states of a photosensitizer can be quenched through 
reactions with molecular oxygen as shown in Scheme 1 (40-48). 
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Scheme 1 
where (PS-O2)* represents an encounter complex, kdiff is the diffusion-controlled rate 
constant, k-diff is the rate constant for separation of the encounter pairs, k∆ and kST are the rate 
constants for quenching of the excited singlet states by oxygen via reactions (1) and (2) that 
result in the formation of O2(1∆g) and O2(3Σg-), respectively, and ket is the rate constant for 
quenching of the excited triplet states by oxygen via reaction (5), which results in the 
formation of O2(1∆g). The fractions of O2(1∆g) generated from quenching of the excited 
singlet states (f∆S) and the excited triplet states (f∆T) have been determined in a number of 
studies (41-48). The values have been demonstrated to be dependent on the type of the 
compound, the type of the solvent, the energy and redox potential of the excited states, etc. In 
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general, the efficiency of singlet oxygen generation from the excited singlet states is much 
lower than that from the excited triplet states of the same compound.  
 In PDT, a photosensitizer in its excited triplet state (3PS*) is believed to be the major 
state responsible for the generation of cytotoxic species that finally cause tumor cell 
destruction. Due to the spin-forbidden nature of the T1-S0 transition, the typical lifetime of a 
molecule in the excited triplet state is tens of microseconds (µs) (49), which allows sufficient 
time for the excited photosensitizer to interact with surrounding molecules to produce 
cytotoxic species. There are two mechanisms that have been proposed for the reaction of 
3PS* with bio-molecules, known as the Type I and Type II reactions (Figure 1-3) (49-52). In 
a Type I process, the 3PS* reacts with the solvent or a substrate molecule through 
electron/hydrogen transfer to produce highly reactive free radicals, such as hydroxyl radical  
(∙OH), superoxide anion radical (O2-*), and hydrogen peroxide (H2O2). In Type II reactions, 
the 3PS* may transfer its energy to O2 leading to the production of singlet oxygen (1O2). 
Although both Type I and Type II reactions may occur during the process of photodynamic 
treatment, 1O2 is believed to have a higher contribution to tumor destruction than the other 
cytotoxic species generated in PDT.  
 Cellular and tissue responses to PDT 1.5.2
At the cellular and tissue levels, the ROS, including 1O2, O2·-, ∙OH, and H2O2, generated in 
PDT can cause direct killing of tumor cells, damage the tumor vasculature, or activate an 
immune response against tumor growth. Both Type I and Type II processes contribute to the 
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production of ROS and their relative contributions depend on various factors such as oxygen 
tension, light dose, and the type, concentration and subcellular localization of the 
photosensitizer (32). Therefore, long-term tumor control will rely on the combination of all 
these factors (32, 53). 
1.5.2.1 Direct killing of tumor cells 
The photodynamic treatment may induce apoptotic, necrotic or autophagic cell death (54-67). 
The primary site of photodynamic damages is generally accepted to coincide with the 
intracellular localization of the photosensitizer since the cytotoxic 1O2 generated during PDT 
treatment has a very short lifetime (<~µs) and hence limited diffusion length (<~100 nm) 
(68). For this reason, PDT is believed to have a relatively low potential of causing DNA 
damages, mutations or carcinogenesis because most PDT drugs do not enter the cell nuclei 
(56). With a relatively low level of oxidative stress, photosensitizers that localize to the 
mitochondria or endoplasmic reticulum (ER) may induce apoptosis (54, 56), a form of 
programmed cell death (PCD) characterized by cytoplasmic membrane blebbing, cell 
shrinkage, chromatin condensation, chromosomal DNA fragmentation, and formation of 
apoptotic bodies. Those photosensitizers targeting the plasma membrane or lysosomes may 
favor the activation of the necrotic pathway (54, 56). In contrast to apoptosis, necrosis results 
in an unregulated release of cellular components into the extracellular space, which usually 
triggers inflammatory responses in the surrounding tissue. 
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 Light dose is another important factor in determining the death pathway following PDT 
treatment. While apoptotic cell death is predominant when cells are photosensitized with low 
light doses, necrosis has been observed at high light doses (55). Although necrosis has been 
considered to be a passive, uncontrolled way of cell death, some recent studies have shown 
that necrosis may also be propagated through a signal transduction pathway (69-71). In PDT, 
a necrotic cell death pathway has not been reported yet, however, some factors, such as 
overload of Ca2+, have been suggested to be involved (57, 62).  
 More recently, it has been indicated that sublethal photodynamic damages may trigger 
autophagy, which involves isolation of damaged cellular components within autophagosomes 
and subsequent fusion with the cell’s own lysosomes for degradation and recycling, and lead 
to cancer cell death (58-60, 63-65). ROS can either stimulate cytoprotection or activate 
autophagic cell death depending on the type of ROS generated, level of oxidative stress 
induced, and the molecular targets affected during PDT treatment (59-61, 63-67, 72). 
Although the molecular mechanisms of autophagy modulation by ROS are still under 
investigation, it has been suggested that autophagy can cause cell death in apoptosis defective 
cells (58, 65). 
1.5.2.2 Vasculature damages 
The tumor vasculature represents an important target for PDT in vivo (37, 66, 73-83). Apart 
from the direct tumor cell killing effects, the ROS generated in PDT can also cause blood 
vessel shutdown leading to nutrient deprivation and hypoxia within the target tumor. Blood 
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vessel dilation has been observed in mice treated with PDT mediated by HpD (73). Elevated 
interstitial pressure following PDT treatment has also been reported suggesting increased 
blood vessel permeability (74, 75). Other effects such as blood flow stasis, thrombus 
formation and over-expression of angiogenic factors have also been observed following PDT 
treatments (66, 77-79, 83). Therefore, PDT-induced vascular damages have been considered 
to be one of the major mechanisms of tumor destruction. The importance of vascular effects 
of PDT has stimulated the development of vascular targeted photodynamic therapy (VTP) as 
a potential approach for improving the effectiveness of PDT (66, 80, 82).  
1.5.2.3 Immune responses 
Distinct from the immunologically silent genotoxic damages induced by chemotherapy or 
radiotherapy, rapid cell death following photo-oxidative damages induced by PDT treatment 
can alert host’s immune system (36, 53, 84-90). It has been shown that PDT can cause acute 
inflammatory and immune responses such as heat shock proteins expression and leukocyte 
infiltration within the tumor (87). In addition, Castano et al. observed an increased level of 
tumor-derived antigen to T cells following PDT treatment (88). Other immune responses, 
including attraction of host leukocytes, lymphocytes and macrophages into treated cancerous 
tissue, have also been observed, and up-regulation of the inflammatory cytokines interleukin 
(IL)-6 and IL-1 and activation of the neutrophil accumulation have been found to be 
responsible to these responses (84, 85, 91). These results indicate that the immune responses 
may be very helpful in long-term tumor control in addition to the direct PDT effects that can 
cause destruction of the bulk of the tumor. More interestingly, some recent investigations 
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have demonstrated that potent vaccines may be generated by treating tumor cells of the same 
origin by PDT in vitro (36, 86, 89, 90). 
 Photosensitizers 1.5.3
A photosensitizer is a chemical compound that can absorb photons of energy equal to the 
energy difference between the ground state and an excited state leading to the production of 
ROS and other radicals. In 1900, acridine (Figure 1-4) was first used as a photosensitizer by 
Oscar Raab to kill infusoria (22), minute aquatic creatures such as unicellular algae and small 
invertebrates. A red crystalline derivative of fluorescein, eosin (Figure 1-4), was used in 
combination with visible light to treat skin tumors by Herman von Tappeiner and Albert 
Jesionek in 1903 (23). 
                     
Figure 1-4: Chemical structures of acridine and eosin. 
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 Later in 1910, W. Hausmann observed toxic effects of haematoporphyrin (Hp) (Figure 
1-5) on the skin of mice after light exposure (92). Three years later, the German scientist 
Friedrich Meyer-Bertz tested Hp and observed pain and swelling in the treatment areas (93). 
In 1955 Samuel Schwartz synthesized a derivative of haem containing ferric ion-free (known 
as “haematoporphyrin derivative” (HpD)) (94). Although HpD was later found to be a 
mixture of several compounds, it was demonstrated to be able to localize in tumors and could 
be administrated at much lower doses than the parent compound Hp, and therefore held 
promise for diagnostic applications (95). In 1978, HpD-mediated PDT was successfully 
applied for the first time to treat skin tumors by Thomas J. Dougherty et al. (27). The first 
photosensitizer approved by FDA was a purified form of HpD known as Photofrin® (Figure 
1-6), which was approved in 1995. 
 
Figure 1-5: Chemical structure of haematoporphyrin (Hp). 
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 Although Photofrin® continues to be the most widely used drug for PDT, the “first-
generation photosensitizers”, including Photofrin® and other commercial HpD variants 
Photosan®, Photogem® and Photocarcinorin®, have several disadvantages. First, they are not 
pure compounds but complex mixtures of monomeric and oligomeric non-metallic 
porphyrins. Second, the patient will have to avoid direct exposure to sunlight and bright 
indoor light up to several weeks after PDT treatment due to prolonged skin sensitivity. Third, 
they are activated by light around 630 nm, where the tissue penetration and resulting 
effective treatment depth are limited (96).  
 
Figure 1-6: Chemical structure of Photofrin®. 
 To overcome these limitations of the “first-generation photosensitizers”, many new 
compounds have been synthesized and some of them have been found to be promising (37, 
97-100). Table 1-1 is a summary of photosensitizers that have been approved for use in 
humans. In the 1990s, several “second-generation photosensitizers”, including 5-
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aminolaevulinic acid (ALA; Figure 1-7) and its methyl ester (methyl aminolaevulinate, 
MAL; Figure 1-7), benzoporphyrin derivatives (Figure 1-8), chlorins (Figure 1-8), 
phthalocyanines (Figure 1-8), porphycenes (Figure 1-8) and others were developed. These 
synthetic dyes are more pure, efficient, selective and safe than the “first-generation 
photosensitizers”. In addition, the skin photosensitivity of these compounds lasts for 
relatively short times. Among them, a few new drugs have been approved for use in PDT.
 
Figure 1-7: Chemical structures of 5-aminolaevulinic acid (ALA), methyl aminolevulinate 
(MAL) and protoporphyrin IX. 
Delta-aminolevulinic acid (ALA; Levulan®), also known as 5-aminolevulinic acid, was 
approved in 1999 by FDA for the treatment of cancerous lesions. This is a biosynthetic “pro-
drug”, which needs to be converted to the active photosensitizer protoporphyrin IX (Figure 
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1-7). In 2004, FDA approved the methyl ester of ALA, methyl aminolevulinate (MAL; 
Metvix®), for the treatment of BCCs and actinic keratosis. The drug benzoporphyrin 
derivative monoacid ring A (BPD-MA; verteporfin), has gained approval in the liposomal 
formulation known as Visudyne® for treating age-related macular degeneration (AMD) in 
Canada, the U.S., most European Union (EU) countries and Japan. Although the approval of 
5,10,15,20-tetra(m-hydroxyphenyl)chlorin (mTHPC; temoporfin; Foscan®) has been declined 
in the U.S., it has been approved for treating head and neck cancer in the EU, Norway and 
Iceland. Mono-(L)-aspartylchlorin-e6 (MACE; LS11; NPe6; talaporfin; Aptocine™) is 
available for lung cancer treatment in Japan. 
 Recently, strategies to improve the efficiency and selectivity of PDT have also been 
investigated extensively (101-121). Direct linking of the photosensitizers with molecules that 
have some affinity for tumor cells, such as antibodies (121), small peptides (122), proteins 
(e.g. transferrin (104, 123, 124), epidermal growth factor (EGF) (125), etc.) and many others 
(116), have been found to be able to either increase the uptake of the drugs by tumor cells or 
make the drugs become active in response to specific tumor activities. The photosensitizers 
can also be encapsulated within drug delivering vehicles, such as liposomes, polymeric 
nanoparticles and gold nanoparticles, which may be further functionalized with the above 
mentioned tumor-targeting molecules (102, 106, 107, 115, 126-130). These biologically or 
chemically modified novel drugs can be classified as belonging to the “third-generation 
photosensitizers”. Visudyne® is a successful example of using liposomes as the delivery 
vehicles for a PDT drug and has been approved for treating AMD. 
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Figure 1-8: Chemical structures of benzoporphyrin derivative, chlorin, phthalocyanines and 
porphycene. 
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Figure 1-9: Chemical structures of verteporfin, temoporfin and talaporfin 
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Table 1-1: Photosensitizers approved for use in humans. 
Photosensitizer Wavelength Description Type of diseases Country 
Photofrin® 630 nm Haematoporphyrin monomers/di-, oligomers 
Barrett‘s dysplasia  U.S., Canada, EU, UK  
Bladder cancer Canada 
Cervical cancer  Japan  
Endobronchial cancer  Canada, Most EU Countries, Japan, U.S.  
Esophageal cancer  Canada, Most EU Countries, Japan, U.S.  
Gastric cancer  Japan  
Early- and late-stage lung cancer Japan (early-stage), Netherlands 
Papillary bladder cancer  Canada  
Stomach Japan 
Levulan® 635 nm 5-aminolevuinate (5-ALA), precursor of endogenous porphyrins 
Actinic keratosis, Basal cell 
carcinoma  U.S., EU 
Metvix® 635 nm ALA methyl ester Some types of actinic keratoses of the face and scalp U.S. 
Foscan® 652 nm Tetra(m-hydroxyphenyl)chlorin (m-THPC), Temoporfin 
Advanced head and neck squamous 
cell carcinoma EU, Norway, Iceland  
Visudyne ® 690 nm Benzoporphyrin derivative monoacid ring A, Verteporfin Age-related macular degeneration  
Canada, Most EU 
Countries, Japan, U.S.  
Aptocine™ 660 nm Mono-(L)-aspartylchlorin-e6 (MACE, LS11, NPe6), Talaporfin Lung cancer Japan 
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 Tissue “optical window” for PDT and near-infrared 1.5.4
photosensitizers 
The tissue “optical window” for PDT, also known as the therapeutic window, defines the 
wavelength range 700 - 950 nm, where light absorption by biological molecules is relatively 
low (96). Figure 1-10 shows that the endogenous chromophores haemoglobin and melanin 
are highly absorbing below ~700 nm, while light absorbance by water becomes dominant at 
wavelengths longer than 900 nm (96, 131).  
• Haemoglobin: There are two types of haemoglobin in blood, namely 
deoxyhaemoglobin (Hb) and oxyhaemoglobin (HbO2). Hb has two absorption 
maxima at 420 and 580 nm, while HbO2 has three major absorption peaks at 410, 550 
and 600 nm. Above 600 nm, the molar extinction coefficient of both Hb and HbO2 
gradually decreases as light wavelength increases. 
• Melanin: Melanin is a natural pigment found in most organisms. In humans, the two 
major forms of melanin are eumelanin, a polymer of 5,6-dihydroxyindole (DHI) and 
5,6-dihydroxyindole-2-carboxylic acid (DHICA) having a brown-black color, and 
pheomelanin, which is a red-brown polymer of benzothiazine and benzothiazole. 
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Figure 1-10: UV-Vis absorption spectra of water, deoxyhaemoglobin (Hb), oxyhaemoglobin 
(HbO2), eumelanin, pheomelanin and a potential near-infrared photosensitizer indocyanine 
green (ICG). The shaded area indicates the “optical window”. The absorption coefficient data 
were obtained from http://omlc.ogi.edu/spectra/. (Note: the absorption coefficient of water 
has been multiplied by 105.) 
  As shown in Table 1-1, the absorption peaks of all the clinically approved 
photosensitizers are outside the “optical window”. The spectral mismatch between the 
photosensitizer absorption spectrum and the optimum wavelength for tissue penetration has 
hindered the widespread adoption of PDT into clinical practice, especially in the treatment of 
larger or thicker solid tumor masses. Hence, one approach to improve the clinical 
effectiveness of PDT is to develop new photosensitizers that are sensitive to light at near-
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infrared (NIR) wavelengths (52, 100, 132-136). Table 1-2 is a summary of new 
photosensitizers that are currently in clinical trials. 
Table 1-2: Photosensitizers in clinical trials. 
Photosensitizer Wavelength Description Type of diseases Country 
Rostaporfin 660 nm Tin ethyl etiopurpurin (SnEt2), Purlytin 
Skin, breast cancers, 
macular degeneration U.S. 
Talaporfin  660 nm 
Mono-(L)-
aspartylchlorin-e6 
(MACE, LS11, 
NPe6) 
Liver, colon, brain 
cancers U.S 
Fotolon 660 nm 
Chlorin e6-
polyvinypyrrolidone 
(Ce6-PVP) 
Malignancy of skin, 
mucosal malignancies 
of hollow organs 
Belarus, 
Russia 
Radachlorin 660 nm Ce6 derivatives Nasopharyngeal, sarcoma, brain cancers Russia 
Photodithazine 660 nm Ce6 derivatives Nasopharyngeal, sarcoma, brain cancers Russia 
Photochlor 665 nm 
2- (1-hexyloxyethyl)-
2-devinyl 
pyropheophorbide-a 
(HPPH) 
Head and neck, 
esophagus, lung 
cancers 
U.S. 
SiPcS 675 nm Silicon phthalocyanine 
Lymphoma, 
non-melanomatous, 
skin cancer, 
precancerous 
condition 
U.S. 
Lutex 732 nm Lutetium texaphyrin (motexafin lutetium) Breast cancer U.S. 
Padoporfin 762 nm 
Palladium 
bacteriochlorophyll 
derivative 
(TOOKAD, WST09) 
Prostate cancer U.S. 
 In this thesis project, we have investigated the potential of increasing the treatment 
depth of PDT through three different approaches, namely two-photon activated PDT, 
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combination of NIR light activated PDT with chemotherapy, and bioluminescence-activated 
PDT, which will be discussed in the following sections. 
1.6 Two-photon activated PDT 
Two-photon excitation (TPE) is a non-linear optical process originally predicted by the 
Nobel Laureate Maria Goeppert-Mayer in the 1930s (137). In a TPE process, a molecule 
absorbs two photons simultaneously leading to the formation of an excited state molecule 
with energy equal to the total energy of the two incident photons. In other words, in a TPE 
process, photons with half the energy (i.e. longer wavelength) required for one-photon 
excitation (OPE) can promote the molecule to the same energy state as that reached in a OPE 
process. In confocal fluorescence microscopy, the concept of TPE has been used successfully 
since 1990 (138-140). Possible applications of TPE in PDT have also been explored over the 
past two decades (141-152). Two-photon activated PDT, denoted here as 2-γ PDT, has 
several potential advantages over conventional one-photon activated PDT (1-γ PDT) using 
(quasi) continuous-wave (CW) illumination, including greater treatment depth in tissue (149, 
152), minimized side effects, and improved spatial targeting (148). 
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Figure 1-11: Jablonski diagram illustrating the one-photon and two-photon excitation 
processes. (S0: ground state; S1: the first excited singlet state; V: the virtual energy state.) 
 However, clinical applications of 2-γ PDT have been limited due to the low 2-γ 
absorption cross sections (σ in Goeppert-Mayer units; 1 GM = 10-50 cm4 s photon-1) of 
conventional PDT photosensitizers. The values of σ for the commonly used 1-γ 
photosensitizers, including Photofrin®, Visudyne® and protoporphyrin IX, range from 2 GM 
to 60 GM (144). Khurana et al. found that, at a peak irradiance of 1.75×1011 W cm-2, the light 
doses required to kill 50% of cells (LD50) through 2-γ activation of Photofrin® (σ = 10 GM at 
800 nm) and Visudyne® (σ = 51 GM at 900 nm) were more than 100 times higher than those 
required for 1-γ PDT treatment (147). Therefore, novel photosensitizers with much higher σ 
values (up to about 17,000 GM) have been synthesized and their photodynamic properties 
have been explored (134, 148-152). For example, in vivo experiments performed by Collins 
et al. demonstrated that a conjugated porphyrin dimer (P2C2-NMeI) could induce single 
blood-vessel closure through a TPE mechanism when activated by a 300 femtosecond (fs) 
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laser beam centered at 920 nm (148). Spangler et al. successfully synthesized a new 2-γ PDT 
triad, which showed effective treatment up to about 2 cm depth in animal experiments (149, 
152). These promising initial results indicate that 2-γ PDT can potentially enable minimally-
invasive treatment of deeper and larger tumors than those treated with conventional 1-γ PDT. 
1.7 Combination of NIR-PDT with chemotherapy 
Thanks to the advances in cancer research, we are becoming more and more aware that 
cancer is not a single disease but a heterogeneous population of cells, which may be grouped 
into more than one hundred diseases. Many cancers traditionally thought as a single disease 
should actually be separated into several subcategories. This understanding helps explain 
why many of the commonly occurring cancers, including breast, lung and ovarian cancers, 
are initially responsive to conventional chemotherapy and radiotherapy, but become resistant 
to the treatment after a while. There are several mechanisms that a cancer cell may be 
resistance to chemotherapy (153-159), which can either be intrinsic or acquired. Intrinsic 
resistance involves the existence of cancer cells that are resistant before receiving the 
treatment, while cancer cells that are initially sensitive may develop resistance during the 
treatment process. At the molecular level, a variety of mechanisms have been proposed to be 
responsible for drug resistance (159). For example, the multi-drug resistance proteins (MRP), 
which belong to the family of ATP-binding cassette (ABC) transporters, can bind to a wide 
range of chemotherapeutic drugs and transport the drug molecules outside the cell leading to 
a decreased intracellular concentration of the drug. Of relevance to this project, CDDP is a 
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substrate for the multi-drug resistance protein 2 (MRP2), also known as ATP-binding 
cassette sub-family C member 2 (ABCC2), while VP-16 has been found to be a substrate for 
multidrug resistance protein 1 (MDR1) or ATP-binding cassette sub-family B member 1 
(ABCB1), MRP1/ABCC1 and MRP2/ABCC2 (151). Some drugs rely on specific 
transporters to enter the cells. Mutations in these receptors may reduce the cellular uptake of 
those drugs. Many other factors, such as decreased drug activation, increased DNA damage 
repair, and increased inactivation of the drug or its toxic intermediates, may also increase the 
resistance to the treatment. Therefore, a permanent cure for many cancers would require a 
combination of two or more cancer therapies (8, 160). 
 Photodynamic therapy is a novel clinical approach, which uses the combination of light 
and light-activatable drugs to treat various types of tumors and some other non-malignant 
conditions (28-37). A few PDT drugs have been approved for clinical use (Table 1-1). 
However, these drugs are activated by visible light (630-690 nm), where light has a tissue 
penetration depth of only 2-4 millimeters (mm) (96, 161) and the resulting effective 
treatment depth is very limited. As have been discussed in Section 1.5.4, using NIR light for 
photosensitizer activation has the potential of treating deep-seated or large tumors. In 
addition, conventional PDT requires the presence of oxygen (Section 1.5), which makes PDT 
ineffective for the treatment of hypoxic solid tumors. Therefore, the combination of PDT, 
especially NIR-light activated PDT, with conventional chemotherapy may have the following 
properties and thus, overcome the limitations of the single therapies: 
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• Minimizing the side effects of chemotherapy: First, the combination treatment may 
produce an additive or even synergistic effect, so that the dose of the most toxic 
component may be reduced and therefore, lessening the severe side effects normally 
associated with the administration of chemotherapeutic drugs. Second, the use of light 
to activate the PDT drug allows local targeting of the treatment site and leads to 
reduced toxic effects on the surrounding normal tissues. 
• Having the potential of overcoming chemotherapy resistance: In general, cancer 
cells resistant to chemotherapy do not show cross-resistance to PDT treatment (162). 
In other words, cancer cells resistant to chemotherapeutic drugs may be sensitive to 
PDT treatment. Moreover, the combination treatment may produce synergistic 
effects, which have the potential of removing resistance to the drugs (9). 
• Having the potential of treating hypoxic solid tumors: The chemotherapeutic 
drugs may replace the requirement of oxygen in conventional PDT. Therefore, the 
combination therapy may be effective in treating hypoxic tumors. 
• Having the potential of treating tumor metastasis: While PDT alone is a local 
treatment, its combination with a systemically administered chemotherapeutic drug 
may be used to treat the primary and metastatic tumors at the same time. 
 Combination of PDT with CDDP 1.7.1
The combination effects of PDT with CDDP, one of the most widely used chemotherapeutic 
cancer drugs, has been studied by several research groups (163-167). In 1998, Canti et al. 
investigated the combination effects of CDDP with PDT, mediated by aluminium 
disulfonated phthalocyanine (AlPcS2), in murine tumor bearing mice and observed an 
additive effect (163). One year later, Duska et al. demonstrated that the combination of 
CDDP with photoimmunotherapy, using chlorin e6 conjugated to the murine monoclonal 
antibody OC-125 as the photosensitizer, enhanced the cytotoxicity of CDDP in a synergistic 
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manner in cisplatin-resistant ovarian cancer cells ex vivo (164). The combination of CDDP 
with Photofrin®-mediated PDT has been found to induce synergistic enhancement of 
cytotoxicity in mouse lymphoma L5178Y (LY) cells (168) and human non-small cell lung 
cancer H1299 cells (166). Interestingly, Crescenzi et al. found that the combination effect of 
low-dose CDDP with ICG-mediated PDT in MCF-7 breast cancer cells was synergistic 
according to the MTT assay results, but additive based on the data from the trypan blue assay 
(165). More recently, Compagnin et al. reported that they did not observe 
additive/synergistic effect in the oesophageal squamous carcinoma cells (KYSE-510) treated 
with the combination of low dose CDDP and Photofrin®-mediated PDT (167). Those results 
suggest that the combination effects may be dependent on many factors such as the drug/light 
dose, type of the photosensitizer, cell type, assay used to evaluate the cytotoxicity, etc.  
 Another approach, in which the photosensitizers are covalently linked with CDDP, has 
been explored by some research groups (169-173). Lottner et al. synthesized 35 new 
compounds, in which CDDP was combined with HpDs in the same molecule, and found that 
some of them showed enhanced cytotoxicity against the bladder cancer cell lines TCC-SUP 
and J82 (169). Mao et al. conjugated CDDP with the photosensitizer silicon(IV) 
phthalocyanine (SiPc) and evaluated the photocytotoxicity against human cervical cancer 
HeLa cells (170). This combination was shown to be able to maintain the intrinsic functions 
of each unit and serve as agents for both DNA-targeting PDT and red light activated 
photochemotherapy.  Bulgakov et al. recently synthesized covalently linked CDDP and 
octacarboxy substituted zinc phthalocyanine conjugates, which were found to be very 
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efficient in generating singlet oxygen with yields ~0.47-0.60 and showed higher activity 
against human laryngeal cancer (НEр2) and lung adenocarcinoma (A549) cells than the 
parent octacarboxy-substituted PcZn (171). The conjugates of hydroxy aluminium 
octacarboxy phthalocyanine and CDDP were found to have higher triplet and singlet oxygen 
quantum yields than the parent phthalocyanine, although their cytotoxicity was not studied 
(172). This approach of combining CDDP and a photosensitizer within the same molecule 
has the advantages of maintaining the functions of the single units and increasing the 
quantum yield of 1O2 due to the heavy atom effect and thus, may be more effective in killing 
cancer cells than the single treatments.  
 Combination of PDT with other chemotherapeutic drugs 1.7.2
The combination effects of PDT with conventional chemotherapeutic drugs other than 
CDDP, including VP-16, doxorubicin (Adriamycin), 5-fluoro-2’-deoxyuridine (5FdUr) and 
gemcitabine, have also been investigated extensively (174-179). Gantchev et al. investigated 
the interactions between VP-16 and PDT with aluminium tetrasulfonated phthalocyanine 
(AlPcS4) as the photosensitizer in human leukaemic K562 cells and observed synergistic 
enhancement of drug cytotoxicity (174). The combination effects of 5-fluoro-2’-deoxyuridine 
(5FdUr) and mTHPC-mediated PDT were studied in human breast (MCF-7) and human 
prostate (LNCaP) cancer cells by Zimmermann et al. (176). Depending on the protocol and 
concentration of 5FdUr, the combination treatment resulted in an additive/antagonistic effect 
in LNCaP cells but an additive/synergistic was observed in MCF-7 cells. The authors found 
 35 
 
that the combination treatment induced much stronger effects than expected in one patient 
with multiple basal cell carcinomas. In another study, Kirveliene et al. found that the degree 
of cytotoxicity enhancement induced by the combination treatment depends on whether the 
chemotherapeutic drug doxorubicin (Dox) was administrated 24 h prior to or immediately 
after light exposure of mTHPC-sensitized murine hepatoma MH-22A cells (177). Animal 
experiments have been performed by Xie et al., who observed significant enhancement of the 
antitumor activity of Photosan®-mediated PDT by low dose gemcitabine in human pancreatic 
cancer cell (SW1990) bearing mice (178). More recently, Diez et al. showed that the 
administration of low dose DOX or vincristine (VCR) increased the anticancer effect ALA-
mediated PDT in a sensitive murine leukemic cell line (LBR) but didn’t affect the 
cytotoxicity of ALA-PDT in the two resistant cell lines LBR-D160 and LBR-V160 (179). 
Again, those studies have demonstrated that the combination effects of PDT and 
conventional chemotherapy may be antagonistic, additive or synergistic depends on many 
factors.     
 In summary, numerous studies have reported the use of PDT in combination with 
conventional chemotherapy aiming to enhance the antitumor activity of single therapies. 
Additive/synergistic enhancement of cytotoxicity has been reported in some studies (163-
166, 168, 174, 176-179), but antagonistic effect has also been observed (167, 176, 179). 
Clearly, the combination effect has a strong dependence upon many factors, including the 
cell type, type of the PDT and chemotherapeutic drug, light dose, and treatment schedule, 
and a molecular mechanism underlying the observed synergistic enhancement of cytotoxicity 
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is still lacking. Therefore, a better understanding of drug interactions in the combination 
therapy is expected to be beneficial to the development of more effective treatment 
approaches. In the case of CDDP, its cytotoxicity is generally accepted to arise from the 
drug’s ability to bind with cellular DNA and induce DNA damages. Hydrolysis is the 
conventional mechanism of the initial action of CDDP (155, 156, 180, 181). Recently, our 
group has obtained the precise molecular mechanism of CDDP action by using femtosecond 
time resolved laser spectroscopy (fs-TRLS) (182, 183). It was found that the dissociative 
electron-transfer (DET) of CDDP with the guanine base, which is most likely to donate an 
electron among the four DNA bases, is responsible for the activation of CDDP. This DET 
mechanism of CDDP has been confirmed both experimentally by Kopyra et al. (184) in 
studying dissociative attachments of nearly zero eV (electron volt) electrons to gas-phase 
CDDP and theoretically by Kuduk-Jaworska et al. (185) in their quantum chemical studies of 
the reaction of epre− with aqueous CDDP. This new mechanistic insight has the potential to 
improve existing therapies using CDDP and enable the development of novel combination 
treatments for challenging cancers. Based on this mechanism, we have developed a novel 
combination therapy, in which a biological electron donor (TMPD; N,N,N′,N′-tetramethyl-p-
phenylenediamine) has been demonstrated to enhance the cytotoxicity of CDDP in a 
synergistic manner and overcome cisplatin-resistance in the human lung A549 and ovarian 
NIH:OVCAR-3 cancer cells (9). These studies show the promise of applying the molecular 
mechanistic understanding of action of drugs to develop novel combination therapies and 
improve the therapeutic efficacy.  
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 Indocyanine green as a potential NIR photosensitizer 1.7.3
Indocyanine green (ICG) is a NIR dye that was approved by FDA in 1956. It has been 
successfully used in various medical applications such as blood volume determination (186), 
cardiac output measurement (187), fluorescence probing of proteins (188), and 
pharmacokinetic analysis (189). The UV-Vis absorption spectrum of ICG in plasma has a 
maximum near 800 nm (Figure 1-10), which falls right into the tissue “optical window” for 
PDT. Therefore, this dye has been considered to be a potential sensitizer for PDT 
applications and its photodynamic efficacy has also been explored (108, 165, 190-201). The 
involvement of 1O2 has been suggested based on the observation that the cell killing effect 
could be inhibited by the 1O2 quencher sodium azide (190, 192), although direct detection of 
1O2 luminescence at 1270 nm was not successful. However, ICG has several intrinsic 
properties, including short blood half-life (2 to 4 minutes (202)), poor photo- and thermal-
stability, non-specific binding with proteins, and vulnerablility to aggregation (203), which 
have limited its application as a photosensitizer and medical imaging probe. One potential 
way of increasing the effectiveness of ICG as a PDT agent is to combine this treatment with 
conventional chemotherapy. Indeed, the combination of ICG-mediated PDT with low-dose 
CDDP induced a synergistic effect in MCF-7 cells, although the combination effect was 
found to be additive according to the trypan blue assay results (165). As has been discussed 
in Sections 1.7.1 and 1.7.2, the combination effect is dependent on a variety of factors. 
Investigation of the combination effects of ICG-mediated PDT with other chemotherapy 
drugs may provide us with a better understanding of the mechanism of drug interactions 
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during the treatment process and thus, helps the development of more effective combinations 
of PDT and chemotherapy. 
 Encapsulation of ICG within micelles and nanoparticles has also been explored 
extensively over the past decade to overcome the above mentioned limitations of ICG (102, 
106, 107, 109, 111-113, 115-118, 201). These encapsulating approaches were demonstrated 
to be able to improve various properties of ICG such as photo- and thermal-stability, 
fluorescence quantum yield, and blood half-life. By using tumor-targeting ligands, these 
systems could further improve the tumor-specificity of the dye (112, 113, 115, 117). 
However, only two of those systems were investigated for photodynamic killing of cancer 
cells. ICG-conjugated gold nanorods were found to be able to increase the yield of 1O2 and 
serve simultaneously as PDT and photothermal therapy (PTT) agents (111). The ICG-ormosil 
nanoparticles showed a similar level of cytotoxicity as that induced by free ICG, while 
having improved aqueous stability (201). Therefore, further experiments will be necessary to 
assess the PDT efficacy of those novel drug systems. Considering the improved stability and 
tumor-specificity of those systems, combination treatments of chemotherapy and PDT using 
those novel systems as the photosensitizers may offer great therapeutic potentials. 
1.8 Bioluminescence-activated PDT 
Bioluminescence is a type of chemiluminescence that takes place inside a living organism 
where the energy of a chemical reaction is released in the form of light emission. Fireflies are 
one of the most famous examples of bioluminescent organisms. Bioluminescence has been 
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widely used in detection and imaging applications (204-208). The fact that no external 
excitation source is required offers the advantage of eliminating any possible background 
noise associated with scattered light and autofluorescent light. The idea of using 
bioluminescence as an internal light source for PDT has been tested by several research 
groups over the past two decades (104, 209-212). It has the potential of overcoming the 
limitation of tissue penetration depth of external light. There are three bioluminescent 
systems that have been investigated for PDT applications: 
• Coelenterazine-luciferase: Coelenterazine is the substrate for many luciferases and 
the light-emitting molecule in many marine invertebrates such as the luminescent 
Aequorea jellyfish. It can emit blue light with a maximum around 458 nm in the 
presence of luciferase, oxygen and calcium. 
 
 
  Figure 1-12: Mechanism of light generation by coelenterazine. 
• Luminol: Luminol can undergo a blue light-emitting process (λmax = 425 nm (213)) 
when mixed with an oxidizing agent such as hydrogen peroxide (H2O2). The reaction 
can be catalyzed by enzymes such as horseradish peroxidase and metal ions (e.g. 
cations of iron and copper). 
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  Figure 1-13: Mechanism of light generation by luminol. 
• Firefly luciferin-luciferase: Firefly luciferin is the light-emitting compound present in 
many firefly species. It can emit yellow light catalyzed by luciferase (EC 1.13.12.7) 
in the presence of Mg2+. 
 
  Figure 1-14: Mechanism of light generation by firefly luciferin. 
In 1994, Carpenter et al. studied the antiviral activity of hypericin activated by the 
bioluminescence of luciferin (209). Almost ten years later, Theodossiou et al. studied the in 
vitro photodynamic activity of Rose Bengal activated by firefly luciferin in luciferase-
transfected mouse embryonic fibroblast (NIH 3T3) cells (210). In contrast, Schipper et al. 
evaluated the photodynamic cytotoxicity of firefly luciferase bioluminescence in several 
malignant and nonmalignant cell lines, including MCF-7, NIH 3T3, 3T3L1 (derived from 
mouse 3T3 cells), CHO (Chinese hamster ovary cells), 293T (a highly transfectable 
derivative of human embryonic kidney 293 cells), and A375M (human melanoma cells) 
(211). They concluded that bioluminescence of firefly luciferase didn’t generate enough light 
to induce hypericin or Rose Bengal photocytotoxicity. However, the study performed by 
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Laptev et al. demonstrated that bioluminescence of luminol could activate bioconjugates 
composed of transferrin (Tf) and Hp and induce significant cell killing in leukaemia K562 
and U-76 cells  (104). Recently, Chen et al. found that bioluminescence of luminol could 
effectively activate 5-ALA-mediated PDT in a human epithelial colorectal adenocarcinoma 
cell line (Caco-2) (214). In the same year, Yuan et al. reported their studies of the anticancer 
and antimicrobial activity of a new bioluminescence system consists of luminol and a 
cationic oligo(p-phenylene vinylene) as the photosensitizer (215). Positive results were 
obtained by Hsu et al., who developed a system containing luciferase-immobilized quantum 
dots for bioluminescent activation of Foscan®-loaded micelles and this system was found to 
be sufficient to induce tumor cell killing in vitro and delay tumor growth in vivo (212). These 
results suggest the potential of using bioluminescence as the internal light source for 
photodynamic treatment of human cancers, with an increased treatment depth compared with 
conventional PDT.  
1.9 PDT dosimetry 
Fluence or radiant exposure represents the amount of energy measured in Joules (J) per unit 
area (i.e. J cm-2). The typical values in conventional PDT are 25-500 J cm-2 for surface 
treatment and 100-400 J cm-2 for interstitial applications (52). 
Penetration depth (δ) refers to the depth at which the light intensity has dropped to 1/e 
(=0.37) of the initial intensity. The penetration depth is not the same as the depth of PDT 
treatment (dt), which depends on a number of factors including the type of the photosensitizer 
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and its mechanism of action, the level of tissue oxygenation, and light dose. Most clinically 
approved photosensitizers have dt values in the range 3-5δ (34). 
Power (P) represents the amount of energy delivered per unit time measured in Watts (W): 1 
W = 1 J s-1. 
Power density or irradiance is the power of electromagnetic radiation per unit area incident 
on a surface measured in W cm-2. The maximum allowed values in conventional PDT are 200 
and 400 mW cm-2 for surface and interstitial treatments, respectively (52). 
1.10 Scope of the thesis 
In Chapter 2, we describe the experimental techniques, namely femtosecond (fs) time-
resolved laser spectroscopy (fs-TRLS) and steady-state spectroscopy, which have been 
applied to characterize the photophysical properties of the potential anticancer drugs 
investigated in the present work. In Chapter 3, we present the results of in vitro cytotoxicity 
studies of a 2nd-generation photosensitizer pyropheophorbide a methyl ester (MPPa) 
activated through one- and two-photon excitation in human cervical (HeLa), lung (A549) and 
ovarian (NIH:OVCAR-3) cancer cell lines. Photophysical properties of MPPa have also been 
investigated by using fs-TRLS and steady-state spectroscopy. The results of the combination 
therapy of PDT mediated by the near-infrared (NIR) dye, indocyanine green (ICG), with two 
types of chemotherapy drugs, namely the type II topoisomerase (TOPII) inhibitors VP-16 
and VM-26, and the platinum-based drugs cisplatin (CDDP) and oxaliplatin (OXP), are 
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presented in Chapter 4 and 5, respectively. The possibility of using bioluminescence of 
luminol as an internal light source for PDT has also been explored and the results are 
presented in Chapter 6. Chapter 7 is a summary of all the key results of this project and 
discussion of future works. 
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2 Experimental Techniques and Theory 
In this project, we have applied both femtosecond time-resolved laser spectroscopy (fs-
TRLS) pioneered by the Nobel Laureate Prof. Ahmed H. Zewail (216) at the California 
Institute of Technology and steady-state spectroscopy to characterize the photophysical 
properties of the compounds used in this study. In our group, the fs-TRLS techniques have 
been successfully applied to study the ultrafast dynamics of a variety of systems. Those 
studies have greatly deepened our understanding of the molecular mechanisms of action of 
drugs used in chemo-, radio- and photodynamic therapy of cancers (19, 20, 182, 183, 217-
221). 
2.1 Femtosecond time-resolved pump-probe transient 
absorption spectroscopy 
The standard methodology for fs time-resolved pump-probe transient absorption 
spectroscopy has been applied (182, 183, 217, 219-223). Figure 2-1 shows a schematic 
representation of the experimental setup and the basic principle of fs time-resolved pump-
probe transient absorption spectroscopy.  
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Figure 2-1: Schematic diagram of the experimental setup for femtosecond time-resolved 
pump-probe transient absorption spectroscopy. (BS: beam splitter; fs: femtosecond; L: lens; 
M: mirror; OPA: optical parametric amplifier). 
 We use a Spectra-Physics Ti:sapphire laser system producing 800 nm laser pulses with 
duration of 100-120 fs, an average energy of 1 mJ, and a repetition rate of 1 kHz. In order to 
achieve a fs time-resolution, two fs laser pulses are required: one, the “pump” pulse, is 
applied to initiate a reaction, for example, to promote a sample molecule to an excited state 
or to generate a reacting species, while the “probe” pulse is used to monitor the evolution and 
decay of a specific reaction intermediate, such as an excited-state molecule. We used two 
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optical parametric amplifiers (OPA), which can produce laser pulses with wavelengths from 
~266 nm to a few micrometers, to generate the pump and probe pulses, respectively. To 
avoid polarization anisotropy, the polarization of the pump pulse is set to be at the magic 
angle of 54.7˚ with respect to the probe pulse. 
 Correct measurement of intensity requires the measured intensity (I = I║ cos2θ + I┴ 
sin2θ, where I║ and I┴ are the intensities parallel and perpendicular to the polarization of the 
pump pulse, respectively, and θ is the angle between the polarization of the pump and probe 
pulses) to be proportional to the total intensity (Itotal = I║ + 2I┴), regardless of the polarization 
degree of the sample (224). Therefore, the value of θ should satisfy the equation 3 cos2θ = 1 
yielding θ = 54.7˚. The use of the magic angle condition is especially important for 
measuring decay kinetic traces due to the fact that I║ and I┴ usually have distinctly different 
kinetics (224). The time delay between the pump pulse and the probe pulse is varied by 
moving a microstepping motor stage, which can change the optical path difference (OPD) 
between these two pulses. For example, an OPD of 1 µm corresponds to a time difference of 
3.3 fs. Therefore, a fs time resolution can be achieved. If the reaction intermediates have 
distinctly different absorption spectra, the behavior of each reaction intermediate may be 
monitored by choosing a probe wavelength that matches the absorption spectrum of each 
species. Labview (Laboratory Virtual Instrument Engineering Workbench; National 
Instruments, Austin, TX, USA) programs are used to control the motion of the microstepping 
motor stage and collection of data from a gated integrator and Boxcar averager system. 
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2.2 Femtosecond time-resolved pump-probe transient 
fluorescence spectroscopy 
In fluorescence spectroscopy, a fs time resolution can be achieved by using the sum 
frequency generation (SFG) technique (225), which is also known as fluorescence 
upconversion. Figure 2-2 shows schematically the experimental setup. The same laser system 
as that described in Section 2.1 is used. The pump pulse is used to excite the molecules to an 
excited state and thus, generate fluorescence emission. The fluorescent light is then collected 
by using two parabolic mirrors and focused onto a BBO (barium borate) crystal. The probe 
pulse is focused on to the same BBO crystal to mix with the fluorescent light. Sum frequency 
generation at the BBO crystal obeys the energy and momentum conservation laws: 
        Energy Conservation:                      ℎ𝑣1 + ℎ𝑣2 = ℎ𝑣3;                                             (2-1) 
          Momentum Conservation:                 ℏ𝑘1����⃗ + ℏ𝑘2����⃗ = ℏ𝑘3����⃗ ,                                            (2-2) 
where h is the Planck's constant, v is the frequency of the photon, ℏ is the reduced Planck 
constant, and 𝑘�⃗  is the wave vector.\\\ 
 According to Equation (2-1), the up-converted photon has an energy that equals the 
sum of the energies of the two incident photons. In other words, the up-converted 
fluorescence light is at a shorter wavelength than the fluorescence of the sample. The 
momentum conservation law requires the BBO crystal to be set at a specific angle and 
orientation in order to obtain the maximum un-converted fluorescence signal. This is also 
known as the phase matching condition. The up-converted fluorescence light is then focused 
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into the entrance slit of a CM112 Compact 1/8 Meter Double Monochromator (Spectral 
Products, Connecticut, USA) coupled with an AD111 Photobyte-P™ Photomultiplier 
Detection System (Spectral Products, Connecticut, USA). Wavelength selection, pump-probe 
time delay and data acquisition are controlled by Labview programs. 
 
Figure 2-2: Schematic diagram of the experimental setup for femtosecond time-resolved 
pump-probe transient fluorescence spectroscopy. (BBO: barium borate; BS: beam splitter; fs: 
femtosecond; L: lens; M: mirror; OPA: optical parametric amplifier; PM: parabolic mirror; 
PMT: photomultiplier tube). 
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2.3 Steady-state fluorescence spectroscopy 
Figure 2-3 is a schematic representation of the experimental setup for one- and two-photon 
induced steady-state fluorescence spectroscopy. The same laser system as that used in fs 
time-resolved absorption and fluorescence spectroscopy is used as the excitation source. The 
excitation wavelength can be tuned by an OPA coupled with a series of colored filters. The 
excitation power can be adjusted by a series of neutral density filters. The laser beam is 
focused vertically into a 5 mm quartz cuvette using a biconvex lens with a focal length of 
75.6 mm. The fluorescence signal that transmitted through the side of the cuvette is focused 
by two parabolic mirrors into the entrance slit of the monochromator. The monochromator 
and photomultiplier tube (PMT) are controlled by Labview programs. A gated integrator and 
Boxcar averager system is used to obtain the fluorescence intensity. 
 
Figure 2-3: Schematic diagram of the experimental setup for steady-state fluorescence 
spectroscopy. (fs: femtosecond; L: lens; M: mirror; ND: neutral density; OPA: optical 
parametric amplifier; PM: parabolic mirror; PMT: photon multiplier tube). 
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 The fluorescence spectra obtained with this homemade fluorescence spectrophotometer 
have been corrected for collection efficiency of the detection system, which can be calculated 
by using the efficiency data of the gratings inside the monochromator and the PMT provided 
by the manufacturer. In order to determine the accuracy of this correction, we have compared 
the corrected one-photon induced fluorescence spectrum of 5 µM ZnPcS4 in methanol with 
that measured on a commercial fluorescence spectrophotometer (Varian Cary Eclipse, Palo 
Alto, CA, USA) (Figure 2-4). The two fluorescence spectra overlap with each other. 
Therefore, all the fluorescence spectra obtained from our homemade fluorescence 
spectrophotometer have been corrected using the same collection efficiency as used here. 
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Figure 2-4: One-photon induced fluorescence spectra of 5 µM ZnPcS4 in methanol measured 
on a commercial (red solid line) and a homemade (blue open circles) fluorescence 
spectrophotometer. The excitation wavelength was 400 nm. 
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2.4 One-photon and two-photon excitation induced 
fluorescence 
One-photon excitation (OPE) is a linear process in which light attenuation is defined by Beer 
Lambert’s law: 
                                                              𝑑𝐼
𝑑𝑥
= −𝛼𝑐𝐼,                                                          (2-3)    
                                                           𝐼(𝑥) = 𝐼0𝑒−𝛼𝑐𝑥 ,                                                              (2-4) 
 
where I0 and I are the incident and transmitted light intensity, respectively, x is the light path 
length, c is the concentration of the sample, and α  is the one-photon absorption cross section.  
Two-photon excitation (TPE) is a non-linear optical process that involves 
simultaneous absorption of two photons by the same molecule (137). The attenuation of light 
by two-photon absorption can be calculated using the following equations: 
                                                                𝑑𝐼
𝑑𝑥
= −𝜎𝑐𝐼2,                                                        (2-5) 
                                                               𝐼(𝑥) = 𝐼0
1+𝜎𝑐𝐼0𝑥
 ,                                                    (2-6) 
 
where I0 and I are the incident and transmitted light intensity, respectively, x is the light path 
length, c is the concentration of the sample, and σ is the two-photon absorption cross section 
in Goeppert-Mayer (GM) units (1 GM = 10−50 cm4 s photon−1). 
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 Measurement of two-photon absorption cross section 2.4.1
The two-photon absorption cross section (σ) of a molecule can be determined by using the 
following equation (226): 
                                                             𝜎𝑠 = Σ𝐹(𝑠)·𝛷𝐹(𝑟)Σ𝐹(𝑟)·𝛷𝐹(𝑠) · 𝜎𝑟,                                                     (2-7) 
 
where the subscripts r and s denote the reference and the sample, respectively, ΣF is the 
integrated intensity of the two-photon induced fluorescence, and ΦF is the fluorescence 
quantum yield, which is assumed to be the same under one- and two-photon excitation. To 
test this assumption, we have measured the one- and two-photon induced fluorescence 
spectra of the two photosensitizers pyropheophorbide a methyl ester (MPPa) and Zn(II) 
phthalocyanine tetrasulfonic acid (ZnPcS4) using our homemade fluorometer. The spectra of 
50 µM MPPa and ZnPcS4 in methanol have been measured with excitation wavelengths of 
400 and 800 nm (Figure 2-5). For both compounds, the one- and two-photon induced 
fluorescence spectra overlap with each other. Therefore, two-photon absorption cross section 
of MPPa can be determined by using Equation (2-7) and ZnPcS4 as the standard. 
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Figure 2-5: One- and two-photon induced fluorescence spectra of (A) 50 µM MPPa and (B) 
50 µM ZnPcS4 in methanol measured on a homemade fluorescence spectrophotometer. The 
excitation wavelength was 400 nm (red solid line) and 800 nm (blue open circle), 
respectively. 
 Measurement of fluorescence quantum yield 2.4.2
The fluorescence quantum yield ΦF can be determined by using a standard reference with a 
known ΦF following the equation below (52): 
                                                             𝛷𝐹(𝑠) = 𝛷𝐹(𝑟) · 𝐺𝑟𝑎𝑑𝑠𝐺𝑟𝑎𝑑𝑟 · 𝑛𝑠2𝑛𝑟2 ,                                          (2-8) 
 
where the subscripts r and s denote the reference and the sample, respectively, ΦF is the 
fluorescence quantum yield, Grad is the gradient from the plot of integrated fluorescence 
intensity versus absorbance, and n is the refractive index of the solvent. 
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3.1 Background 
Photodynamic therapy (PDT) has emerged as a novel clinical approach that involves the 
administration of a photo-activatable compound (photosensitizer) and subsequent exposure 
of the target diseased tissue to light (including laser sources) for the treatment of various 
tumors and other non-malignant conditions (28-37). PDT has potential advantages over 
surgery and other therapies of being minimally invasive, with local targeting, and having few 
systemic side effects. The therapeutic effects of PDT are believed to be caused by cytotoxic 
reactive oxygen species (ROS), including singlet oxygen (1O2), superoxide anion radical   
(O2-∙), hydroxyl radical (OH∙) and hydrogen peroxide (H2O2), generated from reactions 
between the excited triplet state photosensitizer and biological molecules such as O2 and 
water (H2O).  
 Over the past decades, a few photosensitizers have been approved for clinical use 
(Table 1-1) (28-37). Among these, Photofrin® is the first one approved by the U.S. Food and 
Drug Administration (FDA) and continues to be the most widely used PDT drug. However, it 
has several drawbacks. First, Photofrin® is not a pure compound but a mixture of several 
monomeric and oligomeric non-metallic porphyrins. Second, it’s absorption in the optical 
window for PDT is very low leading to a limited effective treatment depth of this drug. The 
penetration depth of light into tissue depends strongly on the wavelength. In particular, there 
is an “optical window” for PDT between 700 and 950 nm, where the absorbance of light by 
biological molecules is relatively low (96). Below about 700 nm endogenous chromophores, 
particularly haemoglobin/oxyhaemoglobin and melanin, are highly absorbing, while above 
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about 900 nm absorption by water becomes dominant (96, 131). The use of near-infrared 
(NIR) light, which can penetrate deeper into tissues, to activate the photosensitizers has the 
potential of improving the treatment efficiency of PDT (52, 134, 135). Moreover, Photofrin® 
accumulates in the skin and remains there for up to six weeks (99) leaving the patients very 
sensitive to sun light and strong room light after the treatment. Several second-generation 
photosensitizers, including δ-aminolevulinic acid, also known as 5-aminolevulinic acid 
(ALA; Levulan®), the methyl ester of ALA (Metvix®), a benzoporphyrin derivative Visudyne 
(Verteporfin®), tetra(m-hydroxyphenyl)chlorin (mTHPC; temoporfin; Foscan®), and a 
chlorophyll derivative mono-(L)-aspartylchlorin-e6 (MACE, LS11, NPe6, Talaporfin; 
Aptocine™) have been approved either worldwide or in some countries for treating cancers. 
Compared with the first-generation photosensitizers, these second-generation 
photosensitizers are chemically pure, highly efficient, and cause much less skin 
photosensitivity.  
 Pyropheophorbide-a methyl ester (MPPa, also known as PPME), a semi-synthetic 
molecule derived from chlorophyll a, is one of a number of emerging second-generation PDT 
agents (129, 227-234). Compared with the FDA-approved photosensitizer Photofrin®, MPPa 
has a much stronger absorption in the red part of the visible spectrum: its molar extinction 
coefficient ε = 47,500 M-l cm-l at λ = 667 nm (229) is about 15 times that of Photofrin® with 
ε = 3,200 M-l cm-l at λ = 630 nm (144). Of particular relevance here, MPPa has a very strong 
absorption peak around 400 nm, nearly double that at 667 nm, as shown in Figure 3-7. 
However, no previous studies have examined the effectiveness of PDT with MPPa via two-
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photon (2-γ) excitation at 800 nm, although its one-photon (1-γ) PDT efficacy has been 
studied in a number of cancer cell lines in vitro (129, 227-234). Two-photon excitation 
(TPE), originally predicted by the Nobel Laureate Maria Goeppert-Mayer in the 1930s (137), 
is a non-linear optical process in which a molecule is promoted to an excited state by 
simultaneous absorption of two photons. This concept has been successfully applied in 
confocal fluorescence microcopy for more than two decades (138-140). Two-photon 
activated photodynamic therapy, denoted here as 2-γ PDT, has also been explored since 1990 
(141, 142, 144-148, 151, 152) and has several potential advantages over conventional 1-γ 
PDT using (quasi) continuous-wave (CW) illumination. First, there is experimental evidence 
in vivo that 2-γ PDT can treat to greater depths in tissue (152) by using NIR light, although a 
rigorous quantitative understanding of this has not been reported. Second, reduced interaction 
of NIR light with tissues leads to higher differential excitation of the photosensitizer and so, 
in principle, minimizes the side effects and allows higher light doses to be administered. 
Third, due to the non-linear nature of 2-γ excitation, activation of the photosensitizer is 
confined to the region of highest light intensity (the basis of 2-γ confocal fluorescence 
microscopy), which further improves 3D control of the spatial localization of treatment. This 
has been demonstrated in the use of 2-γ PDT to target single blood vessels in preclinical 
models (148). However, the utility of 2-γ PDT has been limited by the low 2-γ absorption 
cross section (σ) of currently used photosensitizers. For example, at a peak irradiance of 
1.75×1011 W cm-2, the light doses required to kill 50% of cells (LD50) of two clinically-
approved photosensitizers, Photofrin® with a 2-γ absorption cross section σ = 10 in Goeppert-
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Mayer (GM) units (1 GM = 10-50 cm4 s photon-1) at 800 nm and Visudyne® with σ = 51 GM 
at 900 nm, have been found to be 11,300 J cm-2 and 1,700 J cm-2, respectively (147), which 
are about 2 orders of magnitude higher than those required for 1-γ PDT of the same 
compounds. Several novel photosensitizers designed explicitly to have much higher σ values 
(up to about 17,000 GM) have been synthesized (134, 146, 148, 150-152, 235-242) and some 
of them have been explored for PDT applications, with promising initial results. For 
example, in vivo experiments by Collins et al. have demonstrated single blood-vessel closure 
by 2-γ PDT using a conjugated porphyrin dimer activated by a 300 femtosecond (fs) laser 
beam at 920 nm (148), while Spangler et al. have showed effective treatment up to about 2 
cm depth in tumor tissue in vivo using a new 2-γ PDT triad (149, 152, 237). These positive 
initial findings have inspired further investigation of 2-γ PDT, including the present work. 
 In the present study, we have evaluated the 1-γ and 2-γ PDT efficacy of MPPa in 
cisplatin-sensitive human cervical (HeLa) and cisplatin-resistant lung (A549) and ovarian 
(NIH:OVCAR-3) cancer cells in vitro. While 1-γ PDT experiments were performed by using 
a 674 nm laser, 2-γ PDT cytotoxicity of MPPa was activated at the optimal tissue-penetrating 
NIR wavelength of 800 nm. We have also measured the steady-state fluorescence spectra of 
MPPa under both 1-γ and 2-γ excitation and determined its fluorescence quantum yield and 
2-γ absorption cross section. Finally, we have measured the excited singlet state lifetime of 
MPPa by performing femtosecond (fs) time-resolved transient absorption spectroscopic 
measurements.  
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Figure 3-1: Chemical structures of chlorophyll a and pyropheophorbide a methyl ester 
(MPPa).  
3.2 Materials and methods 
 Chemicals and cell lines 3.2.1
Pyropheophorbide-a methyl ester (MPPa; C34H36N4O3; MW = 548.7 g mol-1; 95% of purity) 
and Zn(II) phthalocyanine tetrasulfonic acid (ZnPcS4; C32H16N8O12S4Zn;                          
MW = 898.19 g mol-1) purchased from Frontier Scientific Inc. (Logan, UT, USA) were used 
without any further purification. A stock solution of 2.5 millimolar (mM) MPPa was made in 
acetone and then stored in the dark at -20˚C. A stock solution of 5 mM ZnPcS4 was made in 
ultrapure water with a resistivity of >18 MΩ/cm obtained from a Barnstead Nanopure 
(Thermo Scientific, Dubuque, IA, USA) water system and stored in the dark at 4˚C. 
Penicillin-streptomycin antibiotics (PS), minimum essential medium Eagle (MEM), nutrient 
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mixture F12 Ham Kaighn’s modification (F12K), RPMI-1640 Medium, and trypsin-EDTA 
(0.5 g L-1 porcine trypsin and 0.2 g L-1 EDTA∙4Na in Hank’s Balanced Salt Solution with 
phenol red) were purchased from Sigma-Aldrich (Sigma-Aldrich Canada Ltd., Oakville, ON, 
Canada) and fetal bovine serum (FBS) from Hyclone Laboratories (Logan, UT, USA). The 
HeLa (ATCC#: CCL-2™), A549 (ATCC#: CCL-185™) and NIH:OVCAR-3 (ATCC#: 
HTB-161™) cell lines were obtained from the American Type Culture Collection (ATCC, 
Manassas, VA, USA). HeLa cells were cultivated in MEM supplemented with 10% FBS,  
100 units mL-1 penicillin G and 100 µg mL-1 streptomycin. A549 cells were cultivated in 
F12K supplemented with 10% FBS, 100 units mL-1 penicillin G and 100 µg mL-1 
streptomycin. The complete growth medium for NIH:OVCAR-3 cells was RPMI-1640 
medium supplemented with 20% FBS, 100 units mL-1 penicillin G, 100 µg mL-1 
streptomycin and 0.01 mg mL-1 bovine insulin. The cell culture was kept at 37˚C in a 
humidified atmosphere containing 5% CO2.  
 Subcellular localization 3.2.2
Exponentially growing HeLa, A549 and NIH:OVCAR-3 cells were seeded in 96-well 
microplates at densities of 3×103, 3×103 and 4×103 cells/well, respectively. After overnight 
incubation, the cells were incubated with 5 µM MPPa for 24 h in the dark. For the last         
30 min of incubation, Hoechst 33342 was added for nuclear staining at a final concentration 
of 1 µg mL-1. After incubation, the cells were washed twice with phosphate-buffered saline 
(PBS) and fixed with 4% paraformaldehyde. The images were taken on a Nikon Eclipse 
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TS100/TS100-F microscope with filter sets of Ex/Em of BP510-560/LP590 nm and     
BP330-380/LP420 nm for MPPa and Hoechst 33342, respectively. 
 Laser treatment conditions 3.2.3
One-photon laser irradiation was carried out by using a 674 nm laser with a pulse duration of 
120 fs and a pulse repetition rate of 500 Hz. The average irradiance and corresponding peak 
irradiance were 1 mW cm-2 and 1.57×107 W cm-2, respectively. Cells were exposed for 
different times to vary the total light dose (J cm-2). 
 Two-photon laser irradiation was carried out by using an 800 nm laser with a pulse 
duration of 120 fs and a pulse repetition rate of 1 kHz. The peak irradiance was          
3.9×1010 W cm-2. The laser spot size was ~0.12 cm2, which illuminated the entire cell 
monolayer in each of the 384 microplate wells uniformly. Cells were exposed for different 
periods of time (0 - 5 min) to achieve different light doses (J cm-2). 
 One-photon PDT treatment 3.2.4
Exponentially growing HeLa, A549 and NIH:OVCAR-3 cells were seeded in 96-well 
microplates at densities of 5×103, 5×103 and 7×103 cells/well, respectively. After overnight 
incubation, cells were incubated with various concentrations of MPPa for 18 h in the dark. 
Cells were then washed twice with PBS and fresh complete culture medium was added 
before irradiation. The irradiated cells were then kept in the incubator for 48 h and cell 
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viability was evaluated by the MTT assay, a widely used colorimetric technique that 
measures cell viability (see below). 
 Apoptosis was assessed by Hoechst 33342 staining, for which HeLa cells were seeded 
in 96-well microplates at a density of 3×103 cells/well. After overnight incubation, the cells 
were incubated with 10 µM MPPa, light-irradiated at 0.04 J cm-2 and incubated for 24 h. For 
the final 30 min of incubation, Hoechst 33342 was added for nuclear staining at a final 
concentration of 1 µg mL-1. After incubation, the cells were washed twice with PBS and 
fixed with 4% paraformaldehyde. Images were taken on a Nikon Eclipse TS100/TS100-F 
microscope with a filter set of Ex/Em of BP330-380/LP420 nm. 
 Two-photon PDT treatment 3.2.5
Cells were grown and incubated in MPPa as for the 1-γ treatments. Photocytotoxicity was 
measured by using the MTT assay at 48 or 72 h post treatment. 
 The cellular morphology changes were observed by a light microscope. HeLa cells 
were incubated with 20 µM MPPa for 18 h in the dark, then washed twice with PBS and 
irradiated with 800 nm, 120 fs laser at a peak irradiance of 3.9×1010 W cm-2. The images 
were taken 24 h later on a Nikon Eclipse TS100 microscope. 
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 MTT cell viability assay 3.2.6
Cell viability was evaluated by the standard MTT assay using a commercial kit (V-13154, 
Invitrogen, Life Technologies Inc., Burlington, ON, CA). The stock solution of 12 mM MTT 
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; MW = 414 g mol-1) was 
prepared by adding 1 mL of sterile PBS to one 5 mg vial of MTT. The SDS-HCl solution 
was prepared by adding 10 mL of 0.01 M HCl to 1 mg of SDS (sodium dodecyl sulfate;   
MW = 288 g mol-1).  
 At the end of incubation period, the medium was replaced with 100 (96-well plates) or 
30 (384-well plates) µL of fresh phenol red-free complete culture medium and 10 (96-well 
plates) or 3 (384-well plates) µL of the MTT solution (5 mg mL-1). After 2-4 h incubation, 
100 (96-well plates) or 30 (384-well plates) µL of SDS-HCl was added to each well. After  
4-18 h incubation, the absorbance at 570 nm was measured with a Multiskan GO microplate 
spectrophotometer (Thermo Scientific, Mississauga, ON, Canada). Cell viability was 
expressed as the percentage of the control cells, and the data are presented as means of at 
least three wells ± S.D (standard deviation). 
 Steady-state absorption and fluorescence spectroscopic 3.2.7
measurements 
Steady-state absorption spectra of MPPa were measured on a DU 530 UV/Vis 
spectrophotometer (Beckman Coulter, Fullerton, CA, USA). Samples were prepared in 5 mm 
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quartz cuvettes. One-photon induced steady-state fluorescence spectra of MPPa and ZnPcS4 
were measured on a fluorescence spectrophotometer (Varian Cary Eclipse, Palo Alto, CA, 
USA). Two-photon induced steady-state fluorescence spectra were measured on a homemade 
fluorescence spectrophotometer (see Chapter 2). Samples were prepared in 5 mm quartz 
cuvettes. All measurements were performed at room temperature. 
3.2.7.1 Fluorescence quantum yield 
The fluorescence quantum yield of MPPa (ΦF) can be determined using Equation (2-8). The 
1-γ absorbance was measured at 400 nm. The 1-γ fluorescence was excited at 400 nm and 
measured on a fluorescence spectrophotometer. The fluorescence quantum yield of the 
reference (Zn(II) phthalocyanine tetrasulfonic acid; ZnPcS4) is ΦF = 0.104 in methanol at  
400 nm (243). 
3.2.7.2 Two-photon excitation cross section 
The 2-γ excitation cross section (σ) of MPPa can be determined using Equation (2-7). The   
2-γ induced fluorescence emissions of MPPa and the reference (ZnPcS4) were excited at   
800 nm and measured with a homemade fluorescence spectrophotometer (see Chapter 2) at 
various excitation powers. The concentration of both MPPa and ZnPcS4 was fixed at 50 µM. 
For ZnPcS4 in methanol, the fluorescence quantum yield is ΦF = 0.104 and the 2-γ absorption 
cross section is σ = 28.6 GM at 800 nm (243). 
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 Femtosecond time-resolved transient absorption spectroscopic 3.2.8
measurements 
The experimental setup for femtosecond time-resolved transient absorption spectroscopy has 
been described in Chapter 2. The pump and probe wavelengths were fixed at 667 and        
475 nm, respectively. Samples were prepared in 5 mm quartz cuvettes. All measurements 
were performed at room temperature. 
 Data analysis 3.2.9
3.2.9.1 Dose-response curve analysis 
The drug- and light-dose response curves were fitted with a sigmoidal logistic function          
(𝑦 = 𝐴1−𝐴2
1+( 𝑥
𝑥0
)𝑝 + 𝐴2, where A1 is the top asymptote, A2 is the bottom asymptote, x0 is the point 
of inflection, and p can be loosely described as the parameter that affects the slope of the area 
about the inflection point) by using Origin software (OriginLab, Northampton, MA, USA). 
The drug concentration (IC50) or light dose (LD50) required to produce a 50% cell killing 
effect were determined on the basis of the fitted data. 
3.2.9.2 Transient absorption and fluorescence decay kinetics analysis 
In order to determine the lifetimes from the transient absorption decay kinetic traces, we 
fitted the curves with multi-exponential functions using the Scientist software (MicroMath 
Inc., Saint Louis, MO, USA). 
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3.3 Results and discussion  
 Subcellular localization of MPPa 3.3.1
Understanding of the intracellular uptake and subcellular distribution of a photosensitizer is 
an important step for evaluating the therapeutic efficacy. Figure 3-2 shows the subcellular 
localization of MPPa in the 3 tumor cell lines. The cells were incubated with 5 µM MPPa for 
24 h and the nuclei were stained with Hoechst 33342. Marked differences were observed in 
the subcellular localization of MPPa between the cell lines. Thus, strong red MPPa 
fluorescence was observed throughout the cytoplasm in HeLa and A549 cells (Figure 3-2, 
upper and middle panels), while bright red spots suggestive of spherical structures such as 
lysosomes were observed in the NIH:OVCAR-3 cells (Figure 3-2, lower panel).  
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Figure 3-2: Subcellular localization of MPPa in HeLa, A549 and NIH:OVCAR-3 cells. The 
cells were incubated with 5 µM MPPa for 24 h. For the final 30 min of incubation, Hoechst 
33342 was added for nuclear staining. After incubation, the cells were washed twice with 
PBS and fixed with 4% paraformaldehyde. The images were taken on a Nikon Eclipse 
TS100/TS100-F microscope. MPPa is shown in red (λex = 510-560 nm; λem > 590 nm). 
Hoechst 33342 is shown in blue (λex = 330-380 nm; λem > 420 nm). 
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 The subcellular localization of MPPa in other cell types has been reported by other 
groups. Matroule et al. (227) found that MPPa mainly accumulated at the cytoplasmic 
membrane, in lysosomes and in the endoplasmic reticulum in HCT-116 colon cancer cells. A 
different distribution was observed in nasopharyngeal (HONE-1), lung (NCI-h446) and 
ovarian (COC1/DDP) carcinoma cells, with co-localization of MPPa with a mitochondria-
specific probe (Mitotracker) (229, 230, 233). Recently, Guelluy et al. (129) demonstrated 
that the co-localization of MPPa with the mitochondria in HCT-116 cells could only be 
observed when its concentration in the culture medium was ≥ 4 µM, which was much higher 
than 0.25 µM used by Matroule et al. (227). In the present study, the three cell lines were 
treated identically (with 5 µM MPPa), and markedly different MPPa distributions were 
observed, supporting the general conclusion that the subcellular localization of MPPa is 
unusually dependent on cell type. The reasons for this behavior have not been determined. 
However, since the PDT sensitivity is known to depend strongly on the subcellular 
localization of the photosensitizer, due to the fact that the light-generated cytotoxic singlet 
oxygen (1O2) generated during PDT has a very short lifetime (<~ µs) and hence diffusion 
length (<~100 nm) (68), this cell-type dependence clearly merits further investigation. 
 One-photon activated photocytotoxicity of MPPa 3.3.2
The MTT cell viability assay has been performed to evaluate the 1-γ activated PDT efficacy 
of MPPa at 674 nm and the results are shown in Figure 3-3. The dark control without 
irradiation showed that MPPa had slight dark cytotoxicity at high concentration. The 
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photocytotoxicity of MPPa was light dose dependent, as expected. Thus, at a very low light 
dose (LD) of 0.03 J cm-2, the IC50 was 7.2 ± 0.4, 6.5 ± 0.7 and 6.8 ± 0.6 µM in HeLa, A549 
and NIH:OVCAR-3 cells, respectively (Table 3-1). At 0.06 J cm-2, the corresponding values 
were 5.3 ± 0.3, 3.4 ± 0.3 and 3.6 ± 0.4 µM. Thus, the IC50 values in cisplatin-resistant A549 
and NIH:OVCAR-3 cells were comparable with those in cisplatin-sensitive HeLa cells. In 
general, cancer cells resistant to chemotherapy do not show cross-resistance to PDT 
treatment (162). Our observation of high sensitivity of cisplatin-resistant lung and ovarian 
cancer cells to MPPa-mediated PDT is therefore likely due to different mechanisms of action 
between these two modalities (159, 162). The present results suggest that MPPa-mediated 
PDT may be developed as an effective treatment for cancers that are resistant to this widely 
used chemotherapeutic drug. Interestingly, the photocytotoxicity was not significantly altered 
by the more localized distribution of MPPa in NIH:OVCAR-3 cells than in HeLa and A549 
cells. This indicates that the photocytotoxicity (IC50) is not only dependent on the localization 
of MPPa but also on the light dose and whether the drug is activated through one- or two-
photon excitation (see further results in Section 3.3.3). 
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Figure 3-3: Drug-dose response curves for cell viability of (A) HeLa, (C) A549 and (D) 
NIH:OVCAR-3 cells treated by 1-γ activated PDT of MPPa. Cells were incubated with 
various concentrations of MPPa for 18 h and then irradiated at 674 nm. Cell viability was 
evaluated by using the standard MTT assay 48 h after laser irradiation. The solid lines are 
best fits to the experimental data using a logistic function in Origin software. (B) Apoptosis 
analyzed by Hoechst 33342 staining. HeLa cells were incubated with 10 µM MPPa, light-
irradiated at 0.04 Jcm-2 and incubated for 24 h. Arrows indicate apoptotic cells. 
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Table 3-1: In vitro 1-γ IC50, 2-γ IC50 and 2-γ LD50 of MPPa calculated from Figure 3-3(A, C 
and D) and Figure 3-4. 
Cell line HeLa A549 NIH:OVCAR-3 
1-
γ 
Ex
ci
ta
tio
n 
Light 
Dose  
(J cm-2) 
0 0.03 0.06 0 0.03 0.06 0 0.03 0.06 
IC50 
(µM) 
 
> 20 7.2 ± 0.4 
5.3 ± 
0.3 > 50 
6.5 ± 
0.7 
3.4 ± 
0.3 > 30 
6.8 ± 
0.6 
3.6 ± 
0.4 
 
2-
γ 
Ex
ci
ta
tio
n 
Light 
Dose  
(J cm-2) 
0 886 0 886 0 886 
IC50  
(µM) 
> 20 4.1 ± 0.3 > 50 9.6 ± 1.0 > 30 1.6 ± 0.3 
MPPa 
Con. 
(µM) 
0 10 0 10 0 10 
LD50*  
(J cm-2) 
- 576 ± 13 - 478 ± 18 - 360 ± 26 
* Normalized to the group treated with 10 µM MPPa alone. 
 The 1-γ photocytotoxicity of MPPa has previously been studied in a number of cell 
lines, including colon (HCT-116), lung (NCI-h446), nasopharyngeal (HONE-1), prostate 
(PC-3M), ovarian (COC1/DDP) and breast carcinomas (MDA-MB-231, MDA-MB-435, and 
MCF-7) (129, 227-234), and has been shown to induce apoptotic cell death. In order to 
determine the mode of cell death in the present study, HeLa cells were incubated with 10 µM 
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MPPa, irradiated at a light dose of 0.04 J cm-2 and stained with Hoechst 33342 at 24 h after 
laser irradiation. Typical characteristics of apoptotic cells, including nuclear condensation 
and fragmentation, were clearly seen (Figure 3-3B).  
Table 3-2: Comparison of 1-γ PD50 (light-drug product required to produce a 50% cell killing 
effect) of MPPa with values calculated from the literature.  
Cell line 
MPPa Con. 
(µM) 
Light Dose 
(J cm-2) 
PD50 
(µM J cm-2) 
Reference 
A549 0 - 20 0 - 0.06 0.20 ± 0.01 This work 
COC1/DDP 0 - 4 0 - 8 0.5 - 0.8 (227) 
HCT-116 
6 0-9.6 15 (222) 
0 - 5 6.6 26 (123) 
HeLa 0 - 20 0 - 0.06 0.27 ± 0.07 This work 
HONE-1 0 - 2 0 - 1 0.2 - 0.25 (224) 
MDA-MB-231 
0 - 4 0 - 8 
14 - 20 
(228) MDA-MB-435 28 
MCF-7 32 
NCI-h446 0 - 6 0 - 6 1.9 - 5.6 (223) 
NIH:OVCAR-3 0 - 20 0 - 0.06 0.21 ± 0.01 This work 
PC-3M 
0 - 4 0 - 8 3.2 - 7.0 (225) 
2 0 - 6 12 (226) 
  
 We note that the light doses of 0.03-0.06 J cm-2 used here are much lower than the 
range ~0.1-10 J cm-2 used in previous studies (129, 227-234). It is known that the light-drug 
product required to produce a 50% cell killing effect (PD50) can be reduced by increasing the 
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extracellular concentration of MPPa (229). Table 3-2 compares the 1-γ PD50 of MPPa in 
different cancer cell lines. In the present study, the PD50 values are 0.27 ± 0.07, 0.20 ± 0.01 
and 0.21 ± 0.01 in HeLa, A549 and NIH:OVCAR-3 cancer cells, respectively. These are 
much lower than the range of 1.9-32 reported for HCT-116 colon, MDA-MB-231,        
MDA-MB-435 and MCF-7 breast, NCI-h446 lung and PC-3M prostate cancer cells (129, 
229-232, 234), but comparable to the results of Tan et al. in COC1/DDP ovarian (233) and Li 
et al. in HONE-1 nasopharyngeal cancer cells (230), confirming that the MPPa-mediated 
PDT sensitivity varies greatly among cancer cell lines. More critically, we have used 
monochromatic 674 nm light, which matches an absorption peak of MPPa (insert in Figure 
3-7). This contrasts with previous studies (129, 227, 229, 230) that used conventional broad-
band light sources, so that there was only partial overlap with the MPPa absorption spectrum. 
The LED (light-emitting diode) used by Tan et al. emitted at 630 nm (233), far from the 
MPPa absorption maximum. Although Tian et al. (231, 232, 234) used 670 ± 11 nm light, 
their PD50 values were much higher than our results. As shown in the insert in Figure 3-7, the 
absorption spectrum of MPPa in the cell culture medium has a high degree of overlap with 
the Gaussian (FWHM = 11 nm) emission profiles of red light centered at both 670 and      
674 nm. The difference between the PD50 values obtained here with those of Tian et al. is 
likely due to the different cell lines used. The fs pulsed laser used in the present study might 
also play an important role in reducing the PD50. Grecco et al. compared the in vitro and in 
vivo photodynamic response to a fs pulsed laser with a CW laser under the same average 
power and light dose conditions and found that the fs laser was about twice as effective as the 
CW laser  (244). Therefore, our observations of low PD50 values suggest that 1-γ PDT of 
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MPPa activated by a fs laser could be developed as an effective treatment for selected 
cancers.   
 Two-photon activated photocytotoxicity of MPPa 3.3.3
We also investigated the photodynamic activity of MPPa under 2-γ excitation with ~120 fs 
pulse of 800 nm light at a repetition rate of 1 kHz. Tightly focused laser beams are 
commonly used in 2-γ studies, due to the requirement of extremely high peak irradiances for 
excitation, so that it has been found to be difficult to quantify the photocytotoxic effect by the 
same colorimetric assays normally used for 1-γ PDT experiments, because of the need to 
irradiate the cells uniformly while using a diffraction-limited focal spot. The first quantitative 
in vitro evaluation of 2-γ PDT was performed by Khurana et al. (147), who developed a 
confocal laser scanning microscope-based technique for both light delivery and response 
measurements. In the present study, we have used a 2.54 cm diameter biconvex lens             
(f = 125 mm) to focus the laser beam and placed an aperture above the microplate to produce 
a quasi-uniform distribution at the cell plane. In order to evaluate the cell response using the 
standard MTT assay, we have replaced the 96-well microplates with 384-well microplates, 
which have a well area (0.11 cm2) that is slightly smaller than the area of the laser spot at the 
cell plane (0.12 cm2).  
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Figure 3-4: Drug- and light-dose response curves for cell viability of (A and B) HeLa,           
(C and D) A549 and (E and F) NIH:OVCAR-3 cells treated by 2-γ activated PDT of MPPa. 
Cells were incubated with various concentrations of MPPa for 18 h and then irradiated with 
800 nm 120 fs laser at an average power of 600 mW and a peak irradiance of        
3.9×1010 W cm-2. Cell viability was evaluated by using the standard MTT assay 48 h after 
laser irradiation. The solid lines are best fits to the experimental data using a logistic 
function in Origin software. 
 As shown in Figure 3-4 and Figure 3-5, MPPa can be effectively activated under these 
conditions. Figure 3-4 shows the drug- and light-dose response of 2-γ activated 
photocytotoxicity of MPPa, and the IC50 and LD50 values are summarized in Table 3-1. At a 
light dose of 886 J cm-2, the IC50 values of MPPa were measured to be 4.1 ± 0.3, 9.6 ± 1.0 
and 1.6 ± 0.3 µM in HeLa, A549 and NIH:OVCAR-3 cells, respectively. The corresponding 
LD50 for 10 µM MPPa were 576 ± 13, 478 ± 18 and 360 ± 16 J cm-2, i.e., approximately   
3~5 times lower than the published value of 1,700 J cm-2 for Visudyne® and 20-30 times 
lower than that of Photofrin® (11,300 J cm-2) (147). These LD50 values of MPPa were about 
half of the LD50 of the conjugated porphyrin dimer (σ = 16,000 GM at 920 nm) used by 
Collins et al. for in vivo blood vessel closure (148), which was ~1,020 J cm-2 (i.e., ~60% of 
the LD50 of Visudyne® under identical experiment conditions) (150). 
 Since the light dose required for significant photodynamic killing by 2-γ excitation is 
much higher than that normally used in 1-γ PDT, it is very important to investigate whether 
any direct photodamage has been caused by laser irradiation in the absence of the 
photosensitizer. It was shown by Karotki et al. (144), for example, in vascular endothelial 
cells that the threshold peak irradiance for direct photomechanical damage from fs laser 
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irradiation is about 8×1011 W cm-2, while Samkoe et al. (146) showed that a 780 nm, 100 fs 
laser beam with a peak irradiance of 3.7×1011 W cm-2 and a fluence of 1.1×108 J cm-2 caused 
no significant photomechanical damage to the chicken chorioallantoic membrane. The peak 
irradiance (Ipeak) can be calculated by: 
                                                          𝐼𝑎𝑣𝑒𝑟𝑎𝑔𝑒 = 𝑃𝑎𝑣𝑒𝑟𝑎𝑔𝑒𝐴 ,                                                  (3-1) 
                                                          𝐼𝑝𝑒𝑎𝑘 = �𝑙𝑛2𝜋 · 2𝜏𝑓 · 𝐼𝑎𝑣𝑒𝑟𝑎𝑔𝑒 ,                                       (3-2) 
where Paverage is the average laser power, A is the area of the laser spot at the cell plane, τ is 
the pulse duration (FWHM; full width at half maximum) and f is the pulse repetition rate. 
The highest average laser power of 600 mW used in the present study corresponds to        
Ipeak = 3.9×1010 W cm-2, which is about one order of magnitude smaller than the published 
threshold value (144), although this may be somewhat cell-type dependent. The 
corresponding average irradiance is 5 W cm-2, about six orders of magnitude lower than 
those (~106 W cm-2) used by Karotki et al. (144) and Khurana et al. (147). As shown in 
Figure 3-4, laser irradiation alone caused no measurable cell death in the absence of MPPa. 
The light microscope images also confirmed the absence of observable direct damage at a 
light dose of 886 J cm-2 in the absence of MPPa (Figure 3-5B). In contrast, morphological 
changes typical of apoptotic cell death were observed at light doses of 222 and 443 J cm-2 in 
the presence of MPPa (Figure 3-5E and F). 
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Figure 3-5: 2-γ PDT of MPPa induced changes in HeLa cell morphology. Cells were 
incubated with 20 µM MPPa for 18 h and then irradiated by 800 nm, 120 fs laser with a 
peak irradiance of 3.9×1010 W cm-2 and light doses in the range 0-886 J cm-2. The images 
were taken on a Nikon Eclipse TS100 microscope 24 h after treatment. 
 Power dependence of one- and two-photon PDT  3.3.4
It has been pointed out by Karotki et al. (144) that 1-γ excitation could also contribute to the 
photocytotoxicity observed in 2-γ PDT treatments, due to the long-wavelength “tail” of the  
1-γ absorption spectrum. As shown in Figure 3-7, however, MPPa has no detectable 
absorption at 800 nm (within the noise level), so there should be minimal cell killing as a 
result of 1-γ activation of MPPa at this wavelength. Moreover, we have investigated the 
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power dependence of the PDT efficiency of MPPa activated at 674 and 800 nm: 1-γ 
absorption should have a linear dependence on light intensity, while 2-γ absorption has a 
quadratic dependence. According to Khurana et al. (141), for an n-photon process, the 
irradiation time required to kill 50% of the cells (t50) and the laser power (P) should satisfy 
the following equations: 
                                                  𝑡50 ∝  𝐼𝑝𝑒𝑎𝑘−𝑛 = (�𝑙𝑛2𝜋 · 2𝜏𝑓 · 𝑃𝐴)−𝑛,                                          (3-3) 
                                              i.e.  
                                             log(𝑡50) = 𝑛 · log(𝑃−1) + 𝑐𝑜𝑛𝑠𝑡𝑎𝑛𝑡,                                      (3-4) 
 
In order to determine log(t50), the cell viability was plotted as a function of the laser 
irradiation time (Figure 3-6A and C) at various laser powers and fitted by non-linear 
regression with variable Hill slope using Origin software. The resultant log(t50) values were 
then plotted against log(P-1) and fitted to Equation (3-4), as shown in Figure 3-6B and D. The 
gradient of the linear fit (Figure 3-6B) was 1.10 ± 0.06, confirming 1-γ activation of MPPa at 
674 nm excitation. The corresponding gradient for 800 nm fs-pulsed laser PDT treatment 
(Figure 3-6D) was 2.04 ± 0.17, confirming 2-γ activation. 
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Figure 3-6: Power dependence of 1- and 2-γ PDT efficiency of MPPa. (A and B) 1-γ PDT in 
NIH:OVCAR-3 cells: 5µM MPPa for 18 h, 674 nm, 120 fs laser at various powers. MTT 
assay at 48 h after treatment: means ± S.D. of 3 replicates. The irradiation time required to 
kill 50% of the cells (t50) was determined for each laser power (150, 300, 450 and 600 µW) 
and log(t50) was plotted against log(P-1). The slope, n = 1.10 ± 0.06, confirming 1-γ 
activation (141). (C and D) 2-γ PDT efficiency of MPPa in HeLa cells: 10 µM MPPa for     
18 h, 800 nm 120 fs laser at various powers. MTT at 72 h after treatment: means ± S.D. of 
3 replicates. The t50 was determined for each laser power (280, 360, 440, 520 and         
600 mW) and log(t50) was plotted against log(P-1). The gradient of the linear fit to these 
points is 2.04 ± 0.17, confirming 2-γ activation as described in Ref. (141). 
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 Steady-state absorption spectra of MPPa 3.3.5
We have measured the UV-Vis absorption spectra of MPPa in acetone and the cell culture 
medium (phenol-red free minimum essential medium (MEM)) (Figure 3-7). MPPa has two 
absorption peaks at 408 and 667 nm in acetone consistent with the values reported in the 
literature (229, 245). In MEM, the peaks are shifted slightly to 400 and 672 nm. 
 
Figure 3-7: UV-Vis absorption spectra of 25 µM MPPa in acetone (blue line) and phenol-red 
free minimum essential medium (MEM: red line). The insert compares the absorption 
spectrum in MEM with the Gaussian (FWHM = 11 nm) emission profiles of red light 
centered at 630, 670 and 674 nm, respectively.  
 Fluorescence quantum yield of MPPa in methanol 3.3.6
We have determined the fluorescence quantum yield (ΦF) of MPPa in methanol, using Zn(II) 
phthalocyanine tetrasulfonic acid (ZnPcS4) as a reference. Figure 3-8A and C show the 
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fluorescence spectra of various concentrations of MPPa and ZnPcS4 in methanol. MPPa has 
an emission maximum of 672 nm and a small shoulder peak around 718 nm. The 
fluorescence peaks of ZnPcS4 are at 678 and 742 nm. Figure 3-8B and D show the integrated 
fluorescence intensities of MPPa and ZnPcS4 as a function of absorbance at 400 nm. The R2 
coefficients of linear fits to the data are 0.987 and 0.996 for MPPa and ZnPcS4, respectively. 
Using Equation (2-8), the ΦF value of MPPa has been determined to be 0.23 ± 0.02, which is 
very close to the published value of 0.21 in dimethylformamide (246). 
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Figure 3-8: 1-γ Fluorescence spectra of (A) MPPa and (C) ZnPcS4 at various concentrations 
excited at 400 nm. (B) and (D) The integrated fluorescence intensities of MPPa and ZnPcS4 
in methanol as a function of optical absorbance at 400 nm. The R2 coefficient of the linear 
fits was 0.987 and 0.996 for MPPa and ZnPcS4, respectively. 
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 Two-photon absorption cross section of MPPa in methanol at 3.3.7
800 nm 
Figure 3-9 shows the 2-γ induced fluorescence spectra of MPPa and ZnPcS4 in methanol at 
various excitation powers at 800 nm. As shown in Chapter 2, the 2-γ induced fluorescence 
spectra of both MPPa and ZnPcS4 are identical to those induced by 1-γ excitation. Therefore, 
the two-photon absorption cross section of MPPa can be determined by using Equation (2-7). 
The inserts show log(Fmax) versus log(Power), where Fmax is the 2-γ induced fluorescence 
intensity at 672 nm for MPPa and at 684 nm for ZnPcS4. The linear fits yield slopes of     
2.06 ± 0.06 and 1.82 ± 0.03 for MPPa and ZnPcS4, respectively, confirming 2-γ excitation. 
Using Equation (2-7), we obtain σ = 3.5 ± 0.3 GM for MPPa in methanol at 800 nm, which is 
consistent with the value of 3.1 GM for Photofrin® in methanol (243). Although the value of 
σ for MPPa is lower by a factor of about 5,000 than the reported σ = 16,000 GM for the 
conjugated porphyrin dimer (148), our measured 2-γ LD50 of 10 µM MPPa is about half of 
the 2-γ LD50 of the dimer in SK-OV-3 cells (150). In fact, the 2-γ LD50 of the dimer has been 
found to be ~60% of that of another currently used 1-γ photosensitizer Visudyne®        
(σ = 51 GM) under identical experiment conditions, in spite of the 300-fold large difference 
in σ (150). This confirms the importance of other factors such as the intracellular 
concentration/localization of the photosensitizer and the mechanisms of action (types of the 
ROS and their yields), in determining the overall photodynamic efficiency (52). 
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Figure 3-9: 2-γ Induced fluorescence spectra of (A) MPPa and (C) ZnPcS4 in methanol at 
various excitation powers, for 800 nm excitation. The solid lines are the best Gaussian fits. 
(B) and (D) Show plots of log(Fmax) versus log(Power), where Fmax is the 2-γ induced 
fluorescence intensity at 672 nm for MPPa and at 684 nm for ZnPcS4. The solid lines are 
the best linear fits, yielding slopes of 2.06 ± 0.06 and 1.82 ± 0.03 for MPPa and ZnPcS4, 
respectively, confirming two-photon excitation. 
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 Femtosecond time-resolved transient absorption spectroscopic 3.3.8
results 
We have obtained fs time-resolved transient absorption decay kinetics of MPPa in water and 
ethanol (Figure 3-10). The excitation and probe wavelengths were 667 and 475 nm, 
respectively. The decay kinetics in water could be fitted adequately with a multi-exponential 
function yielding two short decaying lifetimes of 0.31 ± 0.04 and 11.4 ± 1.2 ps and a much 
longer one on the scale of nanoseconds. In ethanol, the signal was found to be much stronger 
than that observed in water at the same probe wavelength. The transient absorption intensity 
decreased slowly with increasing pump-probe delay time. The decaying lifetime was found 
to be 12.0 ± 0.6 ns. It is known that pheophorbides aggregate in aqueous solutions (245). 
Therefore, the shorter lifetimes of 0.31 and 11.4 ps observed in water are likely the excited-
state lifetimes of the aggregates while the longer lifetime corresponds to the monomeric form 
of MPPa. In ethanol, MPPa has been found to be monomeric up to 50 µM (245). The lifetime 
of 12.0 ns observed in ethanol, which is in good agreement with the fluorescence lifetime of 
6.0 ns inside HCT-116 cells (129), can thus be assigned to the excited singlet state lifetime of 
MPPa monomers.  
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Figure 3-10: Femtosecond time-resolved pump-probe transient absorption decay kinetics of 
(A) 50 µM MPPa in water and (B) 5 µM MPPa in ethanol. The blue open circles are the 
experimental data and the red solid lines are best fits to the experimental data. The pump 
and probe wavelengths were 667 and 475 nm, respectively. The pump powers were 50 and 
5 µW for MPPa in water and ethanol, respectively. 
 It has been suggested that singlet oxygen (1O2) is not the only ROS responsible for cell 
killing following MPPa-mediated PDT treatment (129, 228). Generation of ROS by MPPa 
has previously been measured indirectly by using electron spin resonance (ESR) (129, 245). 
The involvement of hydroxyl radical (∙OH) has been confirmed in those studies, although 
there are some discrepancies with regard to the relative contribution of each species. Those 
findings suggest that MPPa can act as both a Type I and Type II photosensitizer. While a 
Type II reaction mainly takes place in the excited triplet state of a photosensitizer (3PS*) due 
to spin selection rules, a Type I reaction may occur in the excited singlet state of the 
photosensitizer (1PS*) as well as 3PS*. In the case of MPPa, ∙OH has been suggested to be a 
secondary product of superoxide anion radicals (O2-∙) generated from one-electron reduction 
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of molecular oxygen by the excited singlet state of MPPa (1MPPa*) (129, 245). However, to 
the best of our knowledge, no direct transient absorption spectroscopic detection of O2-∙ has 
been reported. Although O2-∙ has an absorption band in the UV range (247), most 
photosensitizers also have very strong absorption in this wavelength range making direct 
spectroscopic detection of O2-∙ extremely difficult. In the present study, we have obtained for 
the first time the fs time-resolved transient absorption decay kinetic traces of MPPa in water 
and ethanol. Our observation of an excited singlet state lifetime of 12.0 ns for MPPa in 
ethanol indicates that fs time-resolved laser spectroscopy (fs-TRLS) may be an useful tool to 
study the initial reactions leading to the generation of O2-∙ by the excited singlet state of 
MPPa (1MPPa*). Furthermore, Delanaye et al. have shown that a ∙OH scavenger reduced the 
ESR signal of light irradiated MPPa in liposomes by ~74% (245). This result suggests that 
the yield of O2-∙ might be high in MPPa-mediated PDT. Therefore, MPPa may be a good 
model compound for studying the Type I reaction pathway of PDT. 
3.4 Summary 
Photodynamic therapy (PDT) is a novel cancer therapy that has been successfully used in 
treating various cancers. However, more widespread application of PDT has been hindered 
due to the limited treatment depth of currently approved photosensitizers. The present study 
demonstrates that the 2nd-generation PDT sensitizer MPPa can be effectively activated not 
only by 1-γ excitation at 674 nm but also by 2-γ excitation at 800 nm using a fs laser. These 
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treatments caused effective cell killing in both cisplatin-sensitive human cervical (HeLa) and 
cisplatin-resistant human lung (A549) and ovarian (NIH:OVCAR-3) cancer cells in vitro.  
 MPPa has a 1-γ absorption maximum at 674 nm in cell culture medium (Figure 3-7), 
which locates at a much longer wavelength than that of Photofrin®, and its molar extinction 
coefficient at 667 nm in acetone is about 15 times that of Photofrin® at 630 nm (144, 229). 
Previously, a number of groups have reported the in vitro 1-γ PDT efficacy of MPPa and the 
cancer cell lines studied have showed different sensitivity to MPPa-mediated PDT treatment 
(Table 3-2) (129, 229-232, 234). In the present study, we have found that both cisplatin-
sensitive HeLa and cisplatin-resistant A549 and NIH:OVCAR-3 cancer cell lines are 
sensitive to MPPa-mediated PDT treatment. Moreover, we note that our values of PD50 in all 
the three cancer cell lines are about 10 times lower than that in lung cancer (NCI-h446) cells 
reported by Sun et al. (229), who have found that MPPa is as effective as                
5,10,15,20-tetrakis(meta-hydroxyphenyl)chlorine (mTHPC), a 2nd-generation photosensitizer 
approved by European Medicines Evaluation Agency for the palliative treatment of patients 
suffering from advanced head and neck squamous cell carcinoma. Therefore, our results 
suggest that MPPa may be developed as an effective 1-γ PDT agent for selected cancers.  
 Recently, 2-γ excitation has been explored as a potential approach to increase the 
treatment depth of PDT (141, 142, 144-148, 151, 152). For example, photosensitizers that 
normally absorbs at 400 nm could be activated by absorbing two photons at 800 nm, which 
can penetrate much deeper into tissues. We note that although the 1-γ PDT efficacy of MPPa 
has been evaluated in a number of cell lines, 2-γ PDT effects of this photosensitizer have not 
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been reported previously. Here, we have determined the value of σ to be 3.5 GM for MPPa in 
methanol at 800 nm. We have also evaluated the 2-γ photocytotoxicity of MPPa in three 
human cancer cell lines, namely the cancers of human cervix (HeLa), lung (A549) and ovary 
(NIH:OVCAR-3). With a peak irradiance of 3.9×1010 W cm-2, which is more than one order 
of magnitude lower than the threshold value for direct photomechanical damage (144), we 
have obtained LD50 values of 576 ± 13, 478 ± 18 and 360 ± 16 J cm-2 in HeLa, A549 and 
NIH:OVCAR-3 cells, respectively. It’s worth pointing out that, our measured σ = 3.5 GM for 
MPPa is lower by a factor of about 5,000 than that of 16,000 GM for the conjugated 
porphyrin dimer (148), but the 2-γ LD50 of MPPa is ~50% of that of the later in SK-OV-3 
cells (150). This observation suggests that although σ is an important factor in determining 
the 2-γ  PDT efficacy of a photosensitizer, other factors such as the intracellular 
concentration/localization and the mechanisms of action of the photosensitizer should also be 
considered when developing novel 2-γ PDT agents. 
 Cisplatin is the most widely used chemotherapeutic drug and the cornerstone in 
treating ovarian, testicular, cervical, bladder, lung, head and neck, lymphomas and brain 
cancers. Cancer cells often have a positive initial response but become refractory over time 
and 70–90% of patients die of progressive chemo-resistant disease, so that it remains a major 
challenge to cure these cancers, especially ovarian and lung cancers (9, 248-250). The 
present observation of effective killing of cisplatin-resistant lung and ovarian cancer cells by 
either 1- or 2-γ PDT of MPPa may provide new strategies for treatment of these challenging 
cancers. 
    
91 
 
 Moreover, we have for the first time obtained the fs time-resolved transient absorption 
decay kinetic traces of MPPa in water and ethanol. Two short lifetimes of 0.31 and 11.4 ps 
have been obtained from the kinetics of MPPa in water, which have been assigned to be the 
excited state lifetime of MPPa aggregates. In ethanol, the excited singlet state lifetime of 
MPPa is determined to be on the nanosecond time scale (12.0 ns). Previous studies have 
demonstrated the involvement of ROS other than 1O2 in MPPa-mediated PDT treatment 
(129, 228, 245) suggesting the importance and effectiveness of the Type I reactions in 
inducing cytotoxicity. Therefore, further fs time-resolved laser spectroscopic studies of 
MPPa may improve our understanding of the initial reactions that lead to the generation of 
O2-∙ in PDT and help develop novel PDT treatment approaches for cancers. 
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4 Combination of Near Infrared Light-Activated Photodynamic Therapy Mediated by Indocyanine Green with Etoposide or Teniposide Chemotherapy 
4.1 Background 
Indocyanine green (ICG) is a near-infrared fluorescent dye approved by the U.S. Food and 
Drug Administration (FDA) for various clinical applications (186-189). As shown in Figure 
1-10, ICG has an absorption maximum near 800 nm. It can be activated by near-infrared 
(NIR) light that penetrates relatively deep into tissues and therefore, has been considered to 
be a potential NIR photosensitizer for photodynamic therapy (PDT). The antitumor activity 
of ICG has been reported by several research groups (190-196, 199, 200). It has been 
suggested that the photocytotoxicity of ICG involves the generation of singlet oxygen (1O2) 
(190, 192). However, the yield of 1O2 has been found to be extremely low due to a low yield 
of excited triplet states (~10-5) (251), which are believed to be responsible for the generation 
of 1O2. Moreover, this dye has a short blood half-life of 2 to 4 minutes (202), poor photo- and 
thermal-stability, non-specific binding with proteins, and is vulnerable to aggregation (203). 
These properties of ICG have greatly limited the application of this dye as a PDT agent. 
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Etoposide (VP-16) and teniposide (VM-26) are two semisynthetic podophyllotoxin 
derivatives that are currently in clinical use for the treatment of various cancers (15, 16). 
Etoposide has been approved for treating acute myeloid leukemia, choriocarcinoma, small 
and non-small cell lung carcinoma, lymphoma, advanced ovarian carcinoma, and testicular 
cancers. Teniposide has been approved for the treatment of bladder cancer, malignant 
lymphoma, and central nervous system tumors. Both drugs are believed to act on type II 
topoisomerases (TOPII), which can bind covalently with the 5’ ends of DNA resulting in the 
formation of transient double strand breaks (DSBs). Binding of VP-16/VM-26 with TOPII 
can create permanent DNA DSBs that may activate cellular pathways leading to cancer cell 
death. Although these two drugs are efficient, they have severe side effects such as alopecia, 
gastrointestinal toxicities, leucopoenia, myelosuppression, and development of secondary 
leukemia (16, 252-255). In fact, in preclinical and clinical studies, etoposide is normally 
given in combination with other chemotherapeutic drugs such as cisplatin (CDDP) and 
carboplatin (255-260), which may lower the effective dose of VP-16 leading to reduced side 
effects associated with VP-16. For example, the combination of VP-16 and CDDP was 
reported to produce a strong synergistic effect in P 388 leukemia cells both in vitro and in 
vivo (256) and to be more effective than the single drugs in treating xenografts of small cell 
lung carcinoma (259). The combination of VP-16 with carboplatin was found to be as 
effective as VP-16-CDDP combination in terms of response and survival but showed less 
toxicity in treating small-cell lung cancers (257). While a number of these combinations have 
been demonstrated to be effective in treating some tumors, toxic side effects associated with 
the chemotherapeutic drugs other than VP-16, such as cisplatin and carboplatin, should also 
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be considered. Moreover, the development of drug-resistance remains a big problem in 
chemotherapy of cancers. 
PDT has several advantages over conventional radio- and chemotherapy, including 
fewer side effects, local targeting, and less acquired resistance to the treatment. Combination 
of PDT with conventional chemotherapy has been explored as a promising approach for 
enhancing the antitumor activity of single therapies and reducing side effects associated with 
the administration of chemotherapeutic drugs. Additive to synergistic enhancement of 
cytotoxicity by the combination treatment has been reported in some studies (163-166, 174, 
176, 178, 179), but antagonistic effects have also been reported (167, 176, 179). Using 
aluminium phthalocyanine (AlPcS4) as the photosensitizer, Gantchev et al. studied the 
combination effects of VP-16 with PDT and observed synergistic enhancement of 
cytotoxicity in human leukaemic cells K562 (174). The combination effects were found to be 
dependent upon treatment protocol and cell type by Zimmermann et al., who observed 
additive/synergistic effects in human breast (MCF-7) cells but antagonistic effects in human 
prostate (LNCaP) cancer cells treated by the combination of PDT mediated by       
5,10,15,20-tetra(m-hydroxyphenyl)chlorin (mTHPC) and chemotherapy mediated by           
5-fluoro-2’-deoxyuridine (5FdUr) (176). Later, Crescenzi et al. studied the combination 
effects of low-dose CDDP with ICG-mediated PDT in MCF-7 breast cancer cells and 
observed synergistic enhancement according to MTT assay data (165). However, their data 
from trypan blue assay showed an additive effect. Those results suggest that the combination 
effects have strong dependence upon a variety of factors, including cell type, the 
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photosensitizer and chemotherapeutic drug under investigation, and the treatment schedule. 
Moreover, a molecular mechanism for synergistic enhancement of cytotoxicity is still not 
available. Therefore, the development of novel treatment approaches may improve our 
understanding of the molecular mechanism underlying synergism induced by the 
combination of PDT and chemotherapy. 
In the present study, we have investigated the combination effects of ICG-mediated 
PDT and chemotherapy mediated by etoposide (VP-16) in human lung (A549), cervical 
(HeLa) and ovarian (NIH:OVCAR-3) cancer cells as well as in a human normal fibroblast 
cell line (GM05757). Cytotoxicity has been evaluated by using the standard MTT cell 
viability assay. We have also examined the cytotoxicity of the laser-irradiated mixtures of 
ICG and VP-16 and altered the sequence of drug addition to see if the combination effects 
are dependent upon the schedule of treatment. Moreover, we have used commercial 
fluorescence kits to detect the generation of DNA DSBs and 1O2. Cytotoxicity of the 
combination of ICG-PDT and VM-26, which is an analog of VP-16, has also been evaluated 
in A549 cells. Finally, we have determined the fluorescence lifetime of VP-16 and studied 
the reaction between ICG and VP-16 by performing steady-state and femtosecond (fs) time-
resolved laser spectroscopic measurements. 
 96 
 
4.2 Materials and methods 
4.2.1 Chemicals and cell lines 
4,5-Benzoindotricarbocyanine (indocyanine green; ICG; C43H47N2NaO6S2; MW =             
775 g mol-1), 4’-demethylepipodophyllotoxin-9-(4,6-o-ethylidene-b-d-glucopyranoside) 
(etoposide; VP-16; C29H32O13; MW = 588.6 g mol-1) and 4’-dimethyl-9-(4,6-O-2-thenyid)-
epipodophyllotoxin (teniposide; VM-26; C32H32O13S; MW = 656.65 g mol-1) were purchased 
from Sigma-Aldrich (Sigma-Aldrich Canada Ltd., Oakville, Ontario, Canada) and used 
without any further purification. A stock solution of 5 mM ICG was prepared weekly in 
ultrapure water (Barnstead Nanopure, Thermo Scientific, Dubuque, IA, USA) with a 
resistivity of > 18 MΩ cm-1 and stored in the dark at -20˚C. Stock solutions of 50 mM VP-16 
and 10 mM VM-26 were made in dimethyl sulfoxide (DMSO) and stored at -20˚C.  
The culture conditions for the human lung (A549), cervical (HeLa) and ovarian 
(NIH:OVCAR-3) cancer cells were the same as those described in Chapter 3. The human 
normal fibroblast cell line GM05757 was obtained from the Coriell Institute, Human Genetic 
Mutant Cell Repository (Camden, NJ, USA) and grew in minimum essential medium Eagle 
(MEM) supplemented with 10% fetal bovine serum (FBS), 100 units mL-1 penicillin G and 
100 µg mL-1 streptomycin. The cell culture was kept at 37◦C in a humidified atmosphere 
containing 5% CO2.  
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4.2.2 Laser treatment conditions 
Irradiation was carried out by using an 800 nm laser with a pulse duration of 120 fs and a 
pulse repetition rate of 1 kHz. The average power was 360 mW and the corresponding 
average irradiance was 81 mW cm-2. Duration of exposure was varied to get different light 
doses (J cm-2). 
4.2.3 Photocytotoxicity of ICG 
Exponentially growing A549 cells were seeded into 96-well microplates at a density of   
5×103 cells/well. After overnight incubation, the cells were incubated with ICG for 5 h in the 
dark. The cells were then washed twice with phosphate-buffered saline (PBS) and fresh 
culture medium was added for irradiation. Cells were placed back into an incubator after 
laser irradiation and cells viability was evaluated 20 h later by using the standard MTT assay 
as described in Chapter 3. 
4.2.4 Cytotoxicity of the combination treatment of ICG-PDT and 
VP-16/VM-26 chemotherapy in vitro 
Exponentially growing A549, HeLa, NIH:OVCAR-3 and GM05757 cells were seeded into 
384-well microplates at densities of 3×103, 3×103, 4×103 and 3×103 cells/well, respectively. 
After overnight incubation, the cells were incubated with various concentrations of ICG,  
VP-16 or VM-26 for 4 h in the dark. Cells were then washed twice with PBS and fresh 
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complete culture medium was added before irradiation. The irradiated cells were then kept in 
an incubator for 45 h and cell viability was evaluated by the standard MTT cell viability 
assay as described in Chapter 3. 
4.2.5 Effects of treatment sequence on cytotoxicity induced by the 
combination of ICG-PDT and VP-16 in A549 and HeLa cells 
Exponentially growing A549 and HeLa cells were seeded into 384-well microplates at a 
density of 3×103 cells/well. Cells were incubated with 50 µM of ICG for 4 h, washed twice 
with PBS, and fresh complete culture medium was added for irradiation. After laser 
irradiation, various concentrations of VP-16 were added. After 4 h incubation, cells were 
washed twice with PBS, fresh complete medium was added, and cells were then put back 
into an incubator. Cell viability was evaluated by the standard MTT cell viability assay 45 h 
later as described in Chapter 3. 
4.2.6 Cytotoxicity of the laser-irradiated mixtures of ICG and VP-16 
in A549 cells 
Exponentially growing A549 cells were seeded into 384-well microplates at a density of 
3×103 cells/well. Mixtures of various concentrations of ICG and VP-16 were made in 
complete F12K medium and then exposed to laser irradiation. The drug mixtures were then 
added to the corresponding wells in 384-well microplates. After 4 h incubation, cells were 
washed twice with PBS and fresh complete culture medium was added. The cells were then 
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put back into an incubator and cell viability was evaluated 45 h later by the standard MTT 
cell viability assay as described in Chapter 3. 
4.2.7 Detection of DNA double-strand breaks by using HCS DNA 
damage kit 
Many chemotherapeutic drugs, including VP-16 and VM-26, produce multiple forms of 
DNA damages. Among them, DNA double-strand breaks (DSBs) are more difficult to repair 
than other forms of damages such as single-strand breaks (SSBs) (19). Failure to reseal the 
DSBs may lead to cell death. Recently, phosphorylation of histone 2AX (H2AX), a member 
of the histone 2A family, has been identified as a sensitive marker of DNA DSBs: this 
process can take place within a few minutes in response to DSBs (261). Therefore, we have 
used the HCS DNA damage kit (Invitrogen, Life Technologies Inc., Burlington, ON, 
Canada) to measure the yield of DNA DSBs induced by the combination treatment of     
ICG-PDT and VP-16 following the manufacturer’s protocol. Briefly, cells were seeded and 
treated with drugs and laser irradiation as described in Section 4.2.4. At the end of the 
incubation period (18 h), cells were fixed using 4% paraformaldehyde (PF) in PBS and 
permeabilized with 0.25% Triton® X-100 in PBS. The cells were then stained with Alexa 
Fluor® 555, which detects phosphorylated H2AX (γH2AX), and Hoechst 33342 for nuclear 
morphology evaluation. The images were taken on a Nikon Eclipse TS100/TS100-F 
microscope with filter sets of Ex/Em of BP510-560/LP590 nm and BP330-380/LP420 nm for 
Alexa Fluor® 555 and Hoechst 33342, respectively. All the images were taken with an 
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exposure time of 6 s. Background images were taken for each channel under the same 
experimental conditions. The final images presented in Section 4.3.8 are corrected images 
obtained after subtracting the background images using Photoshop software (Adobe Systems 
Inc., San Jose, CA, USA).  
It has been reported by Kim et al. that the total area of γH2AX foci is a more sensitive 
parameter than the total number of the foci for measuring the amount of DNA DSBs (262). 
Therefore, in order to quantify the yield of DNA DSBs, we have calculated the average of 
integrated fluorescence intensity from the Alexa Fluor® 555 channel and plotted the results as 
a function of VP-16 concentration. Each data point represents the mean ± S.D. of three to 
five images. 
4.2.8 Detection of singlet oxygen by using singlet oxygen sensor 
green 
Singlet oxygen is believed to be the major ROS that is responsible for the cytotoxic effects 
generated during PDT treatment. In order to determine whether 1O2 is involved in this study, 
we have used a commercial fluorescence probe for 1O2 detection (Singlet Oxygen Sensor 
Green (SOSG)) (Invitrogen, Life Technologies Inc., Burlington, ON, Canada) to measure the 
relative yields of 1O2 under different treatment conditions. Figure 4-1 shows the chemical 
structures of SOSG and SOSG endoperoxide (SOSG-EP). In the parent compound SOSG, 
fluorescence is quenched by an intra-molecular electron transfer reaction. Upon reaction with 
1O2, SOSG is converted to SOSG-EP, in which electron transfer is blocked and fluorescence 
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emission is restored (263). A stock solution of 5 mM SOSG was prepared in methanol and 
stored at -20˚C in the dark. The work solution of 20 µM SOSG was prepared in PBS 
immediately before use. 
 
Figure 4-1: Chemical structures of singlet oxygen sensor green (SOSG) and SOSG 
endoperoxide (SOSG-EP). In SOSG, the fluorescence is quenched by an intra-molecular 
electron transfer reaction. Reaction of SOSG with singlet oxygen (1O2) leads to the formation 
of SOSG-EP, which can emit strong green fluorescence with a maximum of 536 nm (263). 
A549 cells were seeded and incubated with ICG and VP-16 as described in Section 
4.2.4. After incubation, drug containing medium was removed and cells were washed twice 
with PBS. Irradiation was done in the presence of PBS, 20 µM SOSG, 50% D2O or             
20 µM + 50% D2O. Immediately after laser irradiation, cells were washed three times with 
PBS and fresh culture medium was added. Images were then taken on a Nikon Eclipse 
TS100/TS100-F microscope with a filter set of Ex/Em of BP450-490/LP520 nm. All the 
images were taken with an exposure time of 7 s. A background image was taken under the 
same experimental conditions. The final images presented in Section 4.3.9 were corrected 
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images obtained by subtracting the background image using Photoshop software (Adobe 
Systems Inc., San Jose, CA, USA). In order to quantify the yields of singlet oxygen, we 
calculated the average of integrated fluorescence intensity of SOSG-EP. Each data point 
represents the mean ± S.D. of three images. 
4.2.9 Steady-state absorption and fluorescence spectroscopic 
measurements 
Steady-state absorption spectra of mixtures of ICG and VP-16 were measured on a Multiskan 
GO microplate spectrophotometer (Thermo Scientific, Mississauga, ON, Canada). Samples 
were prepared in complete F12K medium in 96-well microplates. Steady-state absorption 
spectra of VP-16 were measured on a DU 530 UV/Vis spectrophotometer (Beckman Coulter, 
Fullerton, CA, USA). Samples were prepared in 5 mm quartz cuvettes using ultrapure water. 
Steady-state fluorescence spectra were measured on a homemade fluorescence 
spectrophotometer (see Chapter 2). Samples were prepared in 5 mm quartz cuvettes using 
ultrapure water. All measurements were performed at room temperature. 
4.2.10 Femtosecond time-resolved transient absorption and 
fluorescence spectroscopic measurements 
The experimental setups for femtosecond time-resolved transient absorption and fluorescence 
spectroscopy have been described in Chapter 2. In the transient absorption experiment, the 
pump wavelength was fixed at 266 nm while two probe wavelengths (299 and 570 nm) were 
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chosen in order to distinguish between different intermediate species. Power dependence of 
transient absorption intensity of water and VP-16 samples was also measured to determine 
whether one- or two-photon excitation process was involved. For transient fluorescence 
measurements, the excitation and detection wavelengths were 266 and 353 nm, respectively. 
Samples were prepared in 5 mm quartz cuvettes using ultrapure water. All measurements 
were performed at room temperature. 
4.2.11 Data analysis 
4.2.11.1 Dose-response curve analysis 
The drug- and light-dose response curves were fitted with a sigmoidal logistic function by 
using Origin software (OriginLab, Northampton, MA, USA). The drug concentration (IC50) 
or light dose (LD50) required to produce a 50% cell killing effect was determined on the basis 
of the fitted data. 
4.2.11.2 Modified fractional effect analysis 
Fractional effect analysis is the most straight forward method for the evaluation of 
combination effects (9, 264). In this study, we have observed that addition of ICG at non-
cytotoxic concentrations can enhance the cytotoxicity of the chemotherapeutic drugs VP-16 
and VM-26 slightly even when cells are not exposed to laser irradiation. Considering this 
“dark effect” of the combination treatment, we have modified the fractional effect analysis 
for calculating the expected additive effects by using the following equation, in which the 
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effect induced by the chemotherapeutic drug has been replaced by the dark effect of ICG and 
the chemotherapeutic drug: 
                                                        𝑓𝑐𝑜𝑚. = 𝑓𝑑𝑎𝑟𝑘 × 𝑓𝑃𝐷𝑇 ,                                                  (4-1) 
where fcom., fdark and fPDT  denote the fraction of survived cell with the combination (ICG-PDT 
+ VP-16/VM-26), dark (ICG + VP-16/VM-26) and PDT (ICG + laser irradiation) treatments, 
respectively. The observed effects of the combination treatment are then compared with the 
expected additive effects: the effect is synergistic if the observed cell viability is lower than 
the expected additive effect and antagonistic if it is higher than the calculated value. 
4.2.11.3 Transient absorption and fluorescence decay kinetics analysis 
In order to determine the lifetimes from the transient absorption and fluorescence decay 
kinetic traces, we have fitted the curves with multi-exponential functions using the Scientist 
software (MicroMath Inc., Saint Louis, MO, USA). 
4.3 Results and discussion 
4.3.1 Drug- and light-dose responses of A549 cells to ICG-PDT 
treatment  
We have evaluated the photodynamic efficacy of ICG activated by an 800 nm laser. In this 
experiment, the cells were incubated with various concentrations of ICG for 5 h and then 
exposed to laser light irradiation. Cell viability was determined by using the standard MTT 
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assay. The results are shown in Figure 4-2. Photocytotoxicity of ICG increased in a drug- and 
light-dose dependent manner. At a light dose of 100 J cm-2, the IC50 of ICG was calculated to 
be 68.5 ± 1.7 µM. The LD50 values were found to be 28.8 ± 1.9 and 14.1 ± 1.2 J cm-2 for 100 
and 200 µM ICG, respectively. 
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Figure 4-2: (A) Drug-dose and (B) light-dose response curves for cell viability of A549 cells 
treated with ICG-mediated PDT. The cells were incubated with ICG for 5 h and then 
irradiated at 800 nm. Cell viability was evaluated by using the standard MTT assay 20 h 
after laser irradiation. The solid lines are best fits to the experimental data using a logistic 
function in Origin software. 
Anticancer activity of ICG has previously been studied by several research groups in 
a number of cell lines, including HeCaT keratinocytes, HT-29 human colon cancer, SCL1 
and SCL2 squamous cell carcinoma, N1 fibroblasts, human SKMEL 188 melanoma, mouse 
S91 melanoma, human skin Sk-Mel-28 melanoma, and MDA-MB231 breast cancer cells 
(190-192, 195, 199, 200, 265). For example, with 24 h drug-incubation and a light dose of  
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24 J cm-2, the IC50 of ICG was reported to be 20.1, 43.9, 61.8, and 62.3 µM in HaCaT, SCL1, 
SCL2, and N1 cells, respectively (265). The photodynamic efficacy of ICG in A549 cells 
observed in the present study is consistent with what have been reported in other cell lines. 
However, ICG is much less efficient in killing cancer cells than Photofrin®, the first 
clinically approved and currently the most widely used photosensitizer, which has an IC50 
value of only 0.5 µM in A549 cells at a lower light dose (266). Moreover, the blood half-life 
of ICG has been reported to be only 2-4 minutes (202). It will be very difficult to achieve an 
ICG concentration high enough to have significant antitumor effects under in vivo conditions. 
Therefore, we have explored the combination of ICG-PDT with conventional chemotherapy 
as a potential way of enhancing the effectiveness of ICG as a promising NIR agent for PDT. 
4.3.2 Drug- and light-dose responses induced by the combination 
treatment of ICG-PDT and VP-16 in A549 cells 
We have measured drug- and light-dose responses of A549 cells to the combination 
treatment of ICG-PDT and VP-16 (Figure 4-3 and Figure 4-4). As shown in Figure 4-3, with 
a drug incubation time of 4 h, IC50 of VP-16 was determined to be 41.7 ± 7.7 µM in A549 
cells. When combining VP-16 with 20 µM ICG, cytotoxicity was not affected significantly 
(IC50 = 37.4 ± 8.7 µM). Laser irradiation, at a light dose of 100 J cm-2, reduced the IC50 
dramatically to be 18.8 ± 1.6 µM, which was ~45% of that of VP-16. With higher ICG 
concentrations of 30 and 50 µM, a slight increase in cytotoxicity was observed even without 
laser irradiation. However, with the range of drug concentration in Figure 4-3B and C, the 
 107 
 
IC50 values could not be determined accurately. At a light dose of 100 J cm-2, the values of 
IC50 were calculated to be 10.9 ± 0.7 and 1.77 ± 0.17 µM, which were 26% and 4% of the 
IC50 of VP-16, for 30 and 50 µM ICG, respectively. We have also investigated the 
dependence of cytotoxicity of the combination treatment on ICG concentration. ICG was 
found to be only slightly cytotoxic in A549 cells with less than 7% of cells killed up to a 
concentration of 80 µM. VP-16 alone at a concentration of 2 µM was found to be not 
cytotoxic. Combination of 2 µM VP-16 with ICG at concentrations of 10 and 20 µM didn’t 
show enhanced cytotoxicity, while at higher ICG concentrations of 60 and 80 µM, 
cytotoxicity was increased from 4.1 ± 7.0% to 14.3 ± 4.7% and from 6.7 ± 2.9% to           
20.7 ± 2.6%, respectively. With laser irradiation, the IC50 of ICG was found to be           
155.7 ± 15.3 µM. In the presence of 2 µM VP-16, the IC50 was reduced by more than 73% 
(41.8 ± 1.8 µM). Moreover, we performed fractional effect analysis to evaluate the 
combination effects as described in Section 3.2.9. Considering the dark cytotoxicity of      
ICG + VP-16, we compared the combination effects with the cytotoxicity of ICG + VP-16 
instead of that of VP-16 alone. As shown in Figure 4-3, the dashed line and solid stars 
represent the predicated additive effects calculated using Equation (4-1). The observed 
effects were found to be the equal to or lower than the predicated additive effects indicating 
additive to synergistic enhancement of cytotoxicity induced by the combination treatment. 
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Figure 4-3: Drug-dose response curves for cell viability of A549 cells treated with the 
combination of ICG-PDT and VP-16. Cells were treated with ICG and VP-16 for 4 h after 
overnight incubation and then irradiated with 800 nm laser at a light dose of 100 J cm-2. 
Cell viability was evaluated by MTT cell viability assay 45 h after laser irradiation. The solid 
lines are best fits to the experimental data using a logistic function in Origin software. The 
dashed line and solid stars represent the calculated additive effect. 
We have observed a wide range of synergistic enhancement of cytotoxicity by the 
combination treatment of ICG-PDT and VP-16 and the degree of synergy has a strong 
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dependence upon the concentration of both ICG and VP-16. Although we have also observed 
slight increases in cytotoxicity in cells treated with ICG and VP-16 but without laser 
irradiation, this effect requires relative high concentrations of ICG and VP-16. It is well 
known that the blood half-life of ICG is about 2-4 min (202) resulting in limited 
accumulation of ICG in tissues and organs. Therefore, the dark effect is not likely to be 
significant under in vivo conditions. Moreover, one objective of this study is to overcome the 
severe side effects of chemotherapeutic drugs. Thus, it is considered to be desirable to lower 
the concentration of VP-16, which is also expected to help reduce dark cytotoxicity of the 
combination treatment. 
We have performed further experiments to study the light-dose dependence of 
cytotoxicity produced by the combination treatment of ICG-PDT and VP-16. The results are 
shown in Figure 4-4. As discussed above, low concentrations of both ICG and VP-16 should 
be used to minimize the dark cytotoxicity induced by the combination of ICG and VP-16. In 
this experiment, we varied the irradiation time to achieve various light doses between 0 and 
100 J cm-2 and evaluated the cytotoxicity of several combinations of ICG and VP-16. As 
shown in Figure 4-4, laser irradiation in the absence of both drugs was not cytotoxic up to a 
light dose of 100 J cm-2. Cytotoxicity of the group treated with VP-16 alone didn’t change 
significantly with increasing light dose. At a concentration of 30 µM, ICG didn’t show 
significant photo-cytotoxicity. When cells were incubated with 50 µM ICG, percentages of 
cell killed were increased from 2.1 ± 1.6% to 14.7 ± 5.1% and from 5.1 ± 3.4% to             
26.1 ± 2.9% at light doses of 50 and 100 J cm-2, respectively. The LD50 of ICG was much 
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higher than 100 J cm-2 and couldn’t be determined accurately from this experiment. Without 
laser irradiation, we observed a 10% increase in cytotoxicity of ICG + VP-16 compared with 
an expected additive effect. With laser irradiation, cell viability of the groups incubated with 
both ICG and VP-16 decreased dramatically with increasing light dose and the LD50 values 
were determined to be 28.0 ± 9.3, 14.4 ± 10.4, 6.55 ± 2.79 and 6.84 ± 6.06 J cm-2. We have 
also performed fractional effect analysis using Equation (4-1) and the expected additive 
effects have been plotted as dashed line and filled stars in Figure 4-4. With laser irradiation, 
the observed combination effects are found to lie below the additive effect curves for all the 
concentrations of ICG and VP-16 evaluated in this experiment confirming synergistic 
enhancement of cytotoxicity by the combination treatment of ICG-PDT and VP-16 in a wide 
range of drug concentration and light dose. 
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Figure 4-4: Light-dose response curves for cell viability of A549 cells treated with the 
combination of ICG-PDT and VP-16. Cells were treated with ICG and VP-16 for 4 h after 
overnight incubation and then irradiated with an 800 nm laser at a light dose of 100 J cm-2. 
Cell viability was evaluated by MTT cell viability assay 45 h after laser irradiation. The solid 
lines are best fits to the experimental data using a logistic function in Origin software. The 
dashed line and filled stars represent the calculated additive effect. 
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 The application of ICG as a PDT agent has been limited by the short blood half-life of 
2-4 min (202), which lowers the accumulation of this drug into tissues and organs. In this 
study, we have found that at a light dose of 100 J cm-2 (the typical light dose range for clinic 
applications of conventional PDT: 25-500 J cm-2 (52)), IC50 of ICG is much larger than       
80 µM in A549 cells. In cells treated with 50 µM ICG and laser irradiation, LD50 is much 
higher than 100 J cm-2. These results indicate that relative high drug- and light-doses are 
required for effective killing of cancer cells by ICG. Here, we have demonstrated that co-
incubation of the human lung cancer A549 cells with ICG and low dose VP-16 can increase 
the cytotoxicity in a synergistic manner leading to reduced effective doses of both drugs as 
well as light doses. A more than 20 times reduction in IC50 of VP-16, from > 40 µM to     
1.77 µM, has been observed in the cells treated with VP-16 and 50 µM ICG. Moreover, we 
have found that the degree of enhancement is light-dose dependent. These observations 
indicate that combining PDT mediated by ICG and VP-16 chemotherapy is a promising 
approach for improving the therapeutic effectiveness of ICG-PDT and reducing the side 
effects of VP-16 chemotherapy at the same time.  
ICG has been chosen in this study for several reasons. First, ICG has already been 
approved by the US FDA for clinical applications other than PDT. Second, ICG-PDT is 
activated by NIR light that can penetrate deeper into tissues. Therefore, the combination of 
ICG-PDT with VP-16 has the potential of treating larger tumor volumes. Combination of 
PDT with VP-16 has been reported by Gantchev et al. (174, 175). However, the 
photosensitizers used in those studies are metallic phthalocyanine (AlPcS4/ZnPcS4), which 
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requires red light for activation (λmax ~ 670 nm (267)). Stolik et al. have reported that the 
penetration depths of 780 and 835 nm light are ~10-130% larger than that of 674 nm light 
depending on tissue type (161). In lung carcinoma, for example, the values were determined 
to be 2.01, 2.82 and 3.89 mm for 674, 780 and 835 nm light, respectively. Therefore, ICG-
mediated PDT has the potential of treating deeper tumors than those can be treated by 
AlPcS4/ZnPcS4-mediated PDT. Third, there have been tremendous efforts on improving the 
tumor specificity of ICG as well as increasing accumulation of the drug into tumors and 
some of these systems have been shown to be superior to free ICG as imaging and 
photothermal therapy agents (109, 112, 115-118, 268). It would be of great interest to explore 
the PDT effectiveness of those systems either alone or in combination with other treatment 
modalities such as VP-16-mediated chemotherapy.  
4.3.3 Cytotoxicity of the combination treatment of ICG-PDT and 
VP-16 in HeLa and NIH:OVCAR-3 cells 
We have evaluated the cytotoxicity of the combination treatment of ICG-PDT and VP-16 in 
two more cancer cell lines: the human cervical cancer HeLa and ovarian cancer 
NIH:OVCAR-3 cells. The treatment procedure was the same as that applied in A549 cells. 
Figure 4-5A and B show the drug-dose response of HeLa cells to the combination treatment. 
The IC50 of VP-16 was determined to be 22.6 ± 6.0 µM. The combination of 20 µM ICG 
with VP-16 didn’t change the cytotoxicity significantly. Laser irradiation, at a light dose of 
100 J cm-2, reduced the IC50 by ~50% (11.3 ± 2.1 µM). ICG treatment alone was found to be 
 114 
 
not toxic up to the highest concentration of 80 µM. At a light dose of 100 J cm-2, the IC50 of 
ICG was determined to be 37.9 ± 1.8 µM. When cells were treated with mixtures of ICG and 
50 µM VP-16, cell viability decreased from 51.7% ± 3.6% to 35.2% ± 2.6% with increasing 
ICG concentration. The combination effects were found to fall below the calculated additive 
effects suggesting synergistic enhancement of cytotoxicity by the combination treatment. 
Figure 4-5C and D show the results obtained in NIH:OVCAR-3 cells. The IC50 of VP-16 was 
determined to be 209.4 ± 19.4 µM, which was about 5 and 9 times those in A549 and HeLa 
cells, respectively. The IC50 of ICG at a light dose of 100 J cm-2, was determined to be   
188.0 ± 36.0 µM, slightly higher than that in A549 cells and 5 times that in HeLa cells. These 
results show that sensitivity to both VP-16 and ICG-PDT treatment decreased in the order of 
HeLa > A549 > NIH:OVCAR-3. At a light dose of 100 J cm-2, the IC50 values of VP-16 and 
ICG were measured to be 81.9 ± 6.4 µM and 73.9 ± 6.1 µM, which were ~40% of those 
without laser irradiation. The results of fractional effect analysis showed that combination 
treatment of ICG-PDT and VP-16 enhanced cytotoxicity of the single treatments in a 
synergistic manner.  
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Figure 4-5: Drug-dose response curves for cell viability of (A) and (B) HeLa and (C) and (D) 
NIH:OVCAR-3 cells treated with the combination of ICG-PDT and VP-16. Cells were treated 
with ICG and VP-16 for 4 h after overnight incubation and then irradiated with an 800 nm 
laser at a light dose of 100 J cm-2. Cell viability was evaluated by MTT assay 45 h after laser 
irradiation. The solid lines are best fits to the experimental data using a logistic function in 
Origin software. The dashed line and filled stars represent the calculated additive effect. 
 Table 4-1 is a summary of IC50 values obtained from Figure 4-3 and Figure 4-5. HeLa 
cells have been shown to be most sensitive to both ICG-PDT and VP-16 among the three cell 
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lines studied here. The combination treatment of ICG-PDT and VP-16 has been shown to 
induce a moderate synergistic effect of ~50% reduction in IC50 of both VP-16 and ICG. A549 
cells are less sensitive to the single treatments than HeLa cells. However, strong synergy has 
been observed with the combination treatment of ICG-PDT and VP-16. We have obtained a 
more than 95% reduction in IC50 of VP-16 in cells treated with 50 µM ICG + 100 J cm-2. 
Table 4-1: A summary of the values of IC50 calculated from Figure 4-3 and Figure 4-5. 
                                             
 
  
 
 
Treatment 
 
IC50 (µM) 
A549 HeLa NIH:OVCAR-3 
VP-16 0 41.7 ± 7.7 22.6 ± 6.0 209.4 ± 19.4 
VP-16 + ICG + 100 J cm-2 
20 18.8 ± 1.6 11.3 ± 2.1 -- 
30 10.9 ± 0.7 -- -- 
50 1.77 ± 0.17 -- -- 
100 -- -- 81.9 ± 6.4 
ICG + 100 J cm-2 0 155.7 ± 15.3 37.9 ± 1.8 188.0 ± 36.0 
ICG + VP-16 + 100 J cm-2 
2 41.8 ± 1.8 -- -- 
20 -- -- 73.9 ± 6.1 
 
Cell Line 
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Compared with HeLa and A549 cells, NIH:OVCAR-3 cells are more resistant to the single 
treatments as well as the combination treatment. Cell viability of ~30% has been observed 
following 100 µM ICG + 200 µM VP-16 + 100 J cm-2 treatment. Therefore, effective killing 
of NIH:OVCAR-3 cells will require relatively high concentrations of both drugs and light 
doses, which may be difficult to achieve in in vivo experiments. 
4.3.4 Photocytotoxicity of the combination treatment of ICG-PDT 
and VP-16 in GM05757 cells 
We have tested the cytotoxicity of the combination treatment of ICG-PDT and VP-16 
chemotherapy in a human normal fibroblast cell line GM05757. The results are shown in 
Figure 4-6. Sensitivity to VP-16 chemotherapy treatment was found to be similar in 
GM05757 normal fibroblast and A549 lung cancer cells with a ~40% cell killing effect 
observed at a VP-16 concentration of 50 µM in both cell lines. No significant difference was 
observed between the groups treated with VP-16 alone or VP-16 + 50 µM ICG. At an ICG 
concentration of 50 µM and a light dose of 50 J cm-2, cell viability was 60.0 ± 3.5% and   
85.3 ± 5.1% in GM05757 and A549 cells, respectively. This result suggests that GM05757 
cells are more sensitive than A549 cells to ICG-PDT treatment. When treated with 50 µM 
ICG and irradiated at 50 J cm-2, there were still 29.5 ± 2.6 % of the cells survived at a VP-16 
concentration of 50 µM in GM05757 cells. In contrast, cell viability was found to be          
9.2 ± 1.8% at a much lower VP-16 concentration of 5 µM in A549 cells. Moreover, although 
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the combination effects have been found to be lower than the expected additive effects, the 
degree of synergy is much lower in GM05757 cells than that observed in A549 cells.  
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Figure 4-6: Drug-dose response curves for cell viability of human normal fibroblast cells 
(GM05757) treated with the combination of ICG-PDT and VP-16. Cells were treated with 
ICG and VP-16 for 4 h after overnight incubation and then irradiated with an 800 nm laser 
at a light dose of 100 J cm-2. Cell viability was evaluated by MTT assay 45 h after laser 
irradiation. The solid lines are best fits to the experimental data using a logistic function in 
Origin software. The dashed line and filled stars represent the calculated additive effect.  
The results in this experiment show that, the normal cells may have similar levels of 
sensitivity to PDT treatment as those of cancer cells. Fortunately, in PDT, local targeting of 
the diseased tissue can be achieved by selective delivery of laser beams. Sensitivity to VP-16 
treatment has been found to be similar in GM05757 and A549 cells. However, the 
combination treatment can induce a much stronger synergistic effect in A549 cells than in 
GM05757 cell and is more effective in killing A549 cells than GM05757 cells. 
 119 
 
We have evaluated the cytotoxicity of the combination treatment of ICG-PDT and 
VP-16 in three human cancer cell lines and one human normal fibroblast cell line. Our results 
show that among all four cell lines studied, HeLa and GM05757 cells are more sensitive to 
ICG-PDT treatment than the other two cell lines. Similar levels of sensitivity to VP-16 
chemotherapeutic treatment have been observed among HeLa, GM05757 and A549 cells, 
while NIH:OVCAR-3 cell are much more resistant to VP-16 as well as ICG-PDT. When 
ICG-PDT is combined with VP-16 chemotherapy, slight synergy is produced in GM05757 
cells. Synergism is most significant in A549 cells. Moderate synergy has also been observed 
in HeLa and NIH:OVCAR-3 cells. However, much higher drug and light doses are required 
to induce significant killing of NIH:OVCAR-3 cells. These findings suggest that the 
combination of ICG-PDT and VP-16 chemotherapy may be developed as an effective 
treatment approach for selected cancers such as lung cancers. 
4.3.5 The effects of treatment sequence on the cytotoxicity of the 
combination of ICG-PDT and VP-16 in A549 and HeLa cells 
We have tested whether the presence of VP-16 at the time of laser irradiation is required for 
synergistic enhancement of cytotoxicity. In this experiment, cells were incubated with ICG 
for 4 h and then irradiated at 800 nm. After laser irradiation, cells were incubated with VP-16 
for 4 h. MTT assay was performed 45 h after the removal of VP-16. The results are shown in 
Figure 4-7.  
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Figure 4-7: Sequence-dependent cytotoxicity of the combination treatment of ICG-PDT and 
VP-16 in (A) A549 and (B) HeLa cells. The cells were incubated with ICG for 4 h and then 
irradiated at 800 nm. VP-16 was added after laser irradiation. Cell viability was evaluated 
45 h after laser irradiation by using the standard MTT assay. The solid lines are best fits to 
the experimental data using a logistic function in Origin software. 
 At the highest VP-16 concentration of 50 µM tested, we observed a cell viability of 
~50% in both A549 and HeLa cells similar to the level of cytotoxicity observed in Sections 
4.3.2 and 4.3.3, where cells were treated with VP-16 before laser irradiation. No significant 
difference in cell viability was observed among the groups treated with VP-16, VP-16 + ICG 
and VP-16 + ICG + 50 J cm-2 in either A549 or HeLa cells. This is in contrast to the strong 
synergistic effects observed in cells co-incubated with ICG and VP-16 before laser 
irradiation. This observation suggests that the presence of VP-16 at the time of laser 
irradiation is essential for synergistic enhancement of cytotoxicity induced by the 
combination treatment of ICG-PDT and VP-16.  
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4.3.6 Cytotoxicity of the laser-irradiated mixture of ICG and VP-16 
in A549 cells 
We performed another experiment in which we made several mixtures of ICG and VP-16 in 
the complete cell culture medium and irradiated them with various light doses. Cells were 
incubated with the laser-irradiated mixtures of drugs for 4 h and then incubated with drug-
free medium for 45 h before adding MTT. The results are shown in Figure 4-8. Cytotoxicity 
of the cell culture medium and VP-16 at all three concentrations evaluated in this experiment 
didn’t show significant dependence on light dose (Figure 4-8A). In cells treated with the 
mixtures of 50 µM ICG and VP-16, cytotoxicity didn’t change significantly with increasing 
light dose (Figure 4-8B). When ICG was combined with VP-16, we noted that the cell 
viability decreased slightly compared with the groups treated with VP-16 alone. This has 
been attributed to be the dark effect discussed in Section 4.3.2. These results show that the 
cytotoxicity of the combination treatment of ICG-PDT and VP-16 differs dramatically from 
that of the laser irradiated mixtures of the two drugs. Therefore, it is likely that the observed 
synergistic effects induced by the combination treatment involve certain intracellular 
components such as enzymes.   
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Figure 4-8: Cytotoxicity of laser-irradiated mixtures of ICG and VP-16 in A549 cells. Cells 
were treated with the photo-irradiated mixtures of ICG and VP-16 for 4 h. Cell viability was 
evaluated by using the standard MTT assay 45 h after the removal of the drugs. 
 The steady-state absorption spectra of 30 µM ICG and 30 µM ICG + 20 µM VP-16 
were also recorded at all five light doses to see whether the presence of VP-16 affected the 
photo-degradation rate of ICG (Figure 4-9). We have calculated the differences in maximum 
absorbance between the laser-irradiated samples and dark controls and plotted the normalized 
values as a function of light dose in Figure 4-9C. Photo-degradation of ICG alone or in the 
presence of 20 µM VP-16 showed a linear dependence on irradiation dose. We didn’t 
observe significant difference between the degradation rate of ICG in the absence and in the 
presence of VP-16. This finding indicates that there is no direct interaction between ICG and 
VP-16 in the complete cell culture medium under laser irradiation at 800 nm up to a light 
dose of 100 J cm-2. 
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Figure 4-9: Spectral changes of 30 µM ICG in complete F12K cell culture medium with 
increasing light dose (A) in the absence and (B) presence of 20 µM VP-16. (C) Shows the 
absorbance difference between the laser irradiated samples and the dark controls as a 
function of light dose normalized to the absorbance of the dark controls. The solid lines are 
the best linear fits to the data. 
Fluorescence measurements have been widely applied in physical, chemical and 
biological studies due to the extreme sensitivity of fluorescence to local environment. In this 
experiment, we measured the steady-state fluorescence spectra of 10 µM ICG in the presence 
of 0, 0.5 and 1 mM VP-16 (Figure 4-10A) to see whether there was direct interactions 
between ICG and VP-16 under laser irradiation. An excitation wavelength of 720 nm instead 
of 800 nm was chosen in order to minimize contribution from scattered light to the 
fluorescence intensity of the samples. Since the stock solution of VP-16 was made in DMSO, 
the fluorescence spectra of ICG in the presence of the same amounts of DMSO as that added 
in Figure 4-10A were also recorded and shown in Figure 4-10B.  
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Figure 4-10: (A) Fluorescence spectra of 10 µM ICG in the presence of 0, 0.5, or 1 mM of 
VP-16. The excitation wavelength was 720 nm. The emission maximum is 829 nm. (B) The 
same amount of DMSO as in (A) was added to ICG in order to account for any effect due to 
the addition of the solvent of VP-16. The solid lines are the best Gaussian fits to the spectra 
of 10 µM ICG. 
The fluorescence of ICG has a maximum at 829 nm consistent with the fluorescence 
maximum of ICG in water reported by Gerega et al. (269). With the addition of VP-16 or 
DMSO, no significant change in the fluorescence spectrum of ICG was observed. This 
observation is in agreement with what has been observed in the steady-state absorption 
experiment confirming the absence of direct interaction between the excited singlet state of 
ICG (1ICG*) and VP-16. 
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4.3.7 Electron-transfer-induced synergistic enhancement of 
cytotoxicity by the combination treatment of ICG-PDT and VP-16 
Previously, Gantchev et al. have suggested that the mechanism for synergistic enhancement 
of cytotoxicity produced by combination of metallic phthalocyanine-mediated PDT and    
VP-16 is PDT-induced depletion of intracellular glutathione (GSH), an antioxidant that is 
believed to be able to reduce the highly cytotoxic radicals of VP-16 (175). In order to see 
whether this mechanism is responsible for the synergism observed in the present study, we 
have performed an experiment in which the cells were treated with VP-16 immediately after 
laser irradiation (see Section 4.3.5). We should have observed synergistic enhancement of 
cytotoxicity, if the ICG-PDT treatment induced cellular damages, which were expected to 
last for hours following laser irradiation (200), had potentiated the cytotoxicity of VP-16. 
Therefore, the strong synergy induced by the combination of ICG-PDT and VP-16 is not 
likely due to ICG-PDT produced cellular damages but involves direct or indirect interaction 
between ICG and VP-16 during the course of laser irradiation.  
In our group, we have identified an electron-transfer reaction between a biological 
electron donor (TMPD; N,N,N′,N′-tetramethyl-p-phenylenediamine) and cisplatin (CDDP) 
responsible for synergistic enhancement to cytotoxicity in selected cancer cell lines (9). 
Based on the following considerations, we have proposed a similar mechanism in the present 
study: the enzyme-mediated electron-transfer reaction from VP-16 to 1ICG* could induce 
synergistic enhancement of cytotoxicity in vitro. First, we have calculated the free energy 
 126 
 
change of the electron-transfer reactions between ICG/1ICG* and VP-16 by using the 
following Rehm-Weller equation (270): 
                                             ∆𝐺 (𝑒𝑉) = 𝑛𝐹(𝐸𝑜𝑥 − 𝐸𝑟𝑒𝑑) − 𝑤𝑝 − 𝐸00,                                      (4-2) 
where n is the number of electrons transferred, F is the Faraday’s constant, Eox and Ered are 
the oxidation potential of the donor and reduction potential of the acceptor, respectively, wp 
describes the Coulombic attraction between ions generated by electron transfer reactions, and 
E00 is the energy of excitation. For most electron transfer reactions, nF is approximately 
equal to one and can be disregarded in the calculations. The work term, wp, can also be 
disregarded due to the lack of electrostatic attraction between a charged species (ICG) and a 
neutral species (VP-16). The oxidation potential of VP-16 is 0.51 eV vs. SHE at pH 7 (271). 
The reduction potentials of ICG in acetonitrile have been reported to be -0.59 eV vs. SHE 
(272). Therefore, the free energy change of one-electron transfer from ICG to VP-16 can be 
estimated to be 1.1 eV suggesting that this reaction is thermodynamically unfavorable. When 
ICG is excited to 1ICG*, the free energy change can be estimated to be -0.45 eV. A negative 
free energy change indicates that one-electron transfer from VP-16 to 1ICG* is 
thermodynamically favorable. Second, we have demonstrated that incubating the cells with 
VP-16 immediately after ICG-PDT treatment didn’t show any synergistic effect. This 
observation cannot be explained by independent action of ICG-PDT and VP-16 to activate 
different cellular pathways. Third, although our steady-state absorption and fluorescence 
spectroscopic results indicate the absence of direct reaction between 1ICG* and VP-16, 
binding of VP-16 with intracellular enzymes such as oxidases may lower the activation 
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energy and increase the reaction rate. In humans, VP-16 can be oxidized by oxidases to 
phenoxy radicals (273), which may be further converted to metabolites that have been shown 
to be more activate than the parent compound VP-16 in inducing DNA DSBs (12-14, 274). 
Therefore, 1ICG* may act as an electron acceptor in those systems and facilitate the 
generation of VP-16 radicals.  
4.3.8 Combination treatment of ICG-PDT and VP-16 increased the 
yield of DNA double strand breaks 
To further investigate the mechanism underlying the synergistic effects observed in MTT 
assay results, we measured the yield of DNA DSBs. For this, the commercial HCS DNA 
damage kit was used. Representative images are shown in Figure 4-11, Figure 4-12 and 
Figure 4-13 for A549, HeLa and NIH:OVCAR-3 cells, respectively. VP-16 is known to 
cause DNA DSBs and γH2AX has been shown to be a sensitive marker of DNA DSBs 
induced by a variety of DNA damaging agents including VP-16 (262, 275-277). In the 
present study, γH2AX foci (red channel) were indeed observed when cells were treated with 
VP-16 (row #2). While the brightness of red fluorescence didn’t change significantly when 
cells were treated with VP-16 and ICG (row #3), laser irradiation produced significantly 
more γH2AX foci as shown in the last row.  
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Figure 4-11: Representative images of the combination treatment of ICG-PDT and VP-16 in 
A549 cells using the HCS DNA damage kit. The cells were treated with VP-16 and ICG after 
overnight incubation. After 4 h incubation, the cells were washed twice with PBS and 
irradiated at 800 nm. DNA damages were measured using the HCS DNA damage kit 18h 
after laser irradiation. The images were taken on a Nikon Eclipse TS100/TS100-F 
microscope. Alexa Fluor® 555 is shown in red (λex = 510-560 nm; λem > 590 nm). Hoechst 
33342 is shown in blue (λex = 330-380 nm; λem > 420 nm). The exposure time was 6 s. 
Background images were taken under the same experimental conditions and subtracted 
using Photoshop software. 
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Figure 4-12: Representative images of cytotoxicity of the combination treatment of ICG-PDT 
and VP-16 in HeLa cells using the HCS DNA damage kit. The experimental conditions were 
identical to those in A549 cells. 
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Figure 4-13: Representative images of cytotoxicity of the combination treatment of ICG-PDT 
and VP-16 in NIH:OVCAR-3 cells using the HCS DNA damage kit. The experimental 
conditions were identical to those in A549 cells. 
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Figure 4-14: Integrated Alexa Fluor® 555 fluorescence intensity per cell as a function of  
VP-16 concentration in (A) A549, (B) HeLa and (C) NIH:OVCAR-3 cells using the HCS DNA 
damage kit. The integrated fluorescence intensity was calculated and the number of cells 
was counted using the Photoshop software. Results represent mean ± S.D. of at least three 
images. 
It has been suggested that the relative yield of DNA DSBs could be measured more 
accurately by using the total area of γH2AX foci than the total number of the foci (262). 
Therefore, we plotted the average of integrated fluorescence intensity of the red channel as a 
function of VP-16 in Figure 4-14. Intensity of γH2AX foci increased with increasing VP-16 
concentration in all three cancer cell lines. When cells were treated with ICG and VP-16, the 
intensity of γH2AX foci was not changed significantly in A549 and NIH:OVCAR-3 cells. A 
slightly higher intensity was obtained in HeLa cells. With a light dose of 100 J cm-2, the 
fluorescence intensity was increased by ~2 fold suggesting increased yields of DNA DSBs. 
These results indicate that increased generation of DNA DSBs by the combination treatment 
of ICG-PDT and VP-16 is at least partially responsible for the synergistic enhancement of 
cytotoxicity observed in MTT experiments. 
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4.3.9 Detection of singlet oxygen induced by the combination 
treatment of ICG-PDT and VP-16 in A549 cells 
In PDT, tumor destruction is believed to be achieved through the generation of cytotoxic 
ROS especially 1O2. Therefore, we detected the intracellular generation of 1O2 following 
laser irradiation by using a fluorescence probe for 1O2 known as the singlet oxygen sensor 
green (SOSG). Representative images are shown in Figure 4-15. The first column shows the 
images from the control group and the groups treated with 50 µM ICG, 100 µM VP-16 and 
ICG + VP-16. No detectible fluorescence was observed. The second column shows the 
images from the same drug treatment groups with the addition of 20 µM SOSG. Weak green 
fluorescence can be seen. The third column shows the results of the groups treated with the 
drugs and laser irradiation at a light dose of 50 J cm-2. The fluorescence of the group treated 
with ICG + VP-16 + 50 J cm-2 was found to be brighter than that of the other groups in the 
same column. In the last column, cells were irradiated in the presence of                               
20 µM SOSG + 50% D2O. Again, the group treated with both drugs and laser irradiation 
showed brighter fluorescence than the other three images. We also noted that the 
fluorescence intensity of images in the last column was stronger than the corresponding ones 
in the other three columns. 
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Figure 4-15: Fluorescence detection of intracellular singlet oxygen generation using Singlet 
Oxygen Sensor Green (SOSG) in A549 cells. The cells were incubated with 50 µM ICG,     
100 µM VP-16 or the combination of the two drugs for 4 h. After incubation, the cells were 
irradiated at 800 nm in the absence or presence of 20 µM SOSG. The enhanced 
fluorescence intensity in the presence of 50% D2O confirms the involvement of 1O2. The 
images were taken on a Nikon Eclipse TS100/TS100-F microscope after irradiation. The 
filter set with λex = 450-490 nm and λem > 520 nm was used. All images were taken with an 
exposure time of 6 s. A background image was taken under the same experimental 
conditions and subtracted using Photoshop software. 
 To quantify the relative yield of 1O2, we calculated the average fluorescence intensity 
per cell by using Photoshop software. The results are plotted in Figure 4-16.  
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Figure 4-16: Integrated SOSG/SOSG-EP fluorescence intensity per cell in A549 cells. The 
integrated fluorescence intensity was calculated and the number of cells was counted using 
the Photoshop Software. Results represent mean ± S.D. of at three images.  
 Without laser irradiation, no significant difference was observed among the groups not 
treated with drug, treated with ICG only, VP-16 only and ICG + VP-16. The difference 
between the groups treated with or without laser irradiation was found to be not significant. 
In the presence of 50% D2O, we observed a ~2-fold increase in the average fluorescence 
intensity compared with the group irradiated in the absence of D2O. It’s worth noting that the 
average fluorescence of SOSG-EP of the samples treated with both ICG and VP-16 didn’t 
differ significantly from those treated with either ICG or VP-16, while the fluorescence 
images from the samples treated with ICG + VP-16 looked brighter than those from the other 
treatment groups (Figure 4-15). We noted that, with laser irradiation, cells in the               
ICG + VP-16 treatment groups appeared to be smaller and more rounded while those in the 
ICG or VP-16 treatment groups were more extended. This is reasonable because cell 
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shrinkage and rounding are morphology characteristics of cell undergoing apoptosis. 
Therefore, the brighter fluorescence observed in Figure 4-15 is likely due to the reduced 
volume of the cells instead of increased yields of SOSG-EP. This is not surprising 
considering the extremely low 1O2 yield of ICG (218, 251). The observation of a 2-fold 
increase in the intensity of the green fluorescence in the presence of D2O suggested 
involvement of 1O2, which was generated probably by cellular metabolism instead of      
ICG-PDT treatment.  
4.3.10 Drug-dose response of the combination treatment of        
ICG-PDT and VM-26 in A549 cells 
We also evaluated the cytotoxicity of ICG-PDT in combination with another 
podophyllotoxin derivative VM-26. The treatment procedure was the same as that applied in 
combination treatment of ICG-PDT and VP-16. The results are shown in Figure 4-17. The 
IC50 of VM-26 was determined to be 3.31 ± 0.54 µM, which was ~8% of that of VP-16. 
When cells were incubated with VM-26 and 50 µM ICG, the IC50 was reduced slightly to 
1.85 ± 0.28 µM, which could be attributed to the dark effects discussed in Section 4.3.2. 
With laser irradiation, further reduction of more than 90% (IC50 = 0.27 ± 0.07 µM) was 
observed at a light dose of 100 J cm-2.  
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Figure 4-17: Drug-dose response curves for cell viability of A549 cells treated with the 
combination of ICG-PDT and VM-26. Cells were treated with ICG and VM-26 for 4 h after 
overnight incubation and then irradiated with an 800 nm laser at a light dose of 100 J cm-2. 
Cell viability was evaluated by MTT cell viability assay 45 h after laser irradiation. The solid 
lines are best fits to the experimental data using a logistic function in Origin software. The 
dashed line and solid stars represent the calculated additive effect. 
Both VP-16 and VM-26 are derivatives of podophyllotoxin and their antitumor 
activities have been studied in a number of cell lines (278-281). It has been found that     
VM-26 is about 10 times more effective than VP-16 in a human lymphoblastic leukemia cell 
line (CCRF-CEM (278)) and several human small cell and non-small cell lung carcinoma 
cell lines (NCI-H69, NCI-N592, OC-TOL, OC-ROL, OC-NYH (279), NCI-H460,           
NCI-H187, NCI-H209, NCI-h522, NCI-H1284, NCI-H322, and NCI-H69 (280)). In the 
present study, we have obtained an IC50 of VM-26 that is ~8% of the IC50 of VP-16 
consistent with the higher potency of VM-26 than VP-16 reported by other research groups. 
The lower IC50 of VM-26 has been attributed to be a higher uptake of VM-26 than VP-16 
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(282). In cells treated with VM-26 and ICG-PDT at an ICG concentration of 30 µM, the 
degree of reduction in IC50 has been found to be ~15% higher than that observed with VP-16 
under the same ICG-PDT treatment conditions. A similar level of synergy observed when 
combining ICG-PDT with VP-16 and VM-26 suggests the involvement of the same 
mechanism, which has been proposed in Section 4.3.7. The oxidation potential of VM-26 has 
been reported to be 0.56 eV vs. SHE at pH 7 (283), which is 0.05 eV higher than that of    
VP-16 (271). The free energy change of one-electron transfer from VM-26 to 1ICG* can be 
estimated to be -0.4 eV by using Equation (4-2) indicating that this reaction is also energy 
favorable. The close oxidation potentials of VP-16 and VM-26 are expected to lead to a 
similar level of synergy, which has been confirmed by the MTT cytotoxicity results. This 
finding is in agreement with our proposal of an electron-transfer-based mechanism for 
synergistic enhancement of cytotoxicity. These results also show that synergistic 
enhancement of cytotoxicity is not limited to the combination of ICG-PDT with VP-16. It 
has also been achieved with VM-26. Therefore, studies of the combination effects of       
ICG-PDT with other chemotherapeutic drugs would be of great help in the development of 
clinically effective treatment strategies. 
4.3.11 Steady-state absorption and fluorescence spectra of VP-16 
We have measured the steady-state absorption and fluorescence spectra of VP-16 in water 
(Figure 4-18). VP-16 has an absorption maximum at 283 nm, which is the same as that 
observed in absolute methanol (284). The fluorescence spectrum has been recorded with our 
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homemade fluorometer and corrected by using the collection efficiency of the system as 
described in Chapter 2. When excited at 266 nm, the fluorescence spectrum of 100 µM     
VP-16 has a maximum at 350 nm. Holthuis et al. have reported that the fluorescence 
maximum of VP-16 is ~320 nm in absolute methanol (284). It is well known that solvent 
polarity can have a dramatic effect on fluorescence spectra: a spectral shift may be produced 
as a result of decreased excited-state energy with increasing solvent polarity (224). The red-
shifted fluorescence spectrum obtained in this study is likely due to an increase in solvent 
polarity from methanol to water. 
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Figure 4-18: UV-visible absorption spectrum of 300 µM VP-16 and steady-state 
fluorescence spectrum of 100 µM VP-16 in water. The arrows indicate the pump and probe 
wavelengths in the transient absorption experiment. The excitation wavelength for the 
fluorescence spectrum was 266 nm. The blue solid line is the best Gaussian fit to the 
experimental data. 
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4.3.12 Femtosecond time-resolved transient absorption 
spectroscopic results 
We have obtained the femtosecond time-resolved transient absorption decay kinetic profiles 
of various concentrations of VP-16 in water (Figure 4-19B and Figure 4-20). The pump 
wavelength was 266 nm, where VP-16 had significant absorbance (Figure 4-18). Previously, 
Lu et al. have demonstrated that, in aqueous solution, VP-16 can be ionized by 248 nm laser 
to generate VP-16 cation radicals (VP-16+∙), which have an absorption maximum at 290 nm 
(285). Since the pump wavelength of 266 nm used in this study was very close to 248 nm 
used by Lu et al., our first experiment was conducted with a probe wavelength of 290 nm to 
see whether VP-16+∙ were generated under our experimental conditions. Figure 4-19 shows 
the transient absorption kinetics of the solvent water and 200 µM VP-16 at various pump 
powers. With a pump wavelength of 266 nm, solvated electrons can be generated through 
two-photon excitation of water (222). Indeed, we observed positive signals in pure water at 
all the pump powers used in this experiment (Figure 4-19A). The strong signal at delay time 
zero is the coherent spike produced from the interaction between the ultra-short pump and 
probe pulses (219). The curves can be fitted with a bi-exponential function yielding a short 
lifetime of 34.3 ± 18.8 ps and a much longer one, which is beyond the detection limit of our 
fs-TRLS system. The pre-exponential factor of the short-lived component has been plotted as 
a function of pump power in Figure 4-19D. The linear fit to the data points on a log-log plot 
yields a slope of 2.2 ± 0.3 ps confirming a quadratic dependence of the signal on laser power. 
Therefore, the species detected in pure water can be assigned to be solvated electrons 
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generated from two-photon excitation of water. Figure 4-19B show the transient absorption 
kinetics of VP-16. In Figure 4-19C, the contribution from the solvated electrons has been 
removed by subtracting the signal of pure water from that of VP-16. Fitting of the data with a 
bi-exponential function gives a short lifetime of 74.0 ± 3.8 ps and a longer one of on the scale 
of nanosecond. The lifetime of the short-lived component is much longer than that observed 
in pure water indicating that this species is not solvated electron generated from 
photoionization of VP-16. We have tentatively assigned this short-lived species to be the 
excited singlet state of VP-16 (1VP-16*). The long-lived component, as shown in Figure 
4-19D, has a linear dependence on laser power suggesting that a one-photon process is 
responsible the generation of this species. Previously, Sun et al. reported that VP-16 could 
capture the solvated electrons to produce the anion radicals of VP-16 (VP-16-∙) (286), which 
had absorption at the currently probe wavelength of 290 nm (285). If the VP-16-∙  was 
produced from the reaction of VP-16 with the solvated electron, the absorbance should show 
a quadratic dependence on pump power. Therefore, our observation of a linear dependence of 
the contribution from the long-lived species on pump power ruled out the possibility that this 
component was the VP-16-∙. Moreover, we noted that Lu et al. had obtained the transient 
absorption spectrum of VP-16 from 248 nm laser photolysis and assigned the species having 
an absorption maximum at 290 nm to be VP-16+∙ generated from one-photon ionization of 
VP-16 (285). Accompanying the generation of VP-16+∙, solvated electrons, which have a 
broad absorption band extending from the near-ultraviolet range to the near-infrared range, 
should have also been produced. Therefore, the slow decaying component could be a mixture 
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of solvated electrons, VP-16+∙ and VP-16*. In order to determine the identity of this long-
lived species, we performed more experiments by changing the probe wavelength to 570 nm, 
where absorption by VP-16+∙ was negligible (285).                                                                                                                                                                                                                                                  
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Figure 4-19: Power-dependence of the transient absorption decay kinetics of (A) water and 
(B) 200 µM VP-16. (C) The transient absorption curves for VP-16 after removing the 
contribution from the solvent water. The pump and probe wavelengths were 266 and 290 
nm, respectively. The pink solid lines represent the best fits to the experimental data with a 
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multi-exponential function using Scientist software. (D) The log-log plot of the pre-
exponential factors against pump power. Linear fits to the data yield slopes of 2.2 ± 0.3 
and 0.9 ± 0.2 for water and VP-16, respectively, confirming two-photon generation of 
solvated electrons in water and one-photon excitation of VP-16. 
 Figure 4-20 shows the transient absorption kinetics of various concentration of VP-16 
in water. The pump and probe wavelength were 266 and 570 nm, respectively. As shown in 
Figure 4-20A, pure water has very strong signal at this probe wavelength at a pump power of 
only 6 µW. The intensity of the short-lived component increased with increasing 
concentration of VP-16 without affecting the intensity of the long-lived component. 
Considering that the stock solution of VP-16 was made in DMSO, a pre-solvated electron 
scavenger (19), the kinetic trace of 2% DMSO in water was also recorded to see whether the 
addition of DMSO had any effect on the signal of the solvated electrons. The kinetic trace of 
2% DMSO overlapped with that of pure water indicating that the contribution from DMSO 
was negligible. We further removed the contribution of water to kinetic traces by subtracting 
the signal of pure water from that of VP-16 solutions and the results are shown in Figure 
4-20B. The data can be adequately fitted with a single-exponential function to produce a 
decaying lifetime of 90.0 ± 3.8 ps, which is very close to the lifetime of 74.0 ± 3.8 ps 
observed at 290 nm suggesting that the same species has been detected. However, the long-
lived component observed at 290 nm was not observed at 570 nm. This finding suggests that 
no detectable amount of solvated electrons has been generated from VP-16 under our 
experimental conditions and the long-lived species detected at 290 nm is not the cation 
radical of VP-16. Therefore, the long-lived component is most likely the excited triplet state 
of VP-16 (3VP-16*). However, further investigation is required to confirm the identity of this 
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species, which is beyond the scope of this study. The transient absorption results show that 
under our experimental conditions, VP-16 is not ionized by the laser pulses. The excited 
singlet state of VP-16 has been detected at both 290 and 570 nm and the lifetime has been 
determined to be in the range 70-90 ps. 
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Figure 4-20: Pump-probe transient absorption decay kinetics of 200, 500 and 1000 µM  
VP-16 in water. The pump and probe wavelengths were 266 and 570 nm, respectively. The 
pump power was 6 µW. (A) The experimental data. (B) The decay kinetics of VP-16 after 
removing the contribution from the solvated electrons generated from the solvent. The solid 
lines represent the best fits to the experimental data yielding a decaying lifetime of        
90.0 ± 3.8 ps. 
4.3.13 Femtosecond time-resolved fluorescence spectroscopic results 
To further confirm that the short-lived species detected by the transient absorption 
measurements is 1VP-16*, we have performed transient fluorescence spectroscopic 
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experiments. Figure 4-21 shows the transient fluorescence decay kinetics of 500 µM VP-16 
in water excited at 266 nm. The detection wavelength was 353 nm. 
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Figure 4-21: Pump-probe fluorescence decay kinetics of 500 µM VP-16 in water. The 
excitation and emission wavelengths were 266 and 353 nm, respectively. The open blue 
circles are the experimental data. The solid red line represents the best fits to the 
experimental data yielding a rising lifetime of 0.55 ± 0.10 ps and a decaying lifetime of 
86.7 ± 2.8 ps. 
The kinetic trace can be fitted with a single-exponential function yielding a 
fluorescence lifetime of 86.7 ± 2.8 ps, which is consistent with the excited singlet state 
lifetime of VP-16 determined by transient absorption spectroscopy. 
 The fs time-resolved laser spectroscopy (fs-TRLS) has been demonstrated to be a 
powerful tool in studying the ultrafast dynamics of molecules and unraveling the molecular 
mechanism of action of anticancer drugs (19, 20, 182, 183, 217-221). In the present study, 
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we have performed fs time-resolved transient absorption and fluorescence spectroscopic 
studies on VP-16. The fluorescence lifetime of VP-16 in water has been determined to be 
86.7 ± 2.8 ps. To the best of our knowledge, this has not been reported before. We have also 
obtained the transient absorption kinetic traces of 1VP-16* at 290 and 570 nm. Although the 
pump wavelength of 266 nm is closed to 248 nm used by Lu et al. (285), no significant 
contribution from VP-16+∙ has been observed in the present study. The long-lived species 
detected at 290 nm has been assigned to 3VP-16*. These results suggest that the fs-TRLS may 
be applied in studying the mechanism of anticancer activity of VP-16. 
4.4 Summary 
We have performed in vitro cytotoxicity studies on the combination effects of ICG-PDT with 
VP-16 or VM-26 in three human cancer (A549, HeLa and NIH:OVCAR-3) cell lines and one 
human normal fibroblast (GM05757) cell line. Sensitivity to VP-16 treatment has been found 
to be similar among A549, HeLa and GM05757 cells. HeLa and GM05757 cells have been 
shown to be much more sensitive to ICG-PDT treatment than the other two cell lines. Among 
all four cell lines studied, NIH:OVCAR-3 cells are most resistant to both VP-16 and       
ICG-PDT treatments. With combination treatment of ICG-PDT and VP-16/VM-26, strong 
synergistic enhancement of cytotoxicity has been observed in A549 cells in wide ranges of 
drug concentrations and light doses. A more than 95% reduction in IC50 has been obtained in 
cells co-treated with VP-16 and 50 µM ICG + 100 J cm-2. The degree of enhancement has 
been found to be moderate in HeLa and NIH:OVCAR-3 cells and lowest in GM05757 cells. 
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We have measured the relative yields of DNA DSBs by using the commercial HCS DNA 
damage kit and found that the combination treatment can increase the yields of DSBs by   
~2-fold in the three cancer cell lines. These findings suggest that ICG-mediated PDT may be 
combined with VP-16/VM-26 in treating selected cancers such as lung cancers. Synergistic 
enhancement of cytotoxicity has the potential of increasing the effectiveness of treatment and 
more importantly, reducing toxic side effects of the chemotherapeutic drugs. Furthermore, 
the observation of a strong dependence of the degree of synergy on light dose suggests that 
the reaction can be controlled by light. Targeted delivery of laser beams may further reduce 
the overall toxicity of the treatment. 
 The synergism has been demonstrated to depend on the sequence of treatment. 
Synergistic effects were not observed when VP-16 was added after laser irradiation. This 
finding indicates the involvement of direct or indirect interaction between ICG and VP-16 
during the course of laser irradiation. We have also evaluated the cytotoxicity of the laser-
irradiated mixtures of the drugs and found that intracellular components, probably enzymes, 
might be required for the activation of the drugs. Based on these results, we have proposed an 
electron-transfer-based mechanism for synergistic effects observed in cytotoxicity studies. 
The electron-transfer reaction from VP-16/VM-26 to 1ICG* has been found to be 
thermodynamically favorable with negative free energy changes of -0.45 and -0.4 eV for  
VP-16 and VM-26, respectively. The small difference between the free energy changes of the 
two drugs implies a similar level of cytotoxicity associated with the reactions, which has 
indeed been observed: reductions of 74% and 95% in IC50 have been observed for VP-16 and 
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VM-26, respectively. This result is also in agreement with our proposed mechanism for 
synergism.  
In summary, these studies may help improve our understanding of the molecular 
mechanisms underlying the synergistic enhancement of ICG-PDT with chemotherapeutic 
drugs and thus, facilitate the development of more effective treatment approaches for 
cancers. 
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5 Combination of Near Infrared Light-Activated Photodynamic Therapy Mediated by Indocyanine Green with Cisplatin/Oxaliplatin Chemotherapy 
5.1 Background 
Cisplatin (CDDP) is one of the most widely used chemotherapeutic drugs currently available  
for treating cancers of various organs such as bladder, blood vessel, bone, brain, cervix, 
lymphoma, lung, and ovary (7-9). The major cellular target of CDDP is believed to be 
nuclear DNA. Several forms of damages, including single strand breaks (SSBs), double 
strand breaks (DSBs), and intrastrand or interstrand crosslinks, can be formed upon reaction 
of CDDP with DNA (7, 287, 288). These DNA damages may be repaired through a number 
of DNA repair pathways. However, failure to repair these damages may trigger apoptosis that 
finally leads to cancer cell death. The great success of CDDP as an anticancer drug has 
stimulated the development of many platinum-based anticancer drugs. Among them, 
carboplatin and oxaliplatin (OXP) have been approved by the U.S. Food and Drug 
Administration (FDA) for clinic use (7, 287, 288). Carboplatin is less toxic than CDDP and 
thus, produces fewer side effects. However, its spectrum of activity is identical to that of 
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CDDP making it not effective against CDDP-resistant cancers. Oxaliplatin is currently being 
used in combination with 5-fluorouracil (5FdUr) for the treatment of metastatic colorectal 
cancers. It has also been found to be effective in treating cancers that are resistant to CDDP 
and carboplatin.  
 Despite the wide use of platinum-based anticancer drugs, especially cisplatin, their 
administration is often associated with severe side effects and many cancers acquire 
resistance to the drugs overtime (153, 156, 158, 249, 250). One of the approaches to 
overcome these limitations of platinum-based drugs is to combine conventional 
chemotherapy with photodynamic therapy (PDT). In PDT, both the photosensitizing agents 
and light are not toxic by themselves. It is the combination of these two components that 
produces antitumor effects. Combination of chemotherapy with PDT may produce 
synergistic effects that can reduce the toxic side effects of the chemotherapeutic drugs. 
Moreover, the combination treatment has the potential of overcoming drug resistance. 
Therefore, many research groups have investigated the combination effects of PDT with 
chemotherapy that involves CDDP, 5FdUr, etoposide (VP-16), and a number of other 
chemotherapeutic drugs (163-167, 169, 170, 174, 176-179, 289). Some of these combinations 
have been demonstrated to produce synergistic enhancement of cytotoxicity. However, a 
mechanistic understanding of synergy induced by the combination treatment is still lacking. 
Recently, we have obtained the precise molecular mechanism of action for the 
chemotherapeutic drug CDDP and proposed that the dissociative electron-transfer (DET) 
reactions between CDDP and the guanine base in DNA, which is most likely to donate an 
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electron among the four DNA bases, are responsible for the activation of CDDP (182). In 
another paper, Dr. Lu has demonstrated that one-electron transfer from the excited singlet 
state of indocyanine green (1ICG*) to CDDP can increase the yield of DNA DSBs in plasmid 
DNA and suggested that the combination of these two drugs may produce enhanced 
cytotoxicity against cancer cells (183). Based on this electron-transfer mechanism, we have 
developed a combination therapy of CDDP with a biological electron donor (TMPD; 
N,N,N′,N′-tetramethyl-p-phenylenediamine), which can enhance the cytotoxicity of CDDP in 
a synergistic manner and lead to complete removal of cisplatin-resistance in the human lung 
A549 and ovarian NIH:OVCAR-3 cancer cells (9). These findings suggest that the electron-
transfer reaction between 1ICG* and CDDP may have application in cancer treatment as 
well. More importantly, since ICG is activated by light, selective initiation of the electron-
transfer reaction may be achieved by controlled delivery of light and thus, lead to further 
reduction in toxic side effects of CDDP.  
 In the present study, we have evaluated the in vitro cytotoxicity of the combination of 
ICG-PDT and CDDP or its analog OXP in the human cervical (HeLa and HeLa S3) and lung 
(A549) cancer cells. We have also investigated the dependence of the combination effects on 
treatment sequence. Steady-state absorption spectroscopic experiments have been performed 
to study the electron-transfer reaction between ICG and CDDP or OXP. 
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5.2 Materials and methods 
 Chemicals and cell culture 5.2.1
cis-Diammineplatinum(II) dichloride (cisplatin; CDDP; Pt(NH3)2Cl2; MW = 300 g mol-1), 
[SP-4-2-(1R-trans)]-(1,2-cyclohexanediamine-N,N′)[ethanedioata(2--)-O,O’]platinum 
(oxaliplatin; OXP; C8H14N2O4Pt; MW = 397.29 g mol-1), and 4,5-benzoindotricarbocyanine 
(indocyanine green; ICG; C43H47N2NaO6S2; MW = 775 g mol-1) were purchased from 
Sigma-Aldrich (Sigma-Aldrich Canada Ltd., Oakville, ON, Canada) and used without any 
further purification. Stock solutions of 3 mM CDDP and 5 mM OXP were made in ultrapure 
water with a resistivity of >18 MΩ cm-1 obtained from a Barnstead Nanopure water system 
(Thermo Scientific, Dubuque, IA, USA) and stored at 4˚C. A stock solution of 5 mM ICG 
was made weekly in ultrapure water and stored in the dark at -20˚C.  
The culture conditions for the human lung (A549) and cervical (HeLa) cancer cells 
were the same as those described in the previous Chapter 3. Human cervical cancer HeLa S3 
cells (ATCC#: CCL-2.2™; a clonal derivative of the parent HeLa cell line) were cultured in 
minimum essential medium Eagle (MEM) medium supplemented with 10% fetal bovine 
serum (FBS), 100 units mL-1 penicillin G and 100 µg mL-1 streptomycin. The cell culture 
was kept at 37◦C in a humidified atmosphere containing 5% CO2.  
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 Laser treatment conditions 5.2.2
Irradiation was carried out by using an 800 nm laser with a pulse duration of 120 fs and a 
pulse repetition rate of 1 kHz. The average laser power was 360 mW corresponding to an 
average irradiance of 81 mW cm-2. Duration of exposure was varied to get different light 
doses (J cm-2). 
 Dark cytotoxicity of the combination of ICG and CDDP in 5.2.3
A549 and HeLa cells 
Exponentially growing A549 and HeLa cells were seeded into 96-well microplates at a 
density of 5×103 cells/well. After overnight incubation, the cells were incubated with ICG 
and CDDP for 24 h (HeLa) or 48 h (A549) in the dark. At the end of incubation period, cells 
were washed once with phosphate-buffered saline (PBS) and cell viability was evaluated by 
using the standard MTT assay as described in Chapter 3. 
 Cytotoxicity of the combination treatment of ICG-PDT and 5.2.4
CDDP in A549 and HeLa cells 
Exponentially growing A549 and HeLa cells were seeded into 96-well microplates at a 
density of 5×103 cells/well or 384-well microplates at a density of 3×103 cells/well. After 
overnight incubation, cells were incubated with ICG and CDDP for 5 h in the dark. Cells 
were then washed twice with PBS and fresh complete culture medium was added before laser 
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irradiation. The irradiated cells were then kept in an incubator for 20 h and cell viability was 
evaluated by the MTT assay as described in Chapter 3. 
 Effects of treatment sequence on the cytotoxicity of the 5.2.5
combination treatment of ICG-PDT and CDDP in A549 cells 
Exponentially growing A549 cells were seeded into 96-well microplates at a density of   
5×103 cells/well. After overnight incubation, cells were incubated with various 
concentrations of CDDP for 24 h in the dark. Drug-containing medium was then replaced 
with fresh culture medium and ICG was added at a final concentration of 100 µM. At the end 
of the 5 h incubation period, cells were washed twice with PBS and fresh complete culture 
medium was added for laser irradiation. The irradiated cells were then kept in an incubator 
for 20 h and cell viability was evaluated by the MTT assay as described in Chapter 3. 
 Steady-state absorption spectroscopic measurements 5.2.6
Steady-state absorption spectroscopic results were measured using a DU-530 UV-Vis 
spectrophotometer (Beckman Coulter, Fullerton, CA, USA). Samples were prepared in 
ultrapure water and the absorbance at the peak wavelength of 778 nm was measured 
immediately after sample preparation and recorded again at 18 and 48 h.  
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 Dark cytotoxicity of the combination of ICG and oxaliplatin in 5.2.7
HeLa and HeLa S3 cells 
Exponentially growing HeLa and HeLa S3 cells were seeded into 96-well microplates at a 
density of 5×103 cells/well. After overnight incubation, the cells were incubated with ICG 
and OXP for 24 h in the dark. Cells were washed twice with PBS and fresh culture medium 
was added. Plates were then kept in an incubator for another 24 h. Cell viability was 
evaluated by using the MTT assay as described in Chapter 3. 
 Cytotoxicity of the combination treatment of ICG-PDT and 5.2.8
oxaliplatin in HeLa and HeLa S3 cells 
Exponentially growing HeLa and HeLa S3 cells were seeded into 96-well microplates at a 
density of 5×103 cells/well. After overnight incubation, cells were incubated with ICG and 
OXP for 24 h in the dark. Cells were then washed twice with PBS and fresh complete culture 
medium was added before laser irradiation. The irradiated cells were then kept in an 
incubator for 24 h and cell viability was evaluated by the MTT assay as described in   
Chapter 3. 
 Data analysis 5.2.9
The drug- and light-dose response curves were fitted with a sigmoidal logistic function by 
using Origin software (OriginLab, Northampton, MA, USA). The corresponding half-
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maximal inhibitory concentration (IC50) or light dose (LD50) values were determined on the 
basis of the fitted data. Fractional effect analysis was performed as described in Chapter 4. 
5.3 Results and discussion 
 Dark cytotoxicity of the combination of ICG and CDDP in 5.3.1
A549 and HeLa cells 
As shown in Ref. (183), electron-transfer reactions can take place both in the ground-state 
and excited singlet state of the photosensitizer ICG. In order to see whether the ground-state 
reactions had any effect on cell viability, we first assessed the dark cytotoxicity of the 
combination of ICG and CDDP in cisplatin-resistant A549 and cisplatin-sensitive HeLa cells. 
Cells were separated into two treatment groups: one group of cells were treated with various 
concentration of CDDP and in the second group, cells were co-incubated with ICG and 
CDDP. 
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Figure 5-1: Drug-dose response curves for cell viability of (A) A549 and (B) HeLa cells 
treated with the combination of ICG and CDDP. The cells were incubated with various 
concentrations of ICG and CDDP for 24 h (HeLa) or 48 h (A549). Cell viability was evaluated 
by using MTT cytotoxicity assay at the end of the incubation period. The solid lines are best 
fits to the experimental data using a logistic function in Origin software. The dashed line 
and solid stars represent the calculated additive effect. 
 As shown in Figure 5-1, cell viability in the group treated with both drugs was lower 
than that in the group treated with CDDP only. This result indicates an enhanced cytotoxicity 
induced by the combination of ICG and CDDP. Without ICG, the IC50 of CDDP was 
determined to be 25.2 ± 2.4 and 15.8 ± 0.7 µM in A549 and HeLa cells, respectively. It is 
worth pointing out that drug incubation time for A549 cells is 48 h while that for HeLa is    
24 h. When the two cell lines are treated identically, A549 cells are much more resistant to 
CDDP than HeLa cells. In A549 cells, we observed that ~20% of cells survived at a CDDP 
concentration of 50 µM and further increasing CDDP concentration up to 150 µM didn’t 
affect cell viability significantly. This observation confirms the resistance of A549 cells to 
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CDDP treatment. When CDDP was given in combination with ICG, the IC50 values were 
determined to be 10.3 ± 1.2 and 7.4 ± 0.7 µM in A549 and HeLa cells, respectively, 
approximately 50% of the corresponding ones in the absence of ICG. This result indicates 
that the combination of ICG and CDDP produced a similar level of enhancement of 
cytotoxicity in the two cell lines studied. However, while we were able to decrease HeLa cell 
viability to below 10% with the combination treatment, viability of A549 cells was ~20% 
over a CDDP concentration range of 50-150 µM for both CDDP and ICG + CDDP treatment 
groups. This observation suggests that A549 cells are resistant to the combination treatment 
of ICG and CDDP. We further performed fractional effect analysis as described in Chapter 4. 
In the group treated with both ICG and CDDP, values of cell viability were found to be equal 
to or lower than the predicated additive effects suggesting an additive to synergistic 
enhancement of cytotoxicity by the combination of ICG and CDDP in A549 and HeLa cells. 
 Combination effects of ICG-PDT and CDDP have been studied by Crescenzi et al. 
(165). They found that the combination of low-dose CDDP and ICG-PDT produced a 
synergistic effect in MCF-7 breast cancer cells based on the MTT assay data but an additive 
effect when cell viability was evaluated by the trypan blue assay. They suggested that this 
observation was due to the differences in the mechanisms of these two assays. We noted that 
cytotoxicity data for the combination of ICG and CDDP without laser irradiation were not 
presented in their report. Our studies on the combination effects of ICG and CDDP, VP-16, 
or VM-26 have confirmed that synergistic enhancement of cytotoxicity could be observed in 
the absence of laser irradiation. This finding suggests that it is very important to consider 
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dark cytotoxicity induced by the drugs when evaluating combination effects of PDT and 
other treatment approaches. Failure to do this may lead to an overestimation of combination 
effects. Therefore, in the present study, calculation of additive effects has been based on data 
from ICG + CDDP treatment group instead of those from CDDP treatment group. This 
approach is expected to provide a better way of estimating the contribution from light 
irradiation treatment that can be controlled by targeted delivery of laser beams, while 
enhancement of cytotoxicity in the absence of light irradiation might lead to increased overall 
toxicity in vivo. 
 In 2012, we reported our observations of a highly effective electron-transfer reaction 
between CDDP and a biological electron donor TMPD and demonstrated that this 
combination could dramatically reduce viability of cisplatin-sensitive human cervical (HeLa) 
and highly cisplatin-resistant human lung (A549) and ovarian (NIH:OVCAR-3) cancer cells 
in vitro (9). Moreover, the combination treatment removed resistance to CDDP in A549 and 
NIH:OVCAR-3 cells. Those findings suggest that one-electron reduction of CDDP could be 
an effective way of increasing the anticancer activity of CDDP and even has the potential of 
overcoming resistance to CDDP. ICG, both in its ground state and excited singlet state, has 
been found to be able to donate one electron to CDDP (183). Therefore, our observation of 
synergistic enhancement of cytotoxicity induced by the combination of ICG and CDDP is 
likely a result of electron-transfer reactions between ICG and CDDP. However, unlike what 
have been observed in combination of CDDP and TMPD, A549 cells have been found to be 
resistant to both CDDP and ICG + CDDP treatments in the present study. The season for this 
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observation is not clear. One possible explanation is that the redox potential of ICG (0.96 eV 
vs NHE (290)) is more positive than that of TMPD (0.29 eV vs NHE (291)) making it less 
likely to donate an electron to CDDP. Therefore, it is expected that promoting ICG to an 
excited state may make the electron-transfer reaction more thermodynamically favorable. In 
fact, Dr. Lu has demonstrated that electron-transfer reactions between 1ICG* and CDDP can 
increase the yield of DNA DSBs in plasmid DNA and suggested that this reaction may 
enhance cytotoxicity as well (183). Moreover, although we have observed synergistic 
enhancement of cytotoxicity by the combination of ICG and CDDP in vitro, a 50% in IC50 is 
achieved with a relatively high ICG concentration and a long drug incubation time. As 
mentioned earlier, the blood half-life of ICG is only 2-4 minutes (202). It is difficult to 
maintain an ICG concentration high enough to cause significant damage to tumors in vivo. 
Therefore, we further evaluated the photocytotoxicity of the combination of ICG and CDDP 
to see whether we could achieve more significant synergistic enhancement of cytotoxicity 
and overcome drug-resistant to CDDP by exciting ICG to a higher energy state. 
 Photocytotoxicity of the combination treatment of ICG and 5.3.2
CDDP in A549 cells 
Considering the short blood half-life of IG and strong dark cytotoxicity of the ground-state 
reactions, we shortened the drug incubation time to 5 h. Figure 5-2 shows the drug-dose 
response curves of A549 cells to the combination treatment of ICG-PDT and CDDP. As 
shown in Figure 5-2A, cell viability decreased gradually with increasing CDDP 
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concentration. The IC50 was found to be higher than 100 µM. With the addition of 200 µM 
ICG, cell viability decreased slightly compared with that of CDDP only group in the CDDP 
concentration range ~0-100 µM. At CDDP concentrations higher than 100 µM, cell viability 
curve of ICG + CDDP treatment group overlapped with that of CDDP treatment group. This 
result indicates that dark cytotoxicity of ICG and CDDP may be reduced by shortening the 
drug incubation time. With a light dose of 24.4 J cm-2, cell viability was 69.1 ± 8.7% in the 
absence of CDDP. Fractional effect analysis results showed that the combination effect was 
slightly synergistic at low CDDP concentrations and additive or slightly antagonistic at high 
CDDP concentrations.  
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Figure 5-2: Drug-dose response curves for cell viability of A549 cells treated with the 
combination of ICG-PDT and CDDP by using the standard MTT cell viability assay. The drug 
incubation time was 5 h and MTT was performed 20 h after laser irradiation. The solid lines 
are best fits to the experimental data using a logistic function in Origin software. The 
dashed line and solid stars represent the calculated additive effect. (Note: the dose-response 
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curve of CDDP + ICG + 24.4 J cm-2 treatment group in (A) could not be fitted with a logistic 
function.) 
 As discussed in Section 5.3.1, both ICG and 1ICG* can donate electrons to CDDP and 
induce cytotoxicity. At low CDDP concentrations, the rate of ground-state reactions is 
relatively low. When ICG is promoted to its excited singlet state 1ICG*, which has a redox 
potential of -0.6 eV vs. NHE (290), the electron transfer reaction rate may be increased and 
thus produce a synergistic effect. At high CDDP concentrations, reactions in the ground-state 
of ICG become dominant. However, ground-state reactions have been shown in Section 5.3.1 
to be not effective in overcoming resistance to CDDP. Therefore, additive or slightly 
antagonistic effect was observed. These findings suggest that it is desirable to lower the 
concentration of CDDP in the combination treatment of ICG-PDT and CDDP in order to 
achieve synergistic enhancement of cytotoxicity. 
 We have further studied the dependence of combination effects on ICG concentration 
by fixing CDDP concentration at 15 µM while varying ICG concentration from 0 to 150 µM 
(Figure 5-2B). Without laser irradiation, ICG and ICG + 15 µM CDDP were found to be only 
slightly cytotoxic killing less than 20% of the cells. With a light dose of 100 J cm-2, the IC50 
values were determined to be 68.7 ± 6.9 and 45.4 ± 1.2 µM for ICG and ICG + CDDP 
treatment groups, respectively. Results of fractional effect analysis showed that additive to 
synergistic effects were produced by the combination treatment.  
 Figure 5-3 shows the light-dose response of A549 cells to ICG-PDT and                 
ICG-PDT + CDDP treatment. In the absence of CDDP, the LD50 of 100 µM ICG was found 
 162 
 
to be > 100 J cm-2. Without laser irradiation, cell viability was 86.8 ± 3.2% and 76.0 ± 0.8% 
for ICG in combination with 20 and 30 µM CDDP, respectively. With laser irradiation, cell 
viability decreased in a light-dose dependent manner. The values of LD50 were determined to 
be 25.1 ± 5.9 and 14.6 ± 21.8 J cm-2 for groups treated with 20 and 30 µM CDDP, 
respectively. Fractional effect analysis results showed that the observed effects were equal to 
or lower than the calculated additive effects indicating additive/synergistic enhancement of 
cytotoxicity induced by the combination treatment. However, in the presence of CDDP, there 
were still ~30% of the cells survived at a light dose of 50 J cm-2 and further increasing the 
light dose to 100 J cm-2 didn’t reduce cell viability significantly. This is probably due to a 
limited accumulation of ICG inside the cells with a relatively short drug incubation time of   
5 h and quick consumption of ICG by laser irradiation.  
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Figure 5-3: Light-dose response curves for cell viability of A549 cells treated with ICG-PDT 
alone or in combination with CDDP by using the standard MTT cell viability assay. The drug 
incubation time was 5 h and MTT was performed 20 h after laser irradiation. The solid lines 
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are best fits to the experimental data using a logistic function in Origin software. The 
dashed line and solid stars represent the calculated additive effect. 
 We have observed synergistic enhancement of cytotoxicity induced by combing     
ICG-PDT with CDDP and found that the degree of synergy is dependent on light dose and 
the concentration of both drugs. These findings are consistent with the proposed mechanism 
that electron-transfer reactions between ICG/1ICG* and CDDP are responsible for the 
enhanced cytotoxicity. Indeed, we have observed synergistic enhancement of cytotoxicity 
under specific treatment conditions. The results of our in vitro cytotoxicity studies suggest 
that synergistic effects are more likely to be induced with lower CDDP and ICG 
concentrations, a shorter time interval between drug administration and laser irradiation, and 
higher light doses. Moreover, our observations of electron-transfer-induced synergistic 
enhancement of cytotoxicity in combination therapies of low-dose CDDP and ICG-PDT or 
other treatment approaches may be further explored to develop more effective combinations 
for the treatment of cancers.  
 Sequence dependence of the combination effect in A549 and 5.3.3
HeLa cells 
In order to see whether the combination effect was dependent on the sequence of treatment, 
we treated the cells with various concentrations of CDDP for 24 h and then with ICG for 5 h 
before laser irradiation. Cell viability was determined 20 h after laser irradiation. Figure 5-4A 
shows drug-dose dependence of cell viability in A549 cells. The IC50 of CDDP was found to 
be 16.4 ± 0.7 µM, slightly lower than the value of 25.2 ± 2.4 µM with a drug incubation time 
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of 48 h (Figure 5-1A). This was probably because exposing the cells to ambient air during 
laser irradiation made them more sensitive to CDDP treatment. The combination of CDDP 
with 100 µM ICG didn’t alter the cytotoxicity significantly having an IC50 of 17.9 ± 1.6 µM. 
Laser irradiation reduced cell viability to 67.2 ± 7.5% in the absence of CDDP. In the 
presence of CDDP, the observed effect was found to be close to the predicated additive effect 
at low CDDP concentrations. At CDDP concentrations higher than 20 µM, slight synergy 
was produced by the combination treatment.  
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Figure 5-4: Effect of treatment sequence on cell viability of (A) A549 and (B) HeLa cells 
treated with the combination of ICG-PDT and CDDP. The cells were incubated with various 
concentrations of CDDP for 24 hours and then with 100 µM ICG for 5 hours followed by 
laser irradiation at 800 nm. Cell viability was evaluated by using MTT assay 20 hours after 
laser irradiation. The solid lines are best fits to the experimental data using a logistic 
function in Origin software. The dashed line and solid stars represent the calculated additive 
effect. 
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 In HeLa cells, LD50 of 100 µM ICG was found to be higher than 30 J cm-2          
(Figure 5-4B). Combing ICG with 10 µM CDDP reduced the cell viability to 55.2 ± 3.0%. 
No significant difference was observed between the combination effect and predicated 
additive effect curves indicating an additive effect was produced by the combination 
treatment. 
 By treating the cells with CDDP and ICG separately, we have successfully lowered the 
dark cytotoxicity compared with that observed in cells co-incubated with ICG and CDDP. 
We have also shown that the combination effect of ICG-PDT and CDDP is additive to 
slightly synergistic under the conditions of this experiment. This is reasonable since the 
majority of intracellular CDDP should have been converted to other forms that may not be 
able to react with ICG/1ICG* at the end of 24 h incubation so that the ICG-PDT and CDDP 
treatment can act independently. The lower degree of synergy observed in this experiment 
than that in Sections 5.3.1 and 5.3.2 is consistent with the proposal that synergistic 
enhancement of cytotoxicity produced by the combination treatment involves electron-
transfer reactions between ICG/1ICG* and CDDP.  
 Steady-state absorption spectra change of ICG induced by 5.3.4
CDDP and oxaliplatin 
It has been shown by Dr. Lu that the electron transfer reaction between ICG and CDDP can 
be observed by measuring steady-state absorption spectra changes of the samples (183). In 
this experiment, we studied the reaction between ICG and CDDP or OXP by measuring the 
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steady-state absorbance of the mixtures of ICG and various concentrations of CDDP or OXP 
at 778 nm (A778 nm) 0, 18 and 48 h after sample preparation. The results are plotted in    
Figure 5-5. 
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Figure 5-5: Steady-state absorbance change of ICG at the absorption peak of 778 nm in the 
presence of various concentrations of (A) CDDP and (B) OXP. The values of absorbance were 
recorded immediately after sample preparation and then recorded 18 and 48 h later. 
 Without CDDP or OXP, the absorbance of ICG decreased by 22.3% and 47.9% at      
18 and 48 h, respectively. At 0 h, A778 nm of ICG decreased slightly with increasing 
concentration of CDDP and OXP. At 18 and 48 h, A778 nm decreased more quickly with 
increasing CDDP concentration than at 0 h. Absorbance decreased by more than 85% at a 
CDDP concentration of 50 µM 48 h after sample preparation, which was 39.4% more than 
that in the absence of CDDP. These results are consistent with the spectra change of ICG due 
to electron transfer reaction with CDDP (183). In contrast, A778 nm in the presence of various 
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concentrations of OXP were found to be very close to those of ICG only sample at all three 
time points. This observation suggests that electron transfer reactions between ICG and OXP 
are absent or at least much weaker than that between ICG and CDDP. Therefore, dark 
cytotoxicity by the combination of ICG and OXP is expected to be less significant than that 
observed with the combination of ICG and CDDP. 
 Dark cytotoxicity of the combination of ICG and oxaliplatin in 5.3.5
HeLa and HeLa S3 cells 
We investigated the cytotoxicity of ICG in combination with OXP in HeLa and HeLa S3 
cells by incubating the cells with various concentrations of OXP in the absence or presence 
of 100 µM ICG for 24 h. The cells were then washed and incubated with drug-free medium. 
Cell viability was determined by MTT assay 24 h after the removal of drugs. The results are 
shown in Figure 5-6. Cytotoxicity of OXP increased in a dose-dependent manner in both cell 
lines. In the absence of ICG, IC50 of OXP was determined to be 121.0 ± 5.9 and                
2.52 ± 2.45 µM in HeLa and HeLa S3 cells, respectively. This result shows that HeLa S3 
cells are about 50 times more sensitive to OXP than HeLa cells. At a concentration of       
100 µM, ICG was found to be slightly cytotoxic to both HeLa and HeLa S3 cells, with ~20% 
of the cells killed by ICG treatment. We performed fractional effect analysis on the 
combination effect of ICG and OXP. As shown in Figure 5-6A, the combination effect curve 
overlaps with the calculated additive effect curve at low OXP concentrations suggesting an 
additive effect induced by the combination treatment. A slightly antagonistic effect was 
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observed at OXP concentrations higher than ~120 µM, which was roughly the IC50 of OXP 
in HeLa cells. In HeLa S3 cells, the observed effect curve was found to be higher than the 
additive effect curve indicating an antagonistic effect at all the OXP concentrations tested in 
this experiment. We noted that the lowest OXP concentration of 2 µM tested was close to the 
IC50 of OXP in HeLa S3 cells and data for lower concentrations of OXP was not measured. 
Therefore, the combination effect could not be determined in the OXP concentration range  
0-2 µM. 
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Figure 5-6: Drug-dose response curves for cell viability of (A) HeLa and (B) HeLa S3 cells 
treated with the combination of ICG and OXP. The cells were treated with ICG and OXP for 
24 h and incubated with drug-free medium for another 24 h. Cell viability was evaluated by 
using MTT cytotoxicity assay at the end of the incubation period. The solid lines are best fits 
to the experimental data using a logistic function in Origin software. The dashed line and 
solid stars represent the calculated additive effect. 
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  The absence of a synergistic effect by the combination treatment of ICG and OXP in 
HeLa and HeLa S3 cells is consistent with our steady-state absorption spectroscopic results 
and suggests that OXP is much less reactive than CDDP towards ICG. The season for the 
slightly antagonistic effect observed at high OXP concentrations is not clear. Considering 
that ICG has a broad absorption spectrum in the visible range, it is possible that ICG has 
some absorbance at the detection wavelength of 570 nm for MTT assay and thus, has 
contributed the antagonistic effect observed. However, contribution from free ICG is not 
likely, since we have washed the cells with PBS before performing MTT assay. The 
observation that the combination effect is dependent upon OXP concentration suggests the 
existence of direct/indirect interaction between these two drugs. Determination of the 
mechanism for the observed antagonistic effect will require further experiments that are 
beyond the scope of this thesis. 
 Cytotoxicity of the combination treatment of ICG-PDT and 5.3.6
oxaliplatin in HeLa and HeLa S3 cells 
We evaluated the photocytotoxicity of the combination of ICG and OXP in HeLa and      
HeLa S3 cells. Cells were incubated with various concentrations of ICG and OXP for 24 h 
and then exposed to laser irradiation at 800 nm. Cell viability was determined by MTT assay 
24 h after laser irradiation. Figure 5-7 shows that photocytotoxicity of ICG in HeLa cells 
increased with increasing total light dose. The LD50 of 200 µM ICG was determined to be 
37.6 ± 2.7 J cm-2. Cell viability was decreased to be 74.4 ± 5.4% and 48.8 ± 3.0%, when the 
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cells were treated with ICG in combination with 10 and 40 µM OXP, respectively. Fractional 
effect analysis results showed that the combination of ICG-PDT and OXP produced an 
additive effect at 10 µM OXP and a slightly antagonistic effect at 40 µM OXP in HeLa cells. 
We noted that the combination of ICG and 40 µM OXP produced an antagonistic effect 
without laser irradiation and the degree of antagonism didn’t change significantly with 
increasing light dose. 
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Figure 5-7: Light-dose response curves for cell viability of HeLa cells treated with ICG-PDT 
alone or in combination with OXP by using the standard MTT cell viability assay. The cells 
were incubated with the drugs for 24 hours before exposing to laser irradiation. Cell 
viability was evaluated 24 hours after laser irradiation. The solid lines are best fits to the 
experimental data using a logistic function in Origin software. The dashed line and solid 
stars represent the calculated additive effect. 
 The combination effect of ICG-PDT and OXP was also evaluated in HeLa S3 cells. 
Figure 5-8A compares the light-dose response curves for cell viability to ICG-PDT treatment 
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in HeLa and HeLa S3 cells. At an ICG concentration of 200 µM, the LD50 values were 
calculated to be 37.8 ± 1.9 and 58.9 ± 7.3 J cm-2 in HeLa and HeLa S3 cells, respectively. 
This result shows that HeLa S3 cells are slightly more resistant to ICG-PDT treatment than 
HeLa cells. Figure 5-8B shows the cytotoxicity of the combination treatment of ICG-PDT 
and OXP in HeLa S3 cells. At an ICG concentration of 50 µM, cell viability was found to be 
71.9 ± 10.4%. With a light dose of 25 J cm-2, cell viability was decreased to be 41.6 ± 11.9%. 
The observed effect curve overlapped with the calculated additive effect curve indicating that 
an additive effect was produced by the combination treatment of ICG-PDT and OXP. 
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Figure 5-8: (A) Light-dose response curves for cell viability of HeLa and HeLa S3 cells 
treated with ICG-PDT. (B) Drug-dose response curves for cell viability of HeLa S3 cells 
treated with OXP, OXP + 50 µM ICG, and OXP + ICG + 25 J cm-2 by using the standard MTT 
cell viability assay. The cells were incubated with the drugs for 24 hours before expose to 
laser irradiation. Cell viability was evaluated 24 hours after laser irradiation. The solid lines 
are best fits to the experimental data using a logistic function in Origin software. The 
dashed line and solid stars represent the calculated additive effect. 
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 The combination of ICG and OXP has been demonstrated to produce an additive to 
slightly antagonistic effect in HeLa and HeLa S3 cancer cells both without and with laser 
irradiation. Antagonistic effect has been found to be significant at relatively high OXP 
concentrations and not dependent on light dose. The observation of an additive effect is 
consistent with the lower activity of OXP towards ICG than that of CDDP in aqueous 
solutions (Section 5.3.4). Unfortunately, we haven’t observed any synergistic enhancement 
of cytotoxicity with laser treatment. The finding that the degree of antagonism doesn’t 
depend on light dose implies the absence of direct interaction between 1ICG* and OXP. 
Although synergistic effects are absent, the combination of ICG-PDT with low dose OXP is 
expected to produce an additive effect and thus, has the potential of lowering the effective 
dose of oxaliplatin and reducing the toxic side effects. 
5.4 Summary 
In this chapter, we have evaluated the dark and photocytotoxicity of the combination of ICG 
and CDDP in cisplatin-resistant human lung cancer (A549) and cisplatin-sensitive human 
cervical cancer (HeLa) cells. We have demonstrated that ICG, both in the ground- and 
excited-state, can enhance the cytotoxicity of CDDP in a synergistic manner. The degree of 
synergy has a strong dependence upon treatment conditions. Lower concentrations of CDDP 
and ICG, a shorter time interval between drug and light treatment, and a higher light dose 
have been found to favor the observation of synergistic enhancement of cytotoxicity. We 
have also found that co-incubation of cells with ICG and CDDP can produce a higher level of 
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synergy than pre-treating cells with CDDP for 24 h. However, the combination of ICG or 
ICG-PDT with CDDP cannot overcome CDDP resistance in A549 cells, in contrast with 
what has been observed in the combination therapy of CDDP and the biological electron 
donor TMPD (9). This difference has been attributed to ICG being a thermodynamically less 
favorable electron donor than TMPD. Laser irradiation may provide enough energy to 
increase the reaction rate. However, when high concentrations of CDDP are used, ground-
state reactions may compete with excited-state reactions making it very difficult to 
selectively activate the excited-state reaction pathway.  
 We have also evaluated the dark and photo-cytotoxicity of the combination of ICG and 
OXP in human cervical cancer HeLa and HeLa S3 cell lines. Combination of ICG and OXP 
has been found to produce an additive to slightly antagonistic effect without or with laser 
irradiation. The absence of synergistic effects is consistent with the steady-state absorption 
spectroscopic results, which suggest that OXP is much less reactive than CDDP towards ICG 
in aqueous solutions. The finding that the antagonistic effect is not dependent on light dose 
implies that no direct interaction between 1ICG* and OXP is involved. 
 The observation of additive to synergistic effects induced by combing ICG-PDT with 
low dose CDDP/OXP suggests that ICG-PDT may be applied in combination with 
chemotherapy mediated by CDDP or OXP. These combination treatment approaches has the 
potential of reducing the effective dose of the chemotherapeutic drugs and thus, lowering the 
toxic side effects commonly associated with chemotherapy. All these findings strongly 
support the proposal that electron-transfer from ICG/1ICG* to CDDP is responsible for the 
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synergy induced by the combination of ICG or ICG-PDT with CDDP. Therefore, this 
electron-transfer-based combination therapy of PDT and chemotherapy should be further 
explored in order to develop more effective treatment approaches. 
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6 Bioluminescence of Luminol Activated Photodynamic Killing of Human Cervical Cancer Cells in vitro 
6.1 Background 
Luminol (5-amino-2,3-dihydro-1,4-phthalazine-dione) is a light-emitting chemical that can 
produce blue light at a maximum of 425 nm in the presence of a variety of oxidizing agents 
such as horseradish peroxide and metal cations including iron, cobalt, and copper (213, 292-
295). It has been widely used for the detection of oxidizing radicals in forensic science, 
biochemistry, and clinical diagnostics (205, 296-299). Recently, the therapeutic potential of 
luminol has been demonstrated in several studies, in which the light generated from chemical 
reactions of luminol can serve as an internal light source to initiate photodynamic killing of 
cancer cells through a bioluminescence resonant energy transfer (BRET) mechanism (104, 
214, 215). Compared with conventional photodynamic therapy (PDT), bioluminescence-
activated PDT is, in principle, not limited by the tissue penetration depth of light, which has 
greatly hindered the more widespread application of conventional PDT. In 2006, Laptev et 
al. reported that bioluminescence of luminol could activate bioconjugates composed of 
transferrin (Tf) and Hp and induce significant cell killing in leukaemia K562 and U-76 cells 
(104). More recently, Yuan et al. developed a new bioluminescence system consists of 
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luminol and a cationic oligo(p-phenylene vinylene), which showed significant anticancer 
activity both in vitro and in vivo (215). Using 5-aminolaevulinic acid (5-ALA) as the 
photosensitizer, Chen et al. found that bioluminescence of luminol could effectively activate 
photodynamic killing of human epithelial colorectal adenocarcinoma (Caco-2) cells (214).  
In the past two decades, not only luminol but also other bioluminescence systems 
including firefly luciferin-luciferase and coelenterazine-luciferase have been evaluated for 
PDT applications (209-212). In 1994, Carpenter et al. studied the antiviral activity of 
hypericin activated by the bioluminescence of luciferin (209). Later, Theodossiou et al. 
assessed the in vitro photodynamic activity of Rose Bengal activated by firefly luciferin in 
luciferase-transfected mouse embryonic fibroblast cell line NIH 3T3 (210). Three years later, 
Schipper et al. evaluated the photodynamic cytotoxicity induced by the bioluminescence of 
firefly luciferase in several malignant and nonmalignant cell lines including MCF7 (human 
breast adenocarcinoma), NIH 3T3, 3T3L1 (a continuous substrain of 3T3), CHO (Chinese 
hamster ovary), 293T (a highly transfectable derivative of human embryonic kidney 293 
cells), and A375M (melanoma) and concluded that the bioluminescence system didn’t 
generate sufficient light to induce Rose Bengal or hypericin photocytotoxicity (211). They 
raised an important question of whether bioluminescence could produce enough photons for 
the activation of the photosensitizers. However, a more recent study performed by Hsu et al. 
showed that a luciferase-immobilized quantum dots system could activate Foscan®-loaded 
micelles and induce tumor cell killing in vitro as well as delay tumor growth in vivo (212). 
The results of that study, together with those reported by Yuan et al. and Chen et al. (214, 
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215), suggest that it is possible to develop bioluminescence-activated PDT approaches for 
effective destruction of cancers. 
In the present study, we have evaluated the cytotoxicity of two porphyrin 
photosensitizers meso-tetra(4-sulfonatophenyl)porphine dihydrochloride (TPPS4) and Fe(III) 
meso-tetra(4-sulfonatophenyl)porphine chloride (FeTPPS) activated by the bioluminescence 
of luminol in a human cervical carcinoma cell line (HeLa) and two normal human fibroblast 
cell lines (GM05757 and MRC-5). We have also compared the cytotoxicity of the 
photosensitizers induced by the bioluminescence of luminol and 400 nm light produced by a 
femtosecond (fs) laser. 
                          
Figure 6-1: Chemical structures of TPPS4 and FeTPPS. 
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6.2 Materials and methods 
 Chemicals and cell lines 6.2.1
Meso-tetra(4-sulfonatophenyl)porphine dihydrochloride (TPPS4; C44H32Cl2N4O12S4; MW = 
1007.91 g mol-1) and Fe(III) meso-tetra(4-sulfonatophenyl)porphine chloride (FeTPPS; 
C44H28ClFeN4O12S4; MW = 1024.27 g mol-1) purchased from Frontier Scientific Inc. (Logan, 
UT, USA) and 5-amino-2,3-dihydro-1,4-phthalazinedione (luminol; C8H7N3O2; MW =  
177.2 g mol-1) from Sigma-Aldrich (Sigma-Aldrich Canada Ltd., Oakville, ON, Canada) 
were used without any further purification. Stock solutions of 5 mM TPPS4 and FeTPPS 
were made in ultrapure water with a resistivity of >18 MΩ/cm obtained from a Barnstead 
Nanopure (Thermo Scientific, Dubuque, IA, USA) water system and then stored in the dark 
at -20˚C. Stock solutions of luminol (500 mM) were made in 1 M NaOH immediately before 
the experiments. 
The culture conditions for the human cervical cancer (HeLa) and normal human skin 
fibroblast (GM05757) cells were the same as those described in Chapters 3 and 4. The 
normal human lung fibroblast (MRC-5) cells were obtained from the Coriell Institute, 
Human Genetic Mutant Cell Repository (Camden, NJ, USA) and grew in minimum essential 
medium Eagle (MEM) supplemented with 10% fetal bovine serum (FBS), 100 units mL-1 
penicillin G and 100 µg mL-1 streptomycin. The cell culture was kept at 37◦C in a humidified 
atmosphere containing 5% CO2.  
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 Steady-state absorption spectra 6.2.2
Steady-state absorption spectra of TPPS4 and FeTPPS were measured on a DU 530 UV/Vis 
spectrophotometer (Beckman Coulter, Fullerton, CA, USA). Samples were prepared in 5 mm 
quartz cuvettes using phosphate-buffered saline (PBS).  
 Cytotoxicity of the combination of luminol and TPPS4 in HeLa 6.2.3
cells by MTT assay 
Exponentially growing HeLa cells were plated at a density of 5×103 cells/well in 96-well 
microplates. Following overnight incubation, cells were treated with different concentrations 
of luminol and TPPS4 in phenol red-free medium containing 1% fetal bovine serum (FBS). 
After 24 or 48 h incubation in a humidified incubator, cells were washed twice with PBS. 
Cell viability was determined by the standard MTT assay as described in Chapter 3. 
 Cytotoxicity of the combination of luminol and TPPS4 in HeLa 6.2.4
cells by clonogenic assay 
Exponentially growing HeLa cells were plated in six-well plates at densities of 100, 150 and 
200 cells/well using phenol red-free medium containing 1% FBS. The cells were allowed to 
attach for 4 h prior to the addition of drugs. After 24 h incubation with various concentrations 
of luminol and TPPS4, cells were washed twice with PBS and fresh culture medium 
containing 10% FBS was added. Plates were then put back into an incubator to allow the 
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formation of clearly visible clones (10 days). Cells were fixed with glutaraldehyde (6.0% v/v 
in water), stained with crystal violet (0.5% w/v in water), and counted manually. Survival 
fraction was expressed as the percentage of the control wells. The resulting data are based on 
the mean value of three wells and the error bars represent the standard error of mean (S.E.M). 
 Cytotoxicity of the combination of luminol and FeTPPS in 6.2.5
HeLa cells by MTT assay 
Exponentially growing HeLa cells were plated at a density of 5×103 cells/well in 96-well 
microplates. Following overnight incubation, cells were treated with different concentrations 
of luminol and FeTPPS in phenol red-free medium containing 1% FBS. After 48 h 
incubation in a humidified incubator, cells were washed twice with PBS. Cell viability was 
determined by the standard MTT assay as described in Chapter 3. 
 Cytotoxicity of TPPS4- and FeTPPS-mediated PDT activated 6.2.6
by 400 nm laser light in HeLa cells 
Exponentially growing HeLa cells were plated at a density of 5×103 cells/well in 96-well 
microplates. Following overnight incubation, cells were treated with different concentrations 
of TPPS4 or FeTPPS in phenol red-free medium containing 1% FBS. After 24 h incubation in 
a humidified incubator, cells were washed twice with PBS and irradiated by a 400 nm fs laser 
with a repetition rate of 500 Hz. The average power was 3 mW corresponding to a power 
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density of 4.23 mW cm-2. Twenty four hours after laser irradiation, cell viability was 
determined by the standard MTT assay as described in Chapter 3. 
 Cytotoxicity of the combination of luminol and TPPS4 or 6.2.7
FeTPPS in GM05757 and MRC-5 cells by MTT assay 
Exponentially growing GM05757 and MRC-5 cells were plated at a density of               
5×103 cells/well in 96-well microplates. Following overnight incubation, cells were treated 
with different concentrations of luminol and TPPS4 or FeTPPS in phenol red-free medium 
containing 1% FBS. After 48 h incubation in a humidified incubator, cells were washed twice 
with PBS. Cell viability was determined by the standard MTT assay as described in    
Chapter 3. 
 Data analysis 6.2.8
The drug-dose response curves were fitted with a sigmoidal logistic function by using Origin 
software (OriginLab, Northampton, MA, USA). The corresponding half-maximal inhibitory 
concentration (IC50) values were determined on the basis of the fitted data. Fractional effect 
analysis was performed as described in Chapter 4. 
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6.3 Results and discussion 
 Steady-state absorption spectra of TPPS4 and FeTPPS 6.3.1
We first measured the steady-state absorption spectra of TPPS4 and FeTPPS in PBS. As 
shown in Figure 6-2, TPPS4 has a major absorption peak at 412 nm. The absorption band of 
FeTPPS is much broader than that of TPPS4 with a tail extending beyond 500 nm. It is well 
known that luminol can emit strong blue light in the wavelength range of ~350-550 nm 
(215). The solid blue line in Figure 6-2 indicates the position of the bioluminescence 
maximum of luminol at 425 nm. The absorption spectra of both TPPS4 and FeTPPS overlap 
significantly with the bioluminescence spectrum of luminol. Therefore, energy transfer from 
luminol to TPPS4 or FeTPPS is possible through a fluorescence resonance energy transfer 
(FRET) mechanism, which requires spectral overlap between the donor emission spectrum 
and the acceptor absorption spectrum. 
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Figure 6-2: UV-Vis absorption spectra of TPPS4 and FeTPPS in PBS. The solid blue line 
indicates the position of the emission peak of luminol at 425 nm. 
 Cytotoxicity of the combination of luminol and TPPS4 in 6.3.2
human cervical cancer HeLa cells 
We have evaluated the cytotoxicity of the combination of luminol and TPPS4 in HeLa cells 
by performing the standard MTT cell viability assay and clonogenic assay. Figure 6-3 shows 
the data obtained from the MTT assay. With 24 h drug incubation, the IC50 of TPPS4 was 
determined to be > 500 µΜ, which was reduced to be 190.2 ± 32.9 µM by increasing the 
drug incubation time to 48 h. Luminol at a concentration of 2 mM was found to be slightly 
cytotoxic producing a cell killing effect of ~34% after 24 h drug incubation. Considering the 
cytotoxicity of luminol, we calculated the relative IC50 instead of the absolute values. In 
Figure 6-3A, the value was found to be 361.1 ± 53.0 µM for the group treated with the 
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combination of TPPS4 and 2 mM luminol. Luminol at a lower concentration of 1 mM was 
found to be less cytotoxic even with a longer drug incubation time of 48 h. From Figure 
6-3B, we obtained an IC50 of 53.2 ± 5.0 µM in the presence of luminol, which was ~28% of 
the value in the absence of luminol. The combination effect of luminol and TPPS4 was 
estimated by comparing the observed effect to the additive effect calculated by using 
Equation (4-1) described in Chapter 4. The observed effect curves were found to lie below 
the predicated additive effect curves indicating that the combination treatment induced a 
synergistic effect. For example, at a TPPS4 concentration of 400 µM, more than 90% of the 
cells were killed by the combination treatment, while a predicated additive response yielded 
64.2% cell killing. 
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Figure 6-3: Cytotoxicity of the combination of luminol and TPPS4 in human cervical cancer 
HeLa cells. Cells were incubated with various concentrations of luminol and TPPS4 in cell 
culture medium containing 1% FBS for (A) 24 h or (B) 48 h. At the end of incubation period, 
cell viability was assessed by MTT cell viability assay. The solid lines are best fits to the 
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experimental data using a logistic function in Origin software. The dashed line and solid 
stars represent the calculated additive effect. 
 We have further evaluated the long-term proliferation rate of HeLa cells treated with 
the combination of luminol and TPPS4 by performing clonogenic assay. The results are 
shown in Figure 6-4. In the absence of luminol, the IC50 of TPPS4 was found to be larger than 
400 µM. The survival fraction was approximately 70% at the highest TPPS4 concentration of 
400 µM tested in this experiment. Luminol at concentrations of 1 and 1.5 mM was found to 
be slightly cytotoxic and the corresponding values of survival fraction were 96.5 ± 7.8% and 
83.0 ± 10.0%, respectively. The combination effect of luminol and TPPS4 was assessed by 
performing fractional effect analysis as described in Chapter 4. The observed effects were 
found to be lower than the corresponding predicated additive effects suggesting the induction 
of synergistic effects by the combination treatment. This observation is consistent with what 
have been obtained from the MTT cell viability assay. We found that the relative IC50 values 
were 164.5 ± 49.9 and 68.4 ± 30.9 µM when cells were co-incubated with 1 and 1.5 mM 
luminol, respectively. This result indicates that the degree of synergism is also dependent on 
the dose of luminol. 
 186 
 
0 100 200 300 400
0.0
0.2
0.4
0.6
0.8
1.0
1.2
Su
rv
iva
l F
ra
ct
io
n
TPPS4 Concentration (µM)
 TPPS4
 TPPS4 + 1 mM Luminol
 Predicated Additive Effect
(A)
 
 
0 100 200 300 400
0.0
0.2
0.4
0.6
0.8
1.0
1.2
TPPS4 Concentration (µM)
 TPPS4
 TPPS4 + 1.5 mM Luminol
 Predicated Additive Effect
(B)
 
 
 
Figure 6-4: Clonogenic survival of HeLa cells treated with the combination of luminol and 
TPPS4. Cells were incubated with various concentrations of luminol and TPPS4 in cell culture 
medium containing 1% FBS for 24 h. At the end of incubation period, cells were washed 
twice with PBS and fresh medium containing 10% FBS was added. After 10 days, the 
resulting colonies were fixed, stained with crystal violet, and counted manually. The solid 
lines are best fits to the experimental data using a logistic function in Origin software. The 
dashed line and solid stars represent the calculated additive effect. 
We note that the concentrations of luminol used in the present study are relatively 
high. Luminol has been reported to be relatively nontoxic. The oral drug dose lethal for 50% 
of a test population is > 500 mg kg-1 in rats (300). A luminol dose of 200 mg kg-1 has been 
used in a recently study performed by Gross et al., who have applied the bioluminescence of 
luminol to monitor myeloperoxidase (MPO) activity in mice (205). Assuming that 70% of 
body weight is water, the molar concentration can be calculated by using the following 
equation: 
𝐶 = 𝐷𝜌
0.7𝑀𝑊 × 10−3,                                                            (6-1) 
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where C is the molar concentration in mol L-1, D is the dose in mg kg-1, ρ is water density in 
g L-1, and MW is the molecular weight in g mol-1. Luminol has a molecular weight of     
177.2 g mol-1. Therefore, a luminol dose of 200 mg kg-1 corresponds to a molar concentration 
of 1.6 mM. In another study, Yuan et al. have used luminol concentrations of 0.5 and 2 mM 
in in vitro and in vivo experiments, respectively (215). The results of those studies suggest 
that millimolar (mM) concentrations of luminol can be used in animal studies. 
 Cytotoxicity of the combination of luminol and FeTPPS in 6.3.3
HeLa cells 
It is well known that iron both as free ions and in complexes can greatly enhance the 
bioluminescence intensity of luminol (213, 294, 296, 298, 301-303). Therefore, we have 
evaluated the cytotoxicity of the combination of luminol and FeTPPS, in which an iron atom 
is added to the center of the porphyrin ring of TPPS4 (Figure 6-1), to see whether we can 
observe synergistic enhancement of cytotoxicity as obtained with TPPS4. As shown in  
Figure 6-5A, in the absence of luminol, cytotoxicity of FeTPPS increased with increasing 
FeTPPS concentration. The IC50 was determined to be 48.8 ± 2.6 µM, which was 
approximately 26% of that of TPPS4 under the same treatment conditions. In the presence of 
1 mΜ luminol, the IC50 was reduced to 10.3 ± 0.5 µM. To assess the effects of luminol 
concentration on the cytotoxicity of the combination treatment, we performed one more 
experiment with a fixed FeTPPS concentration of 20 µM and varying concentrations of 
luminol. As shown in Figure 6-5B, luminol alone was only slightly cytotoxic up to a 
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concentration of 1 mM, at which less than 15% of the cells was killed. An IC50 of             
1.98 ± 0.14 mM was obtained. When cells were co-incubated with luminol and 20 µM 
FeTPPS, the relative IC50 was determined to be 0.42 ± 0.08 mM. The results of fractional 
effect analysis showed that the combination of luminol and FeTPPS produced a synergistic 
effect and the degree of synergism was dependent upon the concentrations of both FeTPPS 
and luminol. 
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Figure 6-5: Cytotoxicity of the combination of luminol and FeTPPS in HeLa cells by MTT cell 
viability assay. Cells were incubated with various concentrations of luminol and FeTPPS in 
cell culture medium containing 1% FBS for 48 h. The solid lines are best fits to the 
experimental data using a logistic function in Origin software. The dashed line and solid 
stars represent the calculated additive effect. 
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 Cytotoxicity of TPPS4 and FeTPPS-mediated PDT activated 6.3.4
by 400 nm laser light in HeLa cells 
Cytotoxicity of TPPS4 and FeTPPS activated by an external light source has also been 
evaluated in HeLa cells. Cells were treated with various concentrations of TPPS4 and 
FeTPPS in 1% FBS for 24 h and then irradiated by a 400 nm laser at a light dose of          
0.25 J cm-2. The results are shown in Figure 6-6. Without laser irradiation, the IC50 of TPPS4 
was found to be higher than 400 µM similar to the results obtained in Section 6.3.2. With 
laser irradiation, an IC50 of 161.2 ± 171.6 µM was observed, which was ~45% of the value 
obtained when cells were co-incubated with TPPS4 and 2 mM luminol for 24 h. Therefore, 
the level of cytotoxicity induced by incubating the cells with the mixtures of TPPS4 and        
2 mM luminol was comparable to that achieved when TPPS4 was activated by a 400 nm laser 
at a light dose of 0.25 J cm-2. Figure 6-6B shows the drug-dose response curves for cells 
treated with FeTPPS. The IC50 of FeTPPS was found to be 45.6 ± 3.9 µM, which was not 
affected significantly by laser irradiation at a light dose of 0.25 J cm-2. 
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Figure 6-6: Drug-dose response curves for cell viability of HeLa cells treated with (A) TPPS4- 
and (B) FeTPPS-mediated PDT by using the standard MTT cell viability assay. Cells were 
incubated with various concentrations of TPPS4 and FeTPPS in cell culture medium 
containing 1% FBS for 24 h and then irradiated by a 400 nm fs laser at a light dose of    
0.25 J cm-2. Cell viability was determined 24 h after laser irradiation. The solid lines are best 
fits to the experimental data using a logistic function in Origin software. 
Previously, Schipper et al. have raised an important question of whether the 
bioluminescence system can generate enough light to induce significant photodynamic 
killing of cancer cells (211). They have performed a series of experiments to determine 
whether bioluminescence of firefly luciferase (fLuc) can produce sufficient photons to 
activate photocytotoxicity of two photosensitizers (hypericin and Rose Bengal) in a number 
of nonmalignant and malignant cell lines. In contrast to the results reported by Theodossiou 
et al. (210), Schipper et al. didn’t observe significant photodynamic effects under the same 
experimental conditions as those used in Ref. (210) and suggested that the cell line used by 
Theodossiou et al. contained an unknown contamination making the cells extremely sensitive 
to PDT. However, two novel bioluminescence systems have recently been developed and 
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demonstrated to be efficient in activating photodynamic killing of cancer cells both in vitro 
and in vivo (212, 215). In the present study, we have compared the cytotoxicity of TPPS4 
induced by luminol and an external laser source. We have found that under the same drug 
incubation conditions, laser irradiation at a wavelength of 400 nm and a light dose of        
0.25 J cm-2 produced a similar level of cytotoxicity as that produced by co-incubation of the 
cells with TPPS4 and 2 mM luminol. These promising initial results indicate that 
bioluminescence may be utilized as an internal light source for PDT and has the potential of 
extending the application of PDT to the treatment of deep tumor masses.  
 We didn’t observe significant photocytotoxicity of FeTPPS under the same laser 
irradiation conditions as those applied to TPPS4. In fact, FeTPPS is not considered to be an 
efficient PDT agent probably due to its low yield of cytotoxic ROS. Photocytotoxicity of 
FeTPPS may become significant at higher light doses. However, this was not tested due to 
the limited power of our laser system at 400 nm. Higher light doses will require prolonged 
irradiation of the cells. When FeTPPS was combined with luminol, we did observe a 
synergistic enhancement of cytotoxicity (Figure 6-5). We have further estimated the degree 
of synergism by calculating the ratios between the IC50 values of the photosensitizer in the 
absence and presence of luminol. The value for FeTPPS have been found to be 4.74, which is 
slightly higher than that of 3.58 for TPPS4 suggesting that FeTPPS is more efficient than 
TPPS4 in luminol-activated killing of HeLa cells. This observation is in contrast to the much 
lower activity of FeTPPS than TPPS4 when the photosensitizers are activated by a 400 nm 
laser. One possible explanation is that the presence of iron in FeTPPS can greatly enhance 
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the bioluminescence of luminol and lead to increased cytotoxicity. Indeed, Motsenbocker et 
al. have shown that the relative luminescence intensity of luminol in 0.2 M NaOH is 305 a. u. 
(arbitrary unit) in the presence of FeTPPS, while the value in the presence of TPPS4 is 0 a. u. 
(304). Therefore, the observation of a synergistic effect induced by the combination of 
luminol and FeTPPS supports the assumption that the photosensitizers can be activated by 
the bioluminescence of luminol. 
 Cytotoxicity of the combination of luminol and TPPS4 and/or 6.3.5
FeTPPS in two normal human fibroblast cell lines 
One potential drawback of bioluminescence-activated PDT is a lack of tumor selectivity. 
Although most of the PDT sensitizers have been shown to have a higher affinity towards 
cancer cells than normal cells, selective destruction of tumors by PDT treatment still relies 
strongly on targeted delivery of light. Therefore, we have also evaluated the cytotoxicity of 
luminol and its combination with TPPS4 and FeTPPS in two normal human fibroblast cell 
lines GM05757 and MRC-5. As shown in Figure 6-7A, luminol is slight cytotoxic in 
GM05757 cells. At the highest concentration of 8 mM, less than 40% of the cells were killed 
following 48 h drug incubation. Cytotoxicity of TPPS4 and FeTPPS was also found to be 
lower than that observed in HeLa cells. More importantly, when GM05757 cells were co-
incubated with the photosensitizers and 1 mM luminol, the values of cell viability did not 
differ significantly from those in the absence of luminol. This observation indicates that a 
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synergistic effect is absent under the same treatment conditions as those which induced a 
synergistic enhancement of cytotoxicity in HeLa cells. 
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Figure 6-7: Cytotoxicity of luminol, TPPS4, FeTPPS and the combination of luminol and 
TPPS4/FeTPPS in normal human skin fibroblast GM05757 cells. Cells were incubated with 
various concentrations of luminol, TPPS4 and FeTPPS in cell culture medium containing 1% 
FBS for 48 h. At the end of incubation period, cell viability was assessed by MTT cell 
viability assay. The solid lines are best fits to the experimental data using a logistic function 
in Origin software. 
 In the normal human lung fibroblast MRC-5 cells, luminol showed a low level of 
cytotoxicity with less than 20% of the cells killed up to 2 mM (Figure 6-8A). The IC50 of 
FeTPPS was determined to be 19.4 ± 2.3 µM, which was lower than that in HeLa cells 
indicating higher cytotoxicity of FeTPPS in this cell line. However, when cells were co-
incubated with the photosensitizers and 1 mM luminol, no synergistic enhancement of 
cytotoxicity was observed in MRC-5 cells, while the relative IC50 was found to be reduced by 
nearly 80% in HeLa cells. 
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Figure 6-8: Cytotoxicity of the combination of luminol and FeTPPS in normal human lung 
fibroblast MRC-5 cells. Cells were incubated with various concentrations of luminol and 
FeTPPS in cell culture medium containing 1% FBS for 48 h. At the end of incubation period, 
cell viability was assessed by MTT cell viability assay. The solid lines are best fits to the 
experimental data using a logistic function in Origin software. 
 The absence of synergistic effects in the two normal human fibroblast cell lines treated 
by the combination of luminol and TPPS4 or FeTPPS suggests that the combination treatment 
has the potential of treating selected cancers while causing minimal damages to healthy cells. 
Although the molecular mechanism underlying the observed difference between the HeLa 
cancer cell line and the two normal cell lines has not been investigated in the present study, it 
may be associated with the difference in the level of oxidative stress between the cancer and 
normal cell lines. Chemiluminescence of luminol has been proven to be a powerful tool for 
the detection of various oxidizing agents that can cause light emission from luminol (205, 
213, 294, 296-299, 301, 304, 305). For example, Gross et al. have demonstrated that 
bioluminescence of luminol can be used to MPO activity, whose activation is associated with 
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pathogenesis of inflammatory disease states (e.g. cancer) in animal models (205). Good co-
localization of luminol bioluminescence with tumor sites has been achieved and the signal-
to-background ratio has been found to exceed 3,000. Therefore, bioluminescence of luminol 
may have intrinsic selectivity towards cancerous tissues and thus, may be developed as an 
internal light source for non-invasion PDT treatment of deep tumors that cannot be easily 
reached by conventional PDT. 
6.4 Summary 
Photodynamic therapy (PDT) has been proven to be an effective treatment approach for 
various human diseases including cancer. However, treatment of deep tumors remains a 
major challenge in PDT research due to the limited tissue penetration depth of external light 
(38, 306-308). In the present study, we have employed a novel approach in which 
bioluminescent light generated from luminol serves as an internal light source for the 
activation of the photosensitizers. Synergistic enhancement of cytotoxicity induced by the 
combination treatment of luminol and TPPS4 has been observed in the human cervical cancer 
HeLa cells by performing the MTT cell viability assay and clonogenic assay. Similar effects 
have been observed when luminol is combined with FeTPPS, which is much less active than 
TPPS4 when excited by a 400 nm fs laser. This observation supports the assumption that the 
synergistically enhanced cytotoxicity induced by the combination treatment of luminol and 
TPPS4 or FeTPPS is a result of photodynamic activation of the photosensitizers by the 
bioluminescent light emitted from luminol. More importantly, we have demonstrated that the 
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same combination treatment produce an additive effect in two human normal fibroblast cell 
lines (GM05757 and MRC-5). These results suggest that the bioluminescence of luminol 
activated PDT of TPPS4 or FeTPPS may favor the destruction of diseased tissues that have a 
higher than normal level of oxidative stress and thus, has the potential of treating deep-seated 
tumors in a non-invasive manner. 
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7 Conclusions and Future Research 
The objective of this project has been to develop more effective treatment approaches that 
have the potential of increasing the penetration depth of photodynamic therapy (PDT) for the 
treatment of deeper and thicker tumor masses. In this chapter, we summarize the major 
results presented in the present thesis and discuss possible future research. 
Two-photon activated PDT 
In Chapter 3, we have demonstrated that the second-generation photosensitizer 
pyropheophorbide a methyl ester (MPPa; also known as PPME) can induce effective killing 
of cancer cells of human cervix (HeLa), lung (A549) and ovary (NIH:OVCAR-3) through 
both one-photon (1-γ; at 674 nm) and two-photon (2-γ; at 800 nm) excitation. Our finding 
that the photocytotoxicity induced in cisplatin-sensitive HeLa cells is comparable to that 
observed in cisplatin-resistant A549 and NIH:OVCAR-3 cells indicates that PDT mediated 
by MPPa has the potential of treating cisplatin-resistant cancers. More significantly, effective 
2-γ activation of the drug at the optimal wavelength for tissue penetration offers the 
opportunity of increasing the treatment depth and improving tumor targeting. 
 Recent 2-γ PDT studies have been mainly focused on the development of 
photosensitizers that have high 2-γ absorption cross section (σ) values (134, 146, 148, 150-
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152, 235-242). Our observation that MPPa with a low σ = 3.5 GM can be effectively 
activated at a peak irradiance of 3.9 × 1010 W cm-2, which is about 10 times lower than the 
published threshold value (144), suggests the importance of factors other than σ in 
determining the effectiveness of the treatment and thus, should also be considered when 
developing novel treatment approaches. 
Combination of NIR-PDT and chemotherapy  
In Chapter 4, we have described synergistic enhancement of cytotoxicity in HeLa, A549 and 
NIH:OVCAR-3 cells treated with the combination of PDT mediated by the near infrared 
(NIR) dye indocyanine green (ICG) and etoposide (VP-16) chemotherapy as well as in A549 
cells treated with ICG-PDT and teniposide (VM-26). The presence of VP-16 at the time of 
laser irradiation has been found to be critical for the observation of synergistic effects. We 
have further investigated the mechanism underlying the observed synergistic effects by 
performing steady-state and femtosecond time-resolved spectroscopic studies. An electron-
transfer-based mechanism, in which ICG can act as an oxidizing agent to increase the yield 
of VP-16 metabolites that have been suggested to be more cytotoxic than VP-16 (13, 14, 274, 
309), has been proposed, although direct spectroscopic detection of the reaction products has 
been found to be challenging. 
 In Chapter 5, we have presented the results of the combination of ICG-PDT and the 
platinum-based chemotherapeutic drugs cisplatin (CDDP) and oxaliplatin (OXP). Low dose 
CDDP/OXP in combination with ICG-PDT has been found to produce additive or slight 
 199 
 
synergistic effects. An electron-transfer reaction between ICG and CDDP has been observed 
by performing steady-state absorption spectroscopic studies. This observation supports the 
proposal that this electron-transfer reaction is responsible for synergistic enhancement of 
cytotoxicity induced by the combination treatment. 
 The positive initial results obtained in the present study suggest that the combination of 
ICG-PDT with conventional chemotherapy mediated by VP-16/VM-26 or CDDP/OXP may 
increase the therapeutic effectiveness of ICG-PDT and lower the toxic side effects of the 
chemotherapeutic drugs at the same time. 
Bioluminescence-activated PDT 
In Chapter 6, synergistic enhancement of cytotoxicity has been observed in HeLa cells 
treated with the combination of luminol and TPPS4/FeTPPS while an additive effect has been 
observed in the human normal fibroblast GM05757 and MRC-5 cells. Effective activation of 
TPPS4/FeTPPS by the bioluminescence of luminol suggests that this system may be 
developed as a novel treatment option that is not limited by the tissue penetration depth of 
external light and thus, has the potential of treating deep-seated tumors. 
 All the three approaches explored in the present study have been shown to be able to 
induce significant killing in selected cancer cell lines. Further evaluation using other cell 
types and in animal models are expected to deepen our understanding of the mechanisms 
underlying the observed high effectiveness of the treatment and help the design of more 
effective modalities. 
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 In recent year, drug-delivery systems such as micelles and various types of 
nanoparticles have been studied extensively (102, 106, 107, 109, 111-113, 115-118, 129, 
201, 310, 311). Guelluy et al. have demonstrated that encapsulation of MPPa within 
liposomes of dimyristoyl-L-a-phosphatidylcholine (DMPC) can increase the intracellular 
concentration of the drug by 5 times in a human colon carcinoma (HCT-116) cell line (129). 
Various encapsulating approaches have also been demonstrated to improve the photophysical 
and photochemical properties of ICG as well as enable the use of tumor-targeting ligands, 
which further improves the tumor-specificity of the dye (102, 106, 107, 109, 111-113, 115-
118, 201). Although we are not aware of any nanoparticle-based system for luminol delivery, 
nanoparticles conjugated with luciferase or D-Luciferin have been shown to improve the 
tumor-specificity of the drugs (310, 311). Therefore, encapsulation of the drugs studied in the 
present project within nanoparticles may further increase the therapeutic potential of these 
drugs. 
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